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Abstract 
Glucocorticoids and androgens have both been implicated in the pathogenesis of non-
alcoholic fatty liver disease (NAFLD); androgen deficiency in males, androgen excess in 
females and glucocorticoid excess in both sexes are associated with NAFLD. Glucocorticoid 
and androgen action are regulated at a pre-receptor level by the enzyme 5αR2 (SRD5A2) that 
inactivates glucocorticoids to their dihydrometabolites and converts testosterone to 
dihydrotestosterone (DHT). We have therefore explored the role of androgens and 
glucocorticoids and their metabolism by SRD5A2 upon lipid homeostasis in human 
hepatocytes. 
In both primary human hepatocytes and human hepatoma cell lines, glucocorticoids decreased 
de novo lipogenesis in a dose-dependent manner. Whilst androgen treatment (testosterone and 
DHT) increased lipogenesis in cell lines and in primary cultures of human hepatocytes from 
female donors, it was without effect in primary hepatocyte cultures from men. SRD5A2 
overexpression reduced the effects of cortisol to suppress lipogenesis and this effect was lost 
following transfection with an inactive mutant construct. Conversely, pharmacological 
inhibition using the 5αR inhibitors finasteride and dutasteride, augmented cortisol action. 
We have demonstrated that manipulation of 5αR2 activity can regulate lipogenesis in human 
hepatocytes in vitro. This may have significant clinical implications for those patients 
prescribed 5αR inhibitors, in particular augmenting the actions of glucocorticoids to modulate 
hepatic lipid flux. 
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1.1.Obesity epidemic 
 
Obesity has become a global epidemic, with more than 1.3 billion overweight or obese 
patients worldwide (Chiang et al. 2011); 60% of adults are considered as obese or overweight 
(Hurt et al. 2010). The increase in numbers of overweight children is also alarming, having 
increased from 6% to 19% in the past 25 years (Ogden et al. 2007). Obesity and extreme 
obesity are characterised as a body mass index (BMI) greater than 30 and 40kg/m2, 
respectively. A BMI of more than 25kg/m2 is considered overweight (Hurt et al. 2010).  
According to the World Health Organisation (WHO), in the global disease burdon (GDB) 
study analysing the leading causes of global mortality and disease burden, obesity and 
overweight were ranked within the top ten (Lopez et al. 2006). Obesity is associated with a 
number of diseases including diabetes mellitus, hypertension, hyperlipidemia, and some 
cancers (Field et al. 2001;Renehan et al. 2008). Moreover, obesity conveys a significant 
economic burden to society; in 2006–07, overweight and obesity-related ill health cost the 
National Health Service (NHS) in excess of £5 billion (Scarborough et al. 2011). The 
magnitute of obesity epidemic has highlighted the need to study the consequences and, in 
particular, to understand the regulation of fat metabolism. 
 
1.1.1.Genetics of obesity 
 
Genetics play a key role in the regulation of adiposity affecting human body weight (Barsh et 
al. 2000) and several genes have been implicated in predisposing the human body to weight 
gain. Genome wide association (GWA) scans have identified multiple gene loci that are 
associated with and contribute to the development of obesity. Single nucleotide 
polymorphisms (SNPs) in the fat mass and obesity-associated (FTO) gene have been shown 
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to be associated with obesity in many GWAs (Dina et al. 2007) , as well as insulin induced 
gene 2 (INSIG2) (Herbert et al. 2006). The mutations in FTO were associated with declined 
satiety (Wardle et al. 2008) and increased food intake. INSIG2 is involved in fatty synthesis 
within the liver and overexpression in rats was able to decrease hepatic lipogenesis (Takaishi 
et al. 2004). Mutations in this gene were shown to be associated with abnormal lipid 
metabolism in obese children (Wang et al. 2010).  
 
1.1.2.Obesity and metabolic syndrome 
 
The metabolic syndrome is a cluster of risk factors that increase cardiovascular morbidity and 
mortality. Although there are different definitions, the World Health Organisation (WHO) 
criteria are insulin resistance combined with any two of the following: central obesity, 
hypertriglyceridaemia, low high-density lipoprotein (HDL), cholesterol, hypertension, fasting 
hyperglycaemia, microalbuminuria (Alberti et al. 2006).  
Insulin resistance has a central role in the development of the metabolic syndrome. As insulin 
resistance develops, the pancreatic β-cells produce more insulin in order to maintain glucose 
levels within the normal range. However, if the β-cells fail to produce enough insulin to 
prevent hyperglycaemia, glucose intolerance develops and this may eventually lead to type 2 
diabetes (T2D) (Kahn 2003). Diabetes is associated with cardiovascular disease with 
macrovascular consequences including atherosclerosis and microvascular manifestations 
including retinopathy and nephropathy, causing blindness and renal failure (Creager et al. 
2003). In addition, there is a strong association between obesity and non-alcoholic fatty liver 
disease (NAFLD), the heaptic manifestation of the metabolic syndrome , and also a variety of 
cancers, including hepatocellular carcinoma (Dowman et al. 2014). 
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1.2.Liver   
 
The liver is the largest organ (second only to the skin) and the heaviest gland in the human 
body, weighing between 1200g to 1500g in an average adult. It is located under the 
diaphragm and occupies the upper right region of the abdominal cavity. This organ has two 
main lobes, a large right and a smaller left lobe, divided by the falciform ligament which 
extends from the diaphragm to the surface of the liver (Tortora and Derrickson 2011; Boron 
and Boulpaep 2009).  
The hepatic artery is the main blood vessel feeding the liver with oxygenated blood from the 
aorta (Stevens and Lowe 2005). The liver also receives blood from the portal vein draining 
the splanchnic circulation including the small and large intestines, stomach, pancreas and 
spleen (Young and Heath 2000; Boron and Boulpaep 2009). The blood in these two vessels 
passes through sinusoids within the liver where oxygen and nutrients can be exchanged. 
Blood then leaves the liver through the hepatic vein and eventually joins the inferior vena 
cava to enter the right atrium of heart (Young and Heath 2000; Stevens and Lowe 2005) 
(Figure 1-1).                                
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Figure 1-1 Simplified diagram of blood flow through the liver. The liver receives blood from 
hepatic artery carrying oxygenated blood (red box), and also from the portal vein providing 
high nutrition blood (blue box). The blood in these two vessels passes through sinusoids 
within the liver where oxygen and nutrients can be exchanged. Blood leaves the liver and 
drains in to the hepatic vein where eventually joins the inferior vena cava to enter the right 
atrium of heart. 
 
 
1.2.1.Liver histology and physiology 
 
Hepatocytes are the main functional cells in the liver, occupying 80% of liver parenchymal 
volume. Hepatocytes are polyhedral cells with large round nuclei, containing two to eight 
times the normal complement of chromosomes. These cells can store glycogen and lipid in 
large quantities. The cytoplasm has an eosinophilic granular appearance due to the large 
number of free ribosomes, rough endoplasmic reticulum (ER), and mitochondria which are 
crucial for providing energy for the multiple metabolic functions of the liver. 
Endothelial cells, Kupffer cells and Stellate cells are the other key types of cells within the 
liver. Kupffer cells are a part of monocyte-macrophage defence which remove particulate 
matter from blood by their phagocytic action. Stellate cells store vitamin A in lipid droplets 
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and also produce extracellular matrix and collagen. During liver injury these cells are 
activated and can participate in fibrogenesis through collagen deposition (Boron and 
Boulpaep 2009; Young and Heath 2000) (Figure 1-2). 
Cultures of isolated primary hepatocytes are the best in vitro model compared to cell lines 
which are being used in liver studies, as they resemble the human genes profile and human 
model the most. However, primary hepatocytes are expensive, and as donors with a BMI over 
30, diabetes, viral infection, high alcohol consumption, or are on GC and related medications 
often need to be excluded, samples can be rare. Furthermore, they represent a monolayer 
culture where there is no interaction between hepatocytes and other liver cells. In order to 
reproduce in vitro the functional cell to cell connections observed in vivo, it is important to 
consider cell to cell interaction and proximity. As an example, the importance of the cell 
interaction in fibrogenesis induced by fat accumulation observed in NAFLD has been studied. 
Giraudi et al. designed an experiment in which mono culture hepatocytes and co-culture 
model of hepatocyte with stellate cells were both exposed to free fatty acids for 24h up to 
144h. Increased steatosis by free fatty acids was observed in both simultaneous co-culture and 
monoculture. However, the activation of stellate cells and collagen biosynthesis was greater 
when cells were in close contact (Giraudi et al. 2015). In the current work we used cultures of 
isolated primary hepatocytes to simplify the system. However, animal and human models 
were used with other colleagues in the group in order to compare different models and to have 
a more comprehensive understanding.  
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Figure 1-2 The structure of the hepatocyte cell. The hepatocytes contain a nucleus and many 
cellular organelles associated with secretary functions including ER and Golgi, and 
metabolic functions including mitochondria. Some of the hepatocytes form the sinusoids wall 
by lying adjacent to endothelial cells. Hepatocytes and endothelial cells are separated by 
small spaces called the space of Disse. 
 
 
Liver cells are arranged and aligned to form lobules, and rows of these hexagonal shape 
lobules create defined liver lobes.  Other than hepatocytes, the liver comprises bile cannaliculi 
and hepatic sinusoids containing bile and blood, respectively (Figure 1-3). Therefore, 
hepatocytes have three critical surfaces based on their transporting role; intercellular, 
canalicular and sinusoidal. The major part of the hepatocyte surface is sinusoidal (~70%), 
where material is transferred between hepatocytes and sinusoids through the space of Disse 
(an extracellular gap between sinusoids and hepatocytes (Figure 1-2). The hepatocyte 
membrane is covered with microvilli that extend into this gap increasing the surface area for 
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blood solute transport. Intercellular (transfers substances from cell to cell) and canalicular 
(drains bile from hepatocytes into canaliculi) both account for approximately 15% of the 
hepatocyte surface area (Young and Heath 2000; Stevens and Lowe 2005). 
Anatomically and functionally, the arrangement of the hepatocytes, bile duct and hepatic 
sinusoids has been described in three different models; 1.classic hepatic lobule and 2.portal 
lobule, with the emphasis on the lobule hexagonal shape and bile acid secretion respectively. 
These were thought to be the correct anatomical arrangement for many years (Tortora and 
Derrickson 2011), however,  the hepatic (or portal) acinus has been proposed as the third 
model and describes a zonal relationship between hepatocytes and blood vessels (Rappaport 
1980) (Figure 1-3). This model emphasizes the importance of the oxygenated arterial blood 
supply and proposes an oxygenation gradient from the portal triad (a unit consisting of a bile 
duct, one branch of the hepatic artery and one of the hepatic vein) towards the central hepatic 
vein (Tortora and Derrickson 2011). Only the third model is discussed further below. 
Although the exact boundaries are hard to define, cells in hepatic acinus are organised in three 
zones;  
- Zone I (periportal): cells in this zone receive the highest oxygen and nutrient concentrations 
as a consequence of their location adjacent to the portal triad. These cells are the last to die 
and the first to regenerate following liver injury. However, they have the highest response to 
toxin exposure and bile obstruction.  
- Zone III (pericentral): is the furthest from portal triad and located close to the central vein. 
Zone III cells receive the least oxygen and nutrients and rarely regenerate. However, these 
cells considered to be crucial for detoxication and biotransformation of drugs.  
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- Zone II hepatocytes are located between zone I and III with intermediate functional 
characteristics (Boron and Boulpaep 2009; Tortora and Derrickson 2011).  
      
 
Figure 1-3 The liver lobes are made up of hexagonal lobules which comprise of rows of 
hepatocytes. The hepatocytes are in close contact with sinusoids and canaliculi. The structure 
of the liver lobules, representing three different models for the arrangements of bile duct, 
hepatic artery and portal vein; classic hepatic lobule (a), portal lobule (b) and portal acinus 
(c). 
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The metabolic processes (metabolism of amino acids, carbohydrate and lipid) are also zoned 
as a consequence of this heterogeneity in distribution of metabolic enzymes across the acinus. 
Periportal hepatocytes are shown to be mostly gluconeogenic while pericentral cells are 
predominantly glycolytic (Jungermann and Katz 1982). With regard to lipid metabolism, the 
main focus in this thesis, pericentral hepatocytes in zone III are thought to have greater levels 
of lipogenesis while periportal hepatocytes have higher levels of the β-oxidation (Guzman and 
Castro 1989). The predominant metabolic activity is compared between zone I and III in 
Table 1-1 (the named pathways in this table are only briefly introduced but will be discussed 
in detail in section 1.2.3). This zonation has an important effect on lipid metabolism and the 
development of hepatic steatosis. In obese leptin deficient ob/ob mice, the hepatic steatosis 
observed in these mice was distributed in pericentral hepatocytes (Wiegman et al. 2003). In 
humans, simple steatosis starts in the pericentral area extending towards the intermediate and 
periportal zones as the disease develops (Chalasani et al. 2008). 
 
Table 1-1 The metabolic processes are zoned in hepatocytes. The metabolic activity compared 
between zoneI and zoneIII in hepatocytes is presented in this table. 
 
Zone I Zone III 
Gluconeogenesis  
(from lactate, amino acids, glycerol) 
Glycogen synthesis  
(from glucose) 
Glycogen degradation  
(conversion of glycogen to glucose) 
Glycolysis 
 (conversion of glucose to pyruvate) 
Oxidative energy metabolism 
 (oxygen utilization, β-oxidation - converting 
fatty acids to acyl CoA to generate ATP) 
De Novo Lipogenesis  
(fatty acid synthesis from acetyl CoA)  
Cholesterol synthesis Bile acid biosynthesis 
Amino acid catabolism Ketogenesis  
(conversion of fatty acids to ketone bodies) 
Ureagenesis  
(from ammonia, amino acid nitrogen) 
Glutamine synthesis  
(from ammonia, glutamate)   
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1.2.2.Hepatocyte embryology and proliferation 
 
The liver is embryologically derived from the anterior part of the foregut endoderm at about 
the middle of the third week or early fourth week of pregnancy (Sherwood et al. 2009). 
Although hepatocytes and biliary epithelial cells arise from endoderm, blood vessels, stellate 
and kupffer cells arise from mesodermal progenitor cells (Zorn 2008).  
Hepatocytes have little proliferative activity. However, they have a rapid proliferative 
response following liver injury where hepatocytes can be generated by replication of existing 
mature hepatocytes. When mature hepatocytes replication is delayed or inhibited, 
repopulation occurs by proliferation and differentiation of progenitor liver cells known as oval 
cells (Duncan et al. 2009) (Figure 1-4).  
 
 
Figure 1-4 The Liver growth and repopulation occurs in two different ways; by proliferation 
and differentiation of oval cells or replication of mature hepatocytes.  
 
 
Oval cells derive from the portal area of the lobule where the putative hepatic stem cell is 
located. Oval cells have the ability to differentiate to either biliary epithelial cells or 
hepatocytes, and therefore these cells are termed liver progenitor cells.  
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Hepatocyte regeneration is a multistep process including various cytokines and growth 
factors. The oval cells response to these factors can be divided into four stages; activation, 
proliferation, migration and differentiation.  The first signalling event that initiates oval cell 
activation occurs through interferon gamma (IFNᵧ), interleukin 6 (IL-6) and tumour necrosis 
factor (TNF) receptor type 1. IFNᵧ deficient mice have an impaired oval cell response but 
elevated hepatocyte regeneration after partial hepatectomy. There is also evidence to suggest 
contributions of other members of TNF family in activation of oval cells. TNF-like weak 
inducer of apoptosis (TWEAK) ligand and its receptor, Fn14 are members of the TNF family. 
Transgenic mice overexpressing TWEAK in hepatocytes have increased oval cell numbers 
but no effect on hepatocytes suggesting that TWEAK is selective in its ability to regulate the 
oval cell response (Jakubowski et al. 2005). 
There are other growth factors that can act as primary stimuli for the proliferation step 
including hepatocyte growth factor (HGF), epidermal growth factor (EGF) and transforming 
growth factor (TGF) (Jakubowski et al. 2005). Plasminogen activators are involved in a 
proteolytic cascade that appears to play a crucial role in tissue regeneration. Urokinase-type 
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) are specifically 
involved in oval cell expansion and migration during liver regeneration by conferring a 
proliferative advantage to oval cells in an extracellular matrix containing both latin and fibrin 
growth factors (Bisgaard et al. 1998). Oncostatin M (OSM) and its receptor, from the IL-6 
cytokine family, are also important in the differentiation of oval cells to hepatocytes (Okaya et 
al. 2005). In addition, leukaemia inhibitory factors (LIF) are also known to induce this 
differentiation (Omori et al. 1996) (Figure 1-5).  
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Figure 1-5 Oval cells derive from the portal area of the lobule and have the ability to differentiate to 
either biliary epithelial cells or hepatocytes. The oval cells response to cytokines and growth 
factors for hepatocytes regeneration is divided into four stages; activation, proliferation, 
migration and differentiation. 
 
 
1.2.3.Metabolic functions of the liver 
 
The liver has many metabolic functions including bile acid synthesis and secretion, bilirubin 
excretion, detoxification and elimination of metabolites and storage of fat soluble vitamins 
(Stevens and Lowe 2005). It produces urea, non-essential amino acids and most of the 
circulating plasma proteins from amino acids. However, its major role is in protein, 
carbohydrate and lipid metabolism (Boron and Boulpaep 2009). The principle focus of this 
thesis is lipid metabolism, but a brief over view of carbohydrate metabolism will also be 
presented. 
 
1.2.3.1.Carbohydrate metabolism and in liver 
 
Liver plays a significant role in regulation of carbohydrate metabolism by maintaining 
glucose levels in a normal range. This happens through metabolic processes that either 
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regulate glucose synthesis or break down which in turn are highly controlled by insulin 
(Raddatz and Ramadori 2007).  
 
1.2.3.1.1.Glycogenesis 
 
The process of glycogen synthesis from glucose is called glycogenesis. This includes 
phosphorylation of glucose to glucose 6-phosphate by glucokinase and then conversion to 
glycogen by glycogen synthase (Harvey and Champe 2005) (Figure 1-6, b-1). In the liver, 
insulin increases glycogenesis and so promotes glucose storage in the fed state (Sutherland et 
al. 1993). 
 
1.2.3.1.2.Gluconeogenesis 
 
Gluconeogenesis is the synthesis of glucose from amino acids, glycerol, and lactate (Figure 
1-6, a-2) Release of glucose from liver into the circulation during fasting is of fundamental 
importance to maintain circulatory glucose levels. Therefore, gluconeogenesis increases 
overnight and during prolonged fasting, to maintain blood glucose. However, in the fed state 
in the liver, the elevated insulin to glucagon ratio inactivates the essential enzymes for 
gluconeogenesis including glucose-6- phosphatase (G6Pase), phosphoenolpyruvate 
carboxykinase (PEPCK) (discussed in 1.3.4.4.4) and fructose 1,6-bisphosphatase. Fructose 
1,6-bisphosphatase is inactivated through cyclic adenosine monophosphate (cAMP) and its 
phosphorylation (see section 1.3.4.4.3) (Harvey & Champe 2005). 
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1.2.3.1.3.Glycolysis 
 
Glycolysis is a series of reactions whereby glucose is converted to pyruvate and subsequently 
to acetyl CoA. The acetyl CoA produced in this pathway can be used in fatty acid synthesis or 
can be oxidised through the tricarboxylic acid cycle (TCA) and to generate adenosine 
triphosphate (ATP) (Figure 1-6, b-2). In the liver, insulin drives glycolysis in the fed state 
(Gomez-Lechon et al. 1990) through activation of the rate-limiting enzymes of glycolysis 
including phosphofructokinase (Harvey & Champe 2005). 
 
1.2.3.1.4.Glycogenolysis  
 
The process of glycogen breakdown, by sequential removal of glucose monomers, catalysed 
by glycogen phosphorylase, is termed glycogenolysis (Figure 1-6, a-1). In the liver, 
glycogenolysis is increased during fasting, in order to release of glucose to the circulation 
(Sutherland, Leighton, & Cohen 1993). 
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Figure 1-6 Anabolic and catabolic pathways in fasted (a) and fed state (b) in liver. In fasting 
state; glycogenolysis (glycogen breakdown to glucose monomers) (a-1), gluconeogenesis 
(synthesis of glucose from amino acids, glycerol, and lactate)(a-2) and fatty acid 
uptake(a-3) are increased while VLDL production is decreased, in order to provide 
energy. In fed state; glycogenesis (glycogen synthesis from glucose) (b-1) and glycolysis 
(glucose conversion to pyruvate and subsequently to acetyl CoA) (b-2) as well as de 
novo lipogenesis (acetyl CoA conversion to fatty acids) (b-4), esterification (combination of 
fatty acids with glycerol to produce triglyceride) (b-5) and VLDL packaging (b-5) 
pathways are enhanced while gluconeogenesis is blocked, in order to store energy. 
Abbreviations: Glucose 6-P=glucose 6-phosphate, VLDL= very low density lipoprotein. 
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1.2.3.2.Lipid metabolism in the liver 
The amount of intracellular triglyceride (TAG) is a balance between fat accumulation and fat 
loss. In the liver, this is regulated by fat accumulation through de novo lipogenesis and fatty 
acid uptake or by the breakdown of fatty acid via β-oxidation or TAG can be packaged into 
very low density lipoprotein (VLDL) and released into circulation. 
1.2.3.2.1.Lipogenesis 
Lipogenesis includes both de novo lipogenesis, where fatty acids are synthesised from simple 
sugars in particular glucose, and their subsequent esterification to glycerol to form TAG 
(Figure 1-6, b-3,4,5). During de novo lipogenesis or fatty acid synthesis, carbons from acetyl 
CoA are incorporated into a growing fatty acid chain. The first and rate limiting step in de 
novo lipogenesis is the ATP-dependent carboxylation of acetyl CoA to malonyl-CoA by 
acetyl CoA carboxylase (ACC). The fatty acid synthase (FAS) enzyme then condenses the 
malonyl-CoA produced with acetyl CoA and the subsequent reactions between the growing 
acetyl CoA chain and newly synthesised malonyl-CoA eventually result in the formation of a 
16 carbons fatty acid palmitate (Ruderman et al. 2003) (Figure 1-7). There are two isoforms 
of ACC, ACC1 in cytosol and ACC2 on the outer mitochondrial membrane (Zhao et al. 
2010). In lipogenic tissues, including the liver, ACC1 is the rate-limiting step in lipogenesis. 
Indeed, liver-specific ACC1 knockout mice have decreased hepatic lipid accumulation (Mao 
et al. 2006). Although both isoforms mediate the conversion of acetyl CoA to malonyl-CoA, 
the malonyl-CoA produced by ACC2 inhibits carnitine palmitoyl-CoA transferase I (CPTI) 
and as a consequence results in inhibition of mitochondrial β-oxidation (Zhao et al. 2010). 
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Figure 1-7 De novo lipogenesis and subsequent triglyceride (TAG) synthesis. De novo 
lipogenesis is including rate limiting carboxylation of acetyl CoA to malonyl-CoA by acetyl CoA 
carboxylase (ACC) and the conversion of malonyl-CoA to palmitate by fatty acid synthase (FAS), 
Esterification results from combination of free fatty acids (FFA) with glycerol which can 
produce monoglyceride(MAG), dilyceride(DAG), and triglyceride(TAG). 
 
 
Free fatty acids (FFA) for TAG synthesis are available from fatty acid uptake and de novo 
lipogenesis within the liver (Postic and Girard 2008). Esterification of FFAs to a glycerol 
backbone to form TAG is the next step in lipogenesis. Esterification of glycerol to TAG is 
mediated by two enzymes: diacyly glycerol acyl transferase (DGAT) and glycerol phosphate 
acyl transferase (GPAT). DGAT has two isoforms namely DGAT1 and DGAT2; DGAT1 is 
primarily expressed in white adipose tissue and small intestine while DGAT2 is highly 
expressed in white adipose tissue and liver. There is evidence in literature showing these two 
enzymes play different roles in TAG synthesis. DGAT1 knockout mice have approximately 
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50% less TAG in tissues and are protected from insulin resistance and diet-induced obesity 
through increased energy expenditure pathways (Chen et al. 2002; Smith et al. 2000). 
However, in a study using antisense oligonucleotides (ASO) in rats with diet-induced 
NAFLD, DGAT2 ASO (but not DGAT1 ASO) rat improved hepatic steatosis and insulin 
sensitivity (Choi et al. 2007). Finally, the liver packages TAG into VLDL particles and 
secretes them into the blood to be used by other tissues (Harvey & Champe 2005). TAG is 
nonpolar, and therefore it needs to be packaged into lipoproteins to be transported in the 
plasma. Plasma lipoproteins are separated to five groups according to their size, mobility, 
electrophoretic, hydrated density, and also their relative content of TAG, cholesterol and 
protein. These five major classes are; chylomicron, very low-density lipoprotein (VLDL), 
high-density lipoprotein (HDL), low-density lipoprotein (LDL),and intermediate lipoprotein 
(IDL) (Cox and Garcia-Palmieri 1990). 
Nascent VLDLs are produced in the lumen of the ER in hepatocytes. VLDLs are composed of 
a TAG core covering with phospholipids, cholesterol and apoproteins. Among several 
apoproteins, apoprotein B provides structural ability to the VLDL particle, and therefore is the 
most important one. VLDL size is ranged between 35 to 100nM diameters. After biogenesis, 
they transport from the ER lumen into the golgi in hepatocytes and this transportation is 
facilitated by the VLDL transport vesicles. In golgi they are processed and finally post-golgi 
mature VLDL particles are transported to the plasma membrane and secreted to the 
circulatory system (Tiwari and Siddiqi 2012).  
ACC1 activity is highly regulated through post-transcriptional phosphorylation. ACC1 can be 
phosphorylated at different residues leading to activation or inhibition of ACC1 activity 
(Hardie 1992). For example: phosphorylation at ser-29 induces ACC1 activity (Haystead et al. 
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1988) but phosphorylation at ser-79, 1200, and 1215 negatively regulates its activity (Hardie 
1992). On the other hand, insulin increases lipogenesis via activating AMP-kinase (AMPK) 
which then negatively phosphorylates ACC1 (Witters and Kemp 1992) (see section 1.3.4.4.3). 
 
1.2.3.2.2.Fatty acid Uptake 
 
The liver takes up two forms of fatty acids from dietary lipid; 1.directly from long chain fatty 
acids and 2.in the form of large proteolipids called chylomicrons. Chylomicrons are absorbed 
into enterocytes (intestinal mucosal cells) and are composed predominantly of TAGs which 
are packaged with phospholipids, cholesterol and apoproteins. TAG in chylomicrons is 
hydrolysed by lipoprotein lipase (LPL) on the capillary endothelium walls in muscle and 
adipose tissue. The products of this digestion are glycerol, fatty acids and remnant 
chylomicrons. The first two products of LPL, fatty acids and glycerol, enter the muscle and 
adipose tissue and remnant chylomicrons remain in circulation and move towards liver. 
Remnant chylomicrons are smaller chylomicrons which are mainly TAG, rich in cholesterol, 
and therefore they can enter hepatocytes by endocytosis through a specific low-density 
lipoprotein (LDL) receptor called the LDL related receptor. Long chain fatty acids can enter 
the hepatocytes directly by simple ‘flip–flop’ diffusion across the lipid bilayer or through 
fatty acid transporter FAT/CD36. The importance of FAT/CD36 in fatty acid uptake in 
muscle and adipose tissue is well described (Bonen et al. 2007;Silverstein and Febbraio 2009) 
but the expression of hepatic FAT/CD36 is reported to be low (Berk 2008;Luiken et al. 2002). 
However, there is evidence that FAT/CD36 protein expression is increased with the TAG 
content presenting in different models of hepatic steatosis (Buque et al. 2012). 
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As described in section 1.2.3.3.1, the liver synthesises TAG by de novo lipogenesis which is 
also packaged with phospholipids, cholesterol and apoproteins into VLDL. VLDL enters 
circulation to reach muscle and adipose tissue where it is hydrolysed by LPL to fatty acids, 
glycerol, VLDL remnant and intermediate density lipoprotein (IDL). The fatty acids and 
glycerol are used as fuel in muscle and as storage in adipose tissue. IDL is taken up by liver, 
to a lesser extend compared to LDL, through the LDL receptor. 
Hepatic lipase (HL) is expressed on the basolateral surface of the hepatocytes and on 
endothelial cells (Sanan et al. 1997) as well as in circulation. This is a multifunctional protein 
that works as a lypolytic enzyme as well as a ligand binding function that facilitates lipid 
uptake depending on site of expression. HL directly binds to IDL, LDL, VLDL remnant and 
HDL and enhances their uptake into hepatocytes through cell surface receptors including LDL 
receptor (Krapp et al. 1996;Marques-Vidal et al. 1994) (Figure 1-8).  
 
1.2.3.2.3.Lipolysis 
 
TAG represents the body’s main source of energy and through lipases activity in adipose 
tissue it is hydrolysed to produce FFA which is subsequently get into circulation and can be 
used by other distant tissues such as muscle and liver in the process of β-oxidation to generate 
ATP (see section 1.2.3.3.4).  
As mentioned in section 1.2.3.3.2, HL has a classical function as a lipolytic enzyme 
hydrolysing TAG to diglyceride (DAG) and FFA as well as phospholipid to lysophospholipid 
and FFA, in liver and also in circulation. Patients with HL deficiency accumulate plasma 
VLDL, IDL, LDL, HDL and chylomicron remnants presenting with hypertriglyceridemia and 
hypercholesterolemia (Breckenridge et al. 1982;Hegele et al. 1993).  
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Two other main lipolytic enzymes are hormone sensitive lipase (HSL) and monoglyceride 
lipase (MAGL) which work together to hydrolyse TAG completely. HSL can use both TAG 
and DAG as substrates, removing the first and second fatty acids from TAG. MAGL removes 
the last fatty acid releasing glycerol (Figure 1-8). These enzymes as well as other lipases such 
as adipose triglyceride lipase (ATGL) are highly expressed in adipose tissue where the 
majority of lipolysis within the body occurs. However, HSL and ATGL have been shown to 
directly affect hepatic lipid metabolism as hepatic overexpression of HSL and ATGL promote 
release of fatty acids and β-oxidation (Reid et al. 2008).  
Perilipin is a lipid droplet associated protein family which consists of five members named 
Plin1 to 5 and Plin5 is highly expressed in liver. Plin5 binds directly to ATGL inhibiting the 
ATGL- lipid droplet aggregation (Dalen et al. 2007).  
 
1.2.3.2.4.β-oxidation 
 
Breaking down fatty acids to generate acyl CoA occurs through the process of β-oxidation 
within mitochondria. In the liver, acetyl CoA produced from this pathway can either be used 
to form ketone bodies or can enter the Krebs cycle and generate ATP (Sprecher et al. 1995).  
This oxidation is the main source of energy for the liver, notably during fasting. CPT is the 
rate-limiting enzymatic step in β-oxidation, transferring acyl CoA into the mitochondria. 
CPTI is positioned in the outer mitochondrial membrane and facilitates this transport by 
conjugating the fatty acid chain with carnitine. The free CoA is then released into the cytosol, 
and the Acyl carnitine is transported to the inner membrane (Harvey & Champe 2005;Zammit 
1999). Acyl carnitine is transported across the inner membrane by carnitine acylcarnitine 
translocase (CAT) (Murthy and Pande 1984). Carnitine palmitoyl-CoA transferase II (CPTII) 
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is bound to the matrix side of the inner mitochondria by which Acyl carnitine is converted 
back to fatty acyl CoA releasing the molecule of carnitine (Johnson et al. 1995). In the 
mitochondria matrix, the fatty acids enter a cycle of multiple reactions, producing NADH, 
FADH2 and acetyl CoA. NADH and FADH2 produce ATP when oxidized by the electron 
transport chain. Finally, the acetyl CoA can then enter the tricarboxylic acid (TCA) cycle to 
generate more ATPs. 
As discussed previously CPTI activity is inhibited by malonyl CoA produced by ACC2. In 
addition, ACC2 is negatively regulated by AMPK (see section 1.3.4.4.3) and therefore co-
ordinately decreasing lipogenesis and increasing β-oxidation (Figure 1-8). 
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Figure 1-8 Lipid metabolism within the liver. The FFAs, provided by either de novo 
lipogenesis or fatty acid uptake, undergo esterification to produce TAG. TAG can be 
packaged in VLDL particles and be secreted into circulation. However, during fasting, TAG 
undergoes lipolysis and subsequently β-oxidation to generate ATP (ACC= acetyl CoA 
carboxylase, ATGL= adipose triglyceride lipase, CPT= Carnitine palmitoyl-CoA transferase, 
DAG= diacylglyceride, FAS= fatty acid synthase, FFA= free fatty acid, HL= hepatic Lipase, 
HSL= hormone sensitive lipase, LDL= low density lipoprotein, MAG= 
monoacylglyceride,MAGL= monoacylglyceride lipase, TAG= triglyceride, VLDL= very low 
density lipoprotein). 
 
 
1.2.4.Fatty liver disease 
 
Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of 
the metabolic syndrome (Lim et al. 2010;Pascale et al. 2010). It is associated with the 
development of obesity and insulin resistance, and it may be present in up to 90% of obese 
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individuals (Nugent and Younossi 2007). NAFLD is not only prevalent among adults but its 
incidence is rapidly increasing in children (Franzese et al. 1997;Tominaga et al. 1995). 
NAFLD is characterised by accumulation of fat in the liver and refers to a progressive 
spectrum of disease ranging from simple hepatic steatosis to inflammatory non-alcoholic 
steatohepatitis (NASH), fibrosis, and liver cirrhosis (Trauner et al. 2010) (Figure 1-9). 
.  
 
 
 
Figure 1-9  Stages of liver damage in NAFLD. NAFLD demonstrates a spectrum of liver 
disease ranging from simple hepatic steatosis. Inflammation can convert steatosis to non- 
alcoholic steato-hepatitis (NASH) which can end up in cirrhosis with liver failure. 
 
The earliest stage of NAFLD is reversible hepatic steatosis, where excess TAG accumulates 
in lipid droplets within the cytoplasm of hepatocytes. True hepatic steatosis is defined when 
lipid is present in more than 5% of hepatocytes. Studying biopsy-proven NAFLD patients, a 
simple steatosis has a benign clinical course without excess mortality (Ekstedt et al. 2006). 
However, the disease can progress to inflammation, termed non-alcoholic steatohepatitis 
(NASH). NASH may eventually cause scarring and fibrosis (Jou et al. 2008) and whilst the 
liver may function normally initially, progressive fibrosis and scarring liver cirrhosis is 
associated with cardiovascular and liver mortality (Ekstedt et al. 2015). 
Normal Liver Fatty Liver Liver Fibrosis Cirrhosis
Steatosis NASH
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NAFLD occurs when lipid deposition is excessive reflecting an imbalance between lipid 
accumulation by de novo lipogenesis or fatty acid uptake and lipid clearance via fatty acid β-
oxidation or TAG-rich lipoprotein secretion (Barrows et al. 2005;Lou-Bonafonte et al. 2011) 
(Figure 1-10).  
 
Figure 1-10 The amount of intracellular TAG is a balance between accumulation, by de novo 
lipogenesis or FA uptake and by loss from the breakdown of fatty acids by β-oxidation or it 
can be packaged into VLDL and released into circulation. 
 
 
Liver biopsy remains the ‘gold-standard’ for the diagnosis and staging of NAFLD (Chalasani 
et al. 2012). In a clinical study patients with NAFLD who underwent a liver biopsy also 
received intravenous infusion and oral administration of multiple stable isotopes; [13C1] 
sodium acetate, [1,2,3,4 13C4] potassium palmitate and [2H31] glycerol-tripalmitin, which were 
used to track the rate of fatty acids. This study defined the metabolic pathways that contribute 
to hepatic lipid accumulation, with the greatest proportion (59%) of TAG re-esterified from 
circulating FFAs 26.1% from de novo lipogenesis and 14.9 % from dietary fatty acids 
(Donnelly et al. 2005). A separate study compared the contribution of de novo lipogenesis to 
VLDL-TAG in the fasted and fed states. During fasting, 77.2% of VLDL-TAG was derived 
from serum FFAs with only 4% from de novo lipogenesis. However, after feeding, the 
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proportion derived from circulating FFAs decreased to 43.6% and that from de novo 
lipogenesis increased to 8.6%, with 15.2% from chylomicron remnant-TAG and 10.3% from 
dietary fatty acids (Barrows and Parks 2006). 
Despite the high prevalence of steatosis only a minority (7 out of 127 NAFLD patients or 
5.4%) (Ekstedt et al. 2006) progress to steatohepatitis and therefore poorly defined triggering 
factors are needed in order to develop NASH (Anstee et al. 2013). Both dietary or 
environmental factors and genetics can influence the progression of NAFLD. The best genetic 
predictor of NAFLD is well recognised to be a loss of function mutation (I148M) in papatin-
like phospholipase domain-containing 3 (PNPLA3, also known as adiponutrin) (Romeo et al. 
2008). PNPLA3 is from the papatin family that has nonspecific lipid acyl hydrolase activity 
with the preference for TAG (Galliard 1971). The I148M mutation enhances TAG 
accumulation by inhibiting lipid breakdown (He et al. 2010) and also has been associated with 
progression or complications of NAFLD including NASH, cirrhosis and hepatocellular 
carcinoma (Zimmer and Lammert 2011) . In addition, genetic variation in cytochrome P450 
2E1 (CYP2E1, an endoplasmic monooxygenase oxidising alcohols and FAs) is also reported 
to be related to NASH (Piao et al. 2003). 
There are additional factors that are associated with NAFLD progression. These include, 
elevated levels of tumour necrosis factor α (TNF-α), interleukin 6 (IL-6) (Feldstein 2010), and 
lipotoxicity- induced endoplasmic reticulum (ER) stress resulting from improperly folded 
proteins aggregating in the ER (Yang et al. 2010).  
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1.3.Insulin 
 
Insulin is the principal hormone controlling glucose metabolism. It is secreted from the β-cells 
of the pancreatic islet in response to elevated blood glucose levels although different stimuli 
such as amino acids and gastrointestinal hormones are also able to modulate its secretion 
(Rasmussen et al. 1990). In addition to its metabolic actions, insulin has strong mitogenic and 
anti-apoptotic effects which are regulated via the MAPK (mitogen-activated protein kinase) 
pathway (Chen et al. 2012).  
 
1.3.1.Insulin structure and synthesis 
 
Insulin gene transcription occurs only in pancreatic β-cells resulting in a full length mRNA 
production which is then translated to a single polypeptide precursor called pre-proinsulin. 
This polypeptide is attached to the ER membrane and consists of four domains; two chains (A 
and B), a connecting region known as C-peptide and an N-terminal signal peptide (Sanger 
1960). Once the signal peptide is cleaved, proinsulin is formed and enters the ER lumen. The 
sulphide bridges between A and B chains are formed as a consequence of the oxidising ER 
environment. Proinsulin is transported to the golgi complex where a subsequent removal of 
the C-peptide results in insulin formation. The mature hormone with two peptide chains (A 
and B) is then packaged from the golgi by exocytosis and accumulates within the secretory 
granules in cytoplasm (Boron and Boulpaep 2009) (Figure 1-11). 
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Figure 1-11 The principles of insulin synthesis in pancreatic β-cells. Insulin is synthesised as 
preproinsulin and enters the ER to form proinsulin. Proinsulin is then transported to the golgi 
and converted to insulin.    
 
 
1.3.2.Insulin secretion 
 
Insulin secretion is regulated by a variety of positive and negative stimuli. Nutrients such as 
glucose and amino acids-especially arginine (Tang et al. 2013) and leucine (Yang et al. 2010) 
as well as gastric hormones including glucagon-like intestinal peptide I (GLP-I), gastric 
inhibitory polypeptide (GIP) and cholecystokinin, are known to enhance insulin secretion. 
However due to insulin’s primary role in glucose metabolism, glucose is the major regulator 
of secretion.  
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Elevated blood glucose triggers insulin secretion by the following mechanism. High 
circulating glucose is transported into β-cells through GLUT2 glucose transporters. This 
intracellular glucose is metabolised via glycolysis, producing pyruvate which then enters the 
mitochondria and generates adenosine triphosphate (ATP). The elevation in ATP/ADP ratio 
closes ATP-sensitive potassium channels, results in increased intracellular potassium which 
leads to cell membrane depolarisation (Smith et al. 1989). This activates voltage gated 
calcium channels promoting calcium influx into the cytosol (Bergsten et al. 1994) which also 
triggers intercellular calcium release. A rise in calcium concentration evokes the exocytosis of 
the secondary granules containing insulin (Figure 1-12).  
There are also inhibitory mechanisms controlling insulin secretion especially during stress 
and also when energy mobilization is required for example during physical exercise (Peterson 
2007). Adrenaline, somatostatin and leptin are known to be negative stimuli for insulin 
release. Adrenaline is the most potent of these inhibitors and simultaneously activates 
potassium channels whilst inactivating calcium channels within the β-cells (Debuyser et al. 
1991).    
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Figure 1-12 The processes leading to insulin secretion in pancreatic β-cells. Glucose is 
transported into β-cells through GLUT2 glucose transporters and metabolised to ATP. 
Elevated ATP/ADP ratio closes the ATP-sensitive potassium channels, leading to cell 
membrane depolarisation. Cell-surface calcium channels are opened and promoting calcium 
influx into the β-cells. An increase in calcium triggers the exocytosis of insulin. 
 
 
1.3.3.Metabolic actions of insulin 
 
Insulin plays the key role in the switching of metabolism from the fed to the fasted state.  
In the fed state, anabolic metabolism predominates and nutrients are stored as glycogen, TAG, 
and proteins. Levels of glucose, amino acids, and triglycerides are temporarily raised 2-4 
hours after ingestion of food in the post-absorptive phase. The secretion of insulin is increased 
in response to elevated levels of glucose and amino acid, while, the release of glucagon is 
decreased by the alpha cells of the pancreas. This elevated insulin to glucagon ratio and the 
availability of other substrates are the two key factors which make the absorptive phase an 
anabolic period (Figure 1-13).  
During this period, glucose is the main energy source for all tissues, and the liver takes up 
glucose, lipids, and amino acids which can then be metabolised, stored or routed to other 
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tissues (Harvey & Champe 2005). Acetyl CoA as a glycolytic product is used to synthesise 
fatty acids through de novo lipogenesis. Long-chain fatty acids are taken up into triglycerides, 
cholesterol and phospholipids. These lipids are stored in lipid droplets or secreted into the 
circulation as VLDL particles (Figure 1-13). 
  
 
 
Figure 1-13 Energy balance by anabolism and catabolism and the co-factors involved. 
 
 
The fasted state is a catabolic period where insulin secretion is decreased in response to 
reduced levels of glucose and amino acids, while, the release of glucagon and adrenaline is 
increased. This reduced insulin to glucagon ratio and lower substrate availability drive 
catabolic metabolism (Figure 1-13).  
Insulin target tissues (adipose tissue, muscle, and liver) function in a way to achieve two 
priorities: first, to maintain adequate plasma glucose level, and second, to metabolise fatty 
acids and ketone bodies to provide energy for all tissues (Harvey & Champe 2005). During 
fasting, the liver secretes glucose through both glycogenolysis and gluconeogenesis. Fasting 
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induces lipolysis in adipose tissue to release FFAs which are converted into ATP and ketone 
bodies in the liver by mitochondrial β-oxidation and ketogenesis. Ketone bodies can then be 
used as metabolic fuel for extra-hepatic tissues, mainly the brain (Figure 1-13).  
Detailed liver metabolic processes are regulated by hormonal systems which will be discussed 
in detail in section 1.5.  
 
1.3.4. Insulin signalling 
 
Insulin actions are mediated via the insulin receptor (IR) initiating a cascade of cell-signalling 
responses involving phosphorylation of insulin receptor substrate (IRS) proteins. These 
proteins have a large number of tyrosine and serine phosphorylation sites on their C-terminal 
domains. Tyrosine phosphorylation is required for activation of phospho-inositide 3 Kinase 
(PI3K). PI3K predominantly mediates insulin metabolic actions via activating protein kinase 
B (PKB/Akt) (Alessi et al. 1997a). Finally, activated PKB/Akt can then modulating many 
metabolic actions of insulin within the body (Figure 1-14). 
 
1.3.4.1.Insulin receptor   
 
Insulin mediates its signalling actions through cell surface receptors, tyrosine kinases, in 
particular the insulin receptor (IR) and also the insulin-like growth factor (IGF) receptor. 
However, the IGF receptor has an approximately 100-fold less affinity for insulin compared 
to its cognate ligand, IGF1 (Andersen et al. 1992). IR is composed of two extracellular α-
subunits and two transmembrane β-subunits which are linked by a disulphide bond. The α-
subunits are known as hormone binding domains while the β-subunits confer tyrosine kinase 
activity. When insulin binds to the α-subunits, the receptor undergoes conformational changes 
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leading to the auto-phosphorylation of specific tyrosine residues on the cytosolic β-subunits 
(Ballotti et al. 1989) (Figure 1-14) 
 
1.3.4.2.Insulin receptor substrates 
 
Upon activation by insulin, the auto-phosphorylated insulin receptor then leads the 
phosphorylation of numerous cellular proteins including the insulin receptor substrate (IRS) 
proteins (Figure 1-14). 
Six isoforms of IRS have been identified to date (IRS1-6) (Cai et al. 2003) from which IRS1 
and IRS2 are shown to be more important in mediating metabolic signal transduction (Araki 
et al. 1994;Patti et al. 1995). In liver, IRS2 is the dominant IRS and its downregulation 
appeared to be mainly responsible for insulin resistance, studying the ob/ob mice (Kerouz et 
al. 1997).  
Sharing a high degree of homology, all IRS proteins have both pleckstrin-homology domain 
(PH) and phosphotyrosine binding domain (PTB) close to the N-terminal which is responsible 
for the high affinity of these substrates for IR. The C-terminal is more variable, containing a 
large number of tyrosine and serine phosphorylation sites, and confer IRS activity. Tyrosine 
phosphorylation of IRS, in particular IRS1/2, causes a linkage between IRS and various 
effector proteins containing src-homology 2 (SH2) domains resulting in multi-subunit 
signalling complexes. One of the best known SH2 domain proteins is phosphoinositide-3 
kinase (PI3K). As an example, phosphorylation at tyr612 and tyr632 are required for 
activation of PI3K (Esposito et al. 2001). However, phosphatase SH2 can negatively regulate 
the IRS tyrosine phosphorylation thereby reducing the metabolic actions of insulin.  
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In addition, IRS has serine phosphorylation sites which, for the most part, are inhibitory to 
IRS function. Approximately 124 and 129 serine phosphorylation sites have been identified 
for IRS1 and IRS2, respectively (Park et al. 2013). For example, the serine phosphorylation at 
residue 307 of IRS1, situated on the PTB-domain of insulin receptor (IR), is shown to inhibit 
the IRS1/IR interaction using yeast-tri-hybrid assay (Aguirre et al. 2000).  
Studies carried out in ob/ob  mouse model of obesity demonstrate decreased insulin 
signalling, with lower receptor kinase activity, insulin binding, IRS1 protein expression, IRS1 
associated PI3K activity, in liver, muscle and fat tissue (Anai et al. 1998;Goodyear et al. 
1995;Kerouz et al. 1997). Furthermore, IRS serine phosphorylation is a key regulator of IRS 
function and is considered a major contributor to insulin resistance and diabetes (Bouzakri et 
al. 2006).  
Although IRS proteins have a high degree of homology, their role in insulin/IGF1signaling is 
shown to be complementary rather than identical. IRS1 knockout mice have a growth defect 
due to the IGF resistance, mainly in skeletal muscle (Araki et al. 1994). However, the IRS2 
knockout mice are disruptive to insulin signalling, primarily in liver (Kubota et al. 2000). 
 
1.3.4.3.Phosphoinositide 3-Kinase 
 
Insulin mediates its metabolic actions via IRS activation of PI3K. PI3K is an heterodimer 
consisting of a catalytic subunit (p110), and a regulatory subunit (p85) (Yu et al. 1998). 
Following binding with IRS, PI3K converts the lipid membrane phosphatidylinositol-3, 4-
diphosphate (PIP2) to phosphatidylinositol-3, 4-triphosphate (PIP3). PIP3 is known to be the 
most biologically active 3' phosphor-inositide, and acts as a second messenger activating the 
PH-domains containing proteins including PKB/akt (Alessi et al. 1997) (Figure 1-14). 
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1.3.4.4.Protein Kinase B (PKB/akt) 
 
There are four members of the PKB family; PKBα, PKBβ1&2 and PKBγ (akt1, 2 and 3 
respectively). All isoforms consist of an N-terminal PH-domain, a central kinase 
(serine/threonine) domain, and a C-terminal regulatory domain. The PIP3, generated by PI3K, 
binds with PH-domain of PKB/akt (Downward 1998). This causes the translocation of 
PKB/akt from the cytosol to the plasma membrane, where it is phosphorylated at residue 
Thr308 by phosphoinositide-dependent protein kinase 1 (PDK1) (Stephens et al. 1998). In 
addition, within its regulatory domain, Ser473 phosphorylation by the mammalian target of 
rapamycin (mTOR) results in full PKB/akt activation (Sarbassov et al. 2005) (Figure 1-14). 
  
1.3.4.4.1.Protein Kinase B and glucose uptake 
 
One of the principal roles of activated PKB/akt is to increase glucose transport into the cells 
by inducing the translocation of the glucose transporter, GLUT4, to the plasma membrane. 
GLUT4 is located in cytosolic vesicles containing GTP-activating proteins (Rab GTPase) 
which are required for the movement of these vesicles to the plasma membrane. An AKT 
substrate, AS160, is also present in GLUT4 vesicles, and inhibits the Rab GTPase. Activated 
PKB/akt can directly phosphorylate AS160 which leads to AS160 binding the cytosolic 
scaffold protein, 14-3-3. Upon this association, AS160 is removed from the vesicle, relieving 
its inhibition on Rab GTPase. This allows GLUT4 translocation to the plasma membrane and 
thereby increasing glucose uptake (Ramm et al. 2006;Sano et al. 2003) (Figure 1-14).  
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1.3.4.4.2.Protein Kinase B and enzymatic activation  
 
PKB/akt regulates many metabolic enzymes including glycogen synthase kinase (GSK). 
Glycogen synthase (GS) is a key enzyme in glycogen synthesis which is inhibited by GSK 
when GSK is in the non-phosphorylated state. Activated PKB/akt causes GSK 
phosphorylation, relieving the inhibition on GS and increasing glycogen synthesis (Sutherland 
et al. 1993). In addition, PKB/akt has an important role in the regulation of transcription and 
protein synthesis via inactivation of GSK. Phosphorylated GSK can increase protein synthesis 
by removing a negative phosphorylation on the transcription factor,  eukaryotic initiation 
factor 2B (eIF2B) (Welsh and Proud 1993) (Figure 1-14). 
 
1.3.4.4.3.Protein Kinase B and secondary messengers 
 
PKB/akt also modulates insulin signalling through regulation of second messengers levels 
within the cell, particularly cyclic adenosine monophosphate (cAMP). High levels of cAMP 
activate protein kinase A (PKA) that phosphorylates serine/thereonine kinase 11 (STK11), 
also known as liver kinase B1 (LKB1). Subsequently, phosphorylated LKB1 activates 5’AMP 
activated protein kinase (AMPK) which negatively phosphorylates acetyl CoA carboxylase 
(ACC). ACC is a rate limiting enzyme in lipogenesis as well as inhibiting β-oxidation through 
malonyl CoA production (discussed in detail in section 1.2.3.3.1). In the presence of insulin, 
PKB/akt activates phosphodiesterase 3B (PDE3B) by phosphorylation. Activated PDE3B 
hydrolyses the cAMP to inactive 5’AMP, alleviating the AMPK inhibition on ACC which 
results in a shift from fatty acid oxidation to fatty acid storage or lipogenesis (Kitamura et al. 
1999). In addition, PKA activates glycogen synthase and inhibits the conversion of glycogen 
to glucose (Mehrani and Storey 1993) (Figure 1-14).  
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1.3.4.4.4.Protein Kinase B and transcriptional regulation 
 
PKB/akt can modulate the expression of multiple metabolic enzymes by regulating the 
activity of transcription factors. The forkhead box-containing protein (FOXO) family are key 
transcription factors in metabolic regulation, for example, in the liver, FOXO1 modulates the 
expression of the genes involved both in lipid and glucose metabolism (Altomonte et al. 
2003;Matsumoto et al. 2007).  
FOXO1 drives expression of rate-limiting gluconeogenic enzymes, glucose-6- phosphatase 
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK). In addition, The FOXO family 
is negatively activated by PKB/akt. This means in response to insulin, FOXO1 is inhibited by 
PKB/akt and therefore, gluconeogenesis is blocked through down regulation of G6Pase and 
PEPCK. In fed state, liver-specific FOXO1 overexpressed mice shown an increase in 
expression of genes involved in lipid transport and a decrease in expression of rate-limiting 
genes in glycolysis and lipid synthesis  (Zhang et al. 2006). In contrast, using the same model, 
enhanced lipogenesis and liver steatosis has been reported (Qu et al. 2006) (Figure 1-14).  
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Figure 1-14 The insulin signalling pathways involved in the metabolic actions of insulin. In 
summary, when insulin binds its receptor the receptor auto phosphorylates. This then binds 
and phosphorylates insulin receptor substrate, which activates PI3K which leads via a 
secondary messenger to AKT phosphorylation. This activation of AKT increases glucose 
uptake (through GLUT4 translocation to the plasma membrane), glycogen synthesis (through 
GSK phosphorylation), and lipogenesis (through AMPK activation) whilst inhibiting 
gluconeogenesis (through FOXO1 and PEPCK suppression) and β-oxidation (through AMPK 
activation). Abbreviations: IRS1/2= Insulin receptor substrate1/2, SH2= Src-homology 2, 
PI3K= Phospho-inositide 3 Kinase , PIP2/3= Phosphatidylinositol-3, 4-diphosphate 2/3,  
AKT/PKB= Protein Kinase B,  mTOR= Mammalian target of rapamycin, PDK1= 
Phosphoinositide- dependent protein kinase 1,  cAMP= Cyclic adenosine monophosphate, 
PKA= Protein kinase A,  LKB1= Liver kinase B1, AMPK= AMP-kinase, GSK= Glycogen 
synthase kinase,  FOXO1= Forkhead box-containing protein, PEPCK= Phosphoenolpyruvate 
carboxykinase. 
 
1.4.Steroid hormones; glucocorticoids and androgens 
1.4.1.Adrenal glands 
 
There are two adrenal glands in total, each weighing approximately 4g. One adrenal gland is 
situated on top of each kidney. Each gland is wrapped in a fibrous capsule and comprises two 
distinct structures; an outer structure called the adrenal cortex and an inner structure named 
the adrenal medulla. These two structures have different origins; the cortex is derived from 
39 
 
Chapter 1                                                                                                                                    General Introduction 
 
mesoderm whilst the medulla is derived from neural crest cells. They are functionally and 
anatomically distinct. The cortex can be further subdivided into three layers: an outer layer 
located close to the capsule called, the zona glomerulosa (ZG); a middle layer called, zona 
fasciculata (ZF); and an inner layer close to the medulla called, zona reticularis (ZR). ZG is 
the thinnest layer in adrenal cortex and it is responsible for mineralocorticoid production, 
principally aldosterone. ZF is the thickest layer in the centre of the cortex and secrets GCs 
predominantly. Finally the ZR, which occupies less cortical space than ZF and more than ZG 
and synthesises mainly androgens. The adrenal medulla is a part of neuroendocrine system, 
producing adrenaline and noradrenaline (Arlt and Stewart 2005) (Figure 1-15). 
 
 
Figure 1-15 The adrenal glands are positioned above the kidneys and are divided into 
adrenal medulla and the cortex which itself is divided into three zones; the glomerulosa, 
fasciculata and reticularis. 
 
 
The blood supply to the adrenal glands are the branches of the inferior phrenic artery, renal 
artery and the aorta which penetrates the cortex and medulla. The right adrenal gland is 
drained into the inferior vena cava via a short vein. However the left gland has a longer vein 
which drains into the renal vein (Rieder et al. 2010). 
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1.4.2.Structure of adrenal steroids 
 
Testicular and ovarian cells, specific neuronal cells of the brain, trophoblast cells of the 
placenta and adrenal cortex are the only cells able to synthesise steroids from a cholesterol 
precursor. All steroids share a basic structure of a three cyclohexane rings and one 
cyclopentane ring (Figure 1-16).  
 
Figure 1-16 Standard structure of adrenal steroids, the numbers represent the carbon atoms 
and the letters designate the rings. 
 
 
Differences in biological activity are due to differing number of carbon atoms and the side 
groups on the basic ring structure.  Based on this, steroids are categorised into five major 
groups which are summarised in Table 1-2. 
 
41 
 
Chapter 1                                                                                                                                    General Introduction 
 
 
Table 1-2 Five major groups of adrenal steroid: oestrogen, androgen, progestogen, 
mineralocorticoid and glucocorticoid 
 
 
1.4.3.Steroidogenesis 
 
All the steroids defined in Table 1-2 are synthesised from the precursor cholesterol in the 
adrenal cortex. As discussed in section 1.4.1, each zone of the adrenal cortex is responsible 
for synthesis of a particular steroid subclass as a result of distinct enzymatic profiles.  
The initial step of steroidogenesis is the transportation of cholesterol from the outer to the 
inner mitochondrial membrane by steroidogenic acute regulatory protein (StAR) (Miller 
2007). 
Within mitochondria, cholesterol is converted to pregnenolone in all zones through the rate-
limiting enzyme, cytochrome P450scc (Thiboutot et al. 2003). This enzyme is a member of 
the cytochrome P450 superfamily, which has a diverse array of functions including reduction, 
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oxidation and hydroxylation. P450scc enzyme cleaves between C20 and C22 of the 
cholesterol side group and its action is NADPH dependent. After this step, the bio-pathways 
branch to synthesise mineralocorticoids, glucocorticoids or androgens. The ZG synthesises 
mineralocorticoids as it is the only zone which expresses aldosterone synthase (P450c18). 
Although the ZF and ZR lack P450c18, they both contain P450c17.  This enzyme has 17α-
hydrolylase and 17,20-lyase activity in ZF and ZR, respectively. Its 17α-hydrolylase activity 
results in 17-OH-pregnenolone synthesis and produces GCs as its final products. However, its 
17,20-lyase activity, which itself is dependent upon flavoprotein cytochrome b5 availability, 
predominates in ZR and generates adrenal androgen precursors, androstendione and 
dehydroepiandrosterone (DHEA) (Arlt & Stewart 2005). 
There are also a number of enzymes involved in the androgenic and oestrogenic metabolism 
including hydroxysteroid dehydrogenases (HSD), aromatase and 5α-reductases (5αR) 
(discussed in detail in section 1.4.4.4 and 1.4.5.4). Different isoforms of each enzyme have 
been identified and these enzymes act on multiple substrates, represented in Figure 1-17.  
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Figure 1-17 The major enzymatic reactions in 3 zones of adrenal cortex; allowing the specific 
steroid biosynthesis in each zone. These three zones are named glomerulosa, fasculata and 
reticularis which are responsible for synthesis of mineralocorticoids, glucocorticoids, and 
androgens respectively. 
 
 
1.4.4.Glucocorticoids 
1.4.4.1.Basic HPA axis 
 
The secretion of glucocorticoids by the adrenal glands is under the control of the 
hypothalamo-pituitary-adrenal (HPA) axis. Following neural stimuli from the brain, 
corticotropin-releasing hormone (CRH) is released by hypothalamic neurons and stimulates 
the release of adrenocorticotropic hormone (ACTH) from the anterior pituitary into the 
circulation which can finally lead to cortisol production by acting on the adrenal cortex 
(Taves et al. 2011).  
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Circulating ACTH binds the G protein-coupled melanocortin 2 receptor (MC2R) and 
melanocortin 2 receptor associated protein (MRAP) which are expressed on adrenal gland 
leading to the formation of the cAMP (Hofland et al. 2012). This induces activation of cAMP-
dependent protein kinase A (PKA) (see section 1.3.4.4.3) enhancing cholesterol uptake into 
the mitochondria by increasing StAR phosphorylation (Clark et al. 2000), mRNA expression 
and translation  (Clark et al. 1995).  
The whole process drives steroidogenesis and cortisol production. However, this loop is 
completed by the negative feedback of cortisol on hypothalamus and pituitary gland inhibiting 
CRH and ACTH synthesis and release (Figure 1-18).    
 
 
Figure 1-18 The hypothalamo-pituitary-adrenal (HPA) axis; a negative feedback mechanism 
presents whereby GC inhibits its own release. When cortisol is adequate, a negative feedback 
operates on pituitary gland and hypothalamus to reduce the output of corticotropin-releasing 
hormone (CRH) and adrenocorticotropic hormone (ACTH) which leads to a reduction in 
cortisol secretion. 
 
 
ACTH levels change in a 24 hours cycle in a circadian rhythm and as a consequence cortisol 
secretion follows the same pattern. The circadian rhythm in cortisol secretion peaks just 
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before waking, with a decline through the day and reaches its lowest level in the first few 
hours of the sleep. However, cortisol levels increase in response to stress independently of the 
circadian rhythm (Becker et al., 2001; Larsen et al., 2003). 
In addition to circadian rhythm, the HPA axis exhibits a rapid ultradian rhythm where 
glucocorticoids are released from the adrenal glands in hourly pulses. This causes rapid 
changes of hormone levels in the blood and also within the target tissues such as brain (Droste 
et al., 2008). Ultradian glucocorticoids pulses activates the glucocorticoid receptor and induce 
pulsatile glucocorticoid receptor (GR)-glucocorticoid response elements (GRE) interactions 
(GR and GRE are explained in section 1.4.4.2) which results in pulsatile gene transcription 
(Spiga et al., 2014). 
 
1.4.4.2.Glucocorticoid action 
   
The cellular effects of GCs are classically mediated via the glucocorticoid receptor (GR). The 
importance of the GR is highlighted by studies from global GR-deficient mice which show 
severe abnormalities and die after birth because of lung failure (Cole et al. 1995). GR is a 
ligand dependent nuclear receptor and has four main functional domains: N-terminal, DNA 
binding, and ligand binding domains, and a short amino acid sequence called the hinge region 
(Beato et al. 1996;Giguere et al. 1986) (Figure 1-19).  
In its inactive form, GR is part of a multi-protein complex within the cytoplasm. This 
complex consists of several proteins including two heat shock proteins (HSP90, HSP60), p59, 
calreticulin, (Beato, Truss, & Chavez 1996), immunophilin (Pratt and Toft 1997) and many 
other proteins all with differing function.  
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Figure 1-19 The glucocorticoid receptor. (NTD= N-terminal domain, DBD= DNA binding 
domain, LBD= ligand binding domain and hinge region).  
 
 
The GR- HSP90 association allows access by the steroid ligand through opening the GR 
hydrophobic steroid binding cleft. When the steroid hormone binds, the HSP-immunophilin 
complex dissociates and the GC bound receptor translocates into the nucleus. In the nucleus, 
GR interacts with glucocorticoid response elements (GRE) and activates the transcription of 
the target gene (Beato 1989;Beato, Truss, & Chavez 1996;Jantzen et al. 1987). GRE is formed 
of a palindromic sequence separated by a 3 bp hinge. GR binds to this symmetric structure as 
a dimer, which is known to be the active regulatory form. GR dimerises via its DNA binding 
domain to bind to GRE and induces gene expression (Drouin et al. 1993) (Figure 1-20). In 
contrast, GR activation can also down regulate gene transcription by binding with negative 
GRE sites with promoter regions and have a negative influence on HPA axis subsequently 
(Drouin et al. 1993).  
The GR has two alternative splice variants encoding GRα and GRβ, with different affinities 
for GC. In human, GRα mRNA expression is higher than the β isoform (Rivers et al. 1999). 
GRα has a high affinity for GCs, whereas GRβ has a low affinity for GCs and can also act as 
a negative regulator of GRα and inhibit its activity (Hollenberg et al. 1985;Oakley et al. 
1999).  
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Figure 1-20 The mechanism of glucocorticoid action; upon GC binding, GR disassociates, 
translocates into nucleus and regulates gene transcription. 
 
 
In addition to the classic genomic effects of GCs, there are also rapid nongenomic effects that 
can occur within minutes and without transcription. This can be mediated via alternative 
signalling pathways including G-protein, MAPK, cAMP and protein kinase C (PKC) (Losel et 
al. 2003). Such functions are initiated at the cell membrane through membrane-bound or 
cytoplasmic receptors (Stahn and Buttgereit 2008) and not affected GR or MR (Haller et al. 
2008).  
 
1.4.4.3.Metabolic actions of glucocorticoids 
 
GCs have a potent role in the regulation of growth and development including maturation of 
the lung and CNS, as well as the control of postnatal growth (Buckingham 2006). In addition, 
GCs have anti-inflammatory actions and play a critical role in regulation of carbohydrate and 
energy balance (Arlt and Stewart 2005).  
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With regard to carbohydrate metabolism, GCs promote glycogenolysis and gluconeogenesis 
(Mueller et al. 2012). The role of GCs in lipid metabolism is less clear and it is reported to 
have a tissue specific response (Djurhuus et al. 2002). GCs alone decrease lipogenesis but can 
act synergistically with insulin to augment lipid accumulation (Hazlehurst et al. 2013;Wang et 
al. 2012).  
GCs increase hepatic de novo lipogenesis, and have an opposite actions to insulin they 
stimulate lipolysis in adipose tissue (Baxter and Forsham 1972) resulting in increased 
circulating FFAs (Divertie et al. 1991;Xu et al. 2009). Regarding fat metabolism with liver, 
they also increase VLDL production (Taskinen et al. 1983) as well as TAG synthesis 
(Dolinsky et al. 2004).  
 
1.4.4.4.Pre-receptor glucocorticoid metabolism 
 
Endogenous GCs are metabolised through a series of enzymes that include the 11β-
hydroxysteroid dehydrogenases and the A-ring reductases, which act as pre-receptor 
signalling mechanism controlling the access of active GCs to both GR and MR (Eyre et al. 
2001).  
The two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD1/2) exist in both human 
and rodents. In human, they are responsible for interconversion of inactive cortisone and 
active cortisol while facilitates the conversion between inactive 11dehydrocorticosterone and 
active corticosterone in rodents. They play a key role in controlling the availability of cortisol 
to activate the GR. In contrast, endogenous glucocorticoids (cortisol and cortisone) are 
primarily inactivated via a series of enzymes, termed A-ring reductases. These enzymes, 5α-
reductases (5αRs) and 5β-reductase (5βR) (will be only referred as 5αR and 5βR in the 
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current study), convert cortisol and cortisone to dihydrometabolites which are then 
metabolised to tetrahydrometabolites by 3α-hydroxysteriod dehydrogenase (Nixon et al. 
2012). This results in reduced cortisol availability to bind and activate GR. A-ring reductases 
will be discussed in detail in section 1.4.5.4.   
 
1.4.4.4.1.11β-hydroxysteroid dehydrogenase type one 
 
11β-hydroxysteroid dehydrogenase type one (11β-HSD1) converts inactive cortisone to active 
cortisol and is highly expressed in metabolic target tissues including liver, adipose tissue, and 
muscle. Its role is therefore to enhance local GC action through regeneration of active steroid. 
11β-HSD1 possesses both oxoreductase (cortisone to cortisol) and dehydrogenase (cortisol to 
cortisone) activity that is dependent upon tissue and physical or developmental status of a cell 
type. The oxoreductase direction of 11β-HSD1 is due to the presence of abundant co-factor, 
NADPH which is generated by the enzyme, hexose-6 phosphate dehydrogenase (H6PDH) 
(Bujalska et al. 2008;Lavery et al. 2006). In vivo, 11β-HSD1 has predominantly (although not 
exclusively) oxoreductase role (Tomlinson et al. 2004)(Figure 1-21). 
Selective 11β-HSD1 inhibitors decrease GCs generation, improve glucose tolerance and 
insulin sensitivity, and cause weight loss in rodents and primates (Alberts et al. 2002;Barf et 
al. 2002). In clinical studies in patients with type 2 diabetes, selective 11β-HSD1 inhibitors 
decrease hepatic glucose production rate (without any changes in glucose disposal). In 
addition, studying the plasma, total and LDL cholesterol decreased without any alteration in 
HDL cholesterol or TAG level (Morgan and Tomlinson 2010).  
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Figure 1-21 Pre-receptor glucocorticoid metabolism; In liver, 11β-HSD1 acts predominately 
as an oxoreductase due to the presence of co-factor NADPH which is generated by H6PDH 
enzyme. However, 11β-HSD2 works as a dehydrogenase and requires NAD+ as a co-factor. 
 
 
1.4.4.4.2.11β-hydroxysteroid dehydrogenase type two 
 
11β-HSD2 is mainly expressed in mineralocorticoid target tissues including the kidney, colon, 
and malignant tissue including breast tumours (Yakirevich et al. 2008). In contrast with 11β-
HSD1, 11β-HSD2 is involved in inactivating cortisol to cortisone. 11β-HSD2 requires NAD+ 
as a co-factor to act in the dehydrogenase direction which results in inactivation of 
glucocorticoids (Kim and Cho 2010) (Figure 1-21). In plasma, cortisol is bound to 
corticosteroid-binding globulin (CBG), and to a lesser extend to albumin. Although CBG 
concentration is much lower than albumin in human plasma, it has much higher affinity for 
cortisol (Sandberg and Slaunwhite 1959). Therefore, over 80% of the plasma cortisol is bound 
to CBG (Brien 1981). Cortisol is able to bind and activate the MR with the same efficacy as 
its endogenous ligand, aldosterone and therefore defects in 11β-HSD2 (genetic or 
pharmacological) allow GC- activation of the MR leading to hypertension and renal sodium 
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retention, termed apparent mineralocorticoid excess (Palermo et al. 1996;Stewart et al. 1996). 
The role of 11β-HSD2 is, therefore, to prevent GC activation of MR (Edwards et al. 1988). 
 
1.4.5.Androgen 
1.4.5.1.Regulation of testosterone synthesis and secretion 
 
Testosterone is a steroid hormone belonging to the androgen group and is the predominant sex 
hormone in males. DHEA and its sulphate ester, DHEAS, are known as the most abundant 
steroid hormones in the body produced primarily in adrenal glands. Testosterone is derived 
from cholesterol and synthesised from the precursors dehydroepiandrosterone (DHEA) and 
androstenedione, primarily in the Leydig cells of the testes in males, and secondarily by the 
adrenal cortex in the outer portion of adrenal glands. In addition, a small amount is produced 
in the thecal cells of the ovary in females. Synthesis and secretion are regulated by the HP-
gonadal axis, where gonadotropin releasing hormone (GnRH) stimulates the pituitary to 
release luteinizing hormone (LH). Subsequently, LH stimulates the synthesis and release of 
testosterone from the testes (Rang et al. 1999). 
Testosterone is transported to target tissues via the circulation either as free testosterone or 
bound to specific plasma proteins. Circulating testosterone is bound to sex hormone binding 
globulin (SHBG) (68%) or weakly bound to albumin (30%) and only 1-2% remains unbound 
(Vermeulen and Verdonck 1968). The primary role of androgens is in the development of 
primary and secondary sexual characteristics, driving sexual differentiation, development and 
maintenance of the male phenotype (Silverthorn 1998). 
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1.4.5.2.Androgen action 
 
Testosterone is converted to Dihydrotestosterone (DHT) by 5αRs (see section 1.4.5.4). DHT 
binds the androgen receptor with higher affinity than testosterone and is believed to be the 
most potent circulating androgen (Janne et al. 1993). The androgen receptor (AR) is a ligand 
dependent nuclear receptor with four main structural and functional domains: N-terminal, 
DNA binding, ligand binding domain (LBD), and a short amino acid sequence called the 
hinge region (Figure 1-22).  
 
 
Figure 1-22 The androgen receptor. (NTD= N-terminal domain, DBD= DNA binding 
domain, LBD= ligand binding domain and hinge region).  
 
 
In its inactive form, AR is a part of a multi-protein complex within the cytoplasm. This 
complex consists of several proteins including HSP molecules (HSP90, 70 and 56) 
cytoskeletal proteins and other chaperones (Lonergan and Tindall 2011).  
90% of free testosterone is converted to DHT on entering cells of the prostate and genital 
tissues. Conformational changes in the AR occur once DHT binds to the LBD. Upon binding, 
the complex disassociates and then translocates to the nucleus. In the nucleus and upon 
binding to DNA, AR dimerises via its DNA binding domain (Truss and Beato 1993). The AR 
dimer binds to androgen response elements (ARE) and activates gene transcription 
(Brinkmann et al. 1999)(Figure 1-23).  
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Figure 1-23 The mechanism of androgen action; upon DHT binding, AR disassociates, 
translocates into nucleus and regulates gene transcription.  
 
 
Testosterone can also directly bind to the AR, with the similar mechanism to DHT, resulting 
in gene transcription. However, Testosterone can be metabolised via alternative pathways for 
example, conversion to 17β-estradiol, through the enzymatic activity of aromatase, and 
subsequent activation of the oestrogen receptor (Rommerts 2004). In addition, testosterone 
may also act via non-genomic mechanisms binding a G-protein coupled receptor which 
initiates a cAMP-mediated pathway. This regulates intracellular calcium concentrations which 
can further activate intracellular signalling, influencing specific proteins and cellular 
responses (Benten et al. 1999). 
 
1.4.5.3.Metabolic actions of androgens  
 
Testosterone plays a key role in lipid, carbohydrate and protein metabolism. In liver, 
testosterone deficiency is associated with elevated TAG and cholesterol, decreased insulin 
sensitivity and impaired glucose tolerance (Kelly and Jones 2013). In an in vitro study using 
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human liver cell line, testosterone increased insulin receptor mRNA expression (Parthasarathy 
et al. 2009). Similarly, studying the orchidectomised rats, insulin receptor mRNA and protein 
expressions were significantly increased following testosterone administration (Muthusamy et 
al. 2011). In addition, reduced GLUT4 mRNA expression was observed in liver, adipose and 
muscle tissue by testosterone depreciation via castration of male rats (Muthusamy et al. 2009).  
The role of androgens on hepatic lipid metabolism remains controversial. Vozke et al. (2010) 
reported that low testosterone was associated with hepatic steatosis. Interestingly, DHT has 
been predicted to have an opposing action with increased hepatic Stearoyl-CoA desaturase1 
(SCD1) (Moverare-Skrtic et al. 2006). SCD1 is predominantly expressed in liver, and 
specifically converts de novo lipogenesis-derived saturated fatty acids to monounsaturated 
fatty acids (Li et al. 2009). SCD1 activity, under a high sugar diet, demonstrates a strong 
negative correlation with liver fat content which suggests that SCD1 activity protects from fat 
accumulation (Silbernagel et al. 2012).  
Treating the human prostate cancer cell line LNCaP with synthetic androgen, R1881, 
increased the expression of de novo lipogenesis rate limiting enzymes such as ACC and 
FASN through stimulating expression of sterol regulatory element binding proteins 
(SREBPs). SREBPs are transcription factors that control and coordinate lipogenic enzymes 
(Swinnen et al. 1997).  Studies in animal and human adipose cell lines show that both 
testosterone and DHT inhibit AMPK by down regulating LKB1 expression (McInnes et al. 
2012a). 
In addition, testosterone effects differ in insulin target tissues and the molecular mechanisms 
underpinning the testosterone action on regulating metabolic pathways are not clear. Plus, 
testosterone metabolic effects may be different in the presence / absence of insulin (Kelly and 
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Jones 2013). Therefore, detailed characterisation of testosterone effects in different insulin 
target tissues in presence/absence of insulin is warranted. 
 
1.4.5.4.Pre-receptor androgen metabolism  
1.4.5.4.1.5αRs 
 
In addition to their role in GC clearance by converting cortisol to its dihydrometabolites, 5αRs 
can reduce testosterone to the more potent androgen, DHT, altering the steroid availability 
(less cortisol, more DHT) to bind their nuclear receptors and thereby regulating gene 
transcription (Figure 1-24). However, 5αRs have higher affinity for androgens compared to 
GCs (Andersson and Russell 1990).  Apart from GC and androgens, 5αRs also accept many 
other steroid substrates including progesterone and mineralocorticoids (Purdy et al. 1990).  
5αRs are microsomal enzymes and are NADPH dependent (Frederiksen and Wilson 1971). 
Three isoforms of 5αRs have been identified to date, with different biochemical properties 
and sensitivity to substrates, which will be discussed in detail. 
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Figure 1-24 5αRs convert GCs to their less active dihydrometabolites with subsequent 
conversion to tetrahydrometabolites. In addition, they catalyse the conversion of testosterone 
to the more potent androgen, DHT. Therefore, 5αRs activity make less cortisol and more DHT 
available to attach their nuclear receptor, translocate to the nucleus and activate the 
transcription of the gene. 
 
 
1.4.5.4.1.1.5αR1 
 
The gene encoding 5αR1 (SRD5A1) was identified on chromosomes 5 and has 5 exons and 4 
introns. 5αR1 is a hydrophobic protein with a PH optimum of 6-8.5 (Andersson et al. 1991). It 
consists of 259 amino acids with a molecular weight of 29kDa (Labrie et al. 1992;Russell and 
Wilson 1994). It is expressed in both human and mouse liver and also in skin (nongenital) and 
adipose tissue (Russell and Wilson 1994).  
Although testosterone is the most widely recognized substrate of this enzyme, progesterone 
has a lower Km and therefore enzymatically may be the preferred substrate (Andersson and 
Russell 1990;Normington and Russell 1992).  
Dutasteride is a dual inhibitor of both isoforms, 5αR1 and 5αR2, reducing circulating DHT by 
nearly 95% compared to the baseline (Schwartz et al. 1997). MK-386 was reported to be the 
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selective inhibitor of 5αR1 with 90% efficiency (Schwartz et al. 1996) but this compound is 
neither commercially available nor used in clinical practice.  
The biological diagnosis of 5αR deficiency is normally defined by an increase in the T/DHT 
ratio. To date, no mutation but several polymorphisms have been identified in SRD5A1. For 
example at exon 1, single nucleotide polymorphism (SNP); rs248793 (G>C), has been 
associated with an increase in DHT/T ratio suggesting an elevated 5αR1 activity  (Ellis et al. 
2005). DHT is the most potent hormone considered to be important in prostate cancer and 
therefore 5αR activity is important in determining the prostate cancer risk. In 426 individuals 
(205 controls vs. 221 with prostate cancer), several SNPs in different 5αR isoforms were 
chosen to be studied. They measured the serum DHT and when they correlated this data with 
the patients’ genotype, they found out that in rs1691053 (SRD5A1) SNP the patients with GG 
genotype has the highest serum DHT while the AA genotype has the lowest. They showed 
that GG genotype is the potent genotype in the prostate cancer patients compared to controls 
and therefore suggested that this SNP in SRD5A1 is associated with increased prostate cancer 
risk through increasing 5αR activity (Setlur et al. 2010). 
 
1.4.5.4.1.2.5αR2 
 
The gene encoding 5αR2 (SRD5A2) lies on chromosomes 2 and has 5 exons and 4 introns. 
5αR2 is also a hydrophobic protein with a PH optimum around 5 (Andersson et al. 1991). It 
has 254 amino acids with a molecular weight of 28 kDa, and shares less than 50% homology 
with 5αR1 (Labrie et al. 1992;Russell and Wilson 1994). 
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5αR2 is expressed in human liver but not in mouse liver. 5αR2 is predominantly expressed in 
androgen-target organs such as prostate, epididymis and seminal vesicles (Russell and Wilson 
1994).  
Finasteride is a highly specific enzyme for inhibition of 5αR2. In comparison with 5αR1, 
5αR2 has much higher affinity for androgen substrates such as testosterone. Several mutations 
(Figure 1-25) and polymorphisms have been identified throughout the coding and non-coding 
regions of SRD5A2 (Maimoun et al. 2011). Since 5αR2 converts testosterone to a more potent 
androgen (DHT), mutations in this enzyme lead to 46XY DSD (Disorder of Sex 
Development) where external genitalia fail to develop normally. However, excessive 
androgen generation through the activity of 5αR2 has been implicated in the following 
conditions: polycystic ovary syndrome, breast cancer, prostate cancer and male pattern 
baldness (Ellis et al. 1998;Jakimiuk et al. 1999;Ji et al. 2004;Labrie et al. 1993). 
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Figure 1-25 Mutations identified in SRD5A2; because of consanguinity the prevalence of 
variant mutations would cluster differently in variant ethnic population (Maimoun et al. 
2011). 
 
 
A comparison of human 5αR1 and 2 is summarised in Table 1-3. 
 5αR1 5α2 
Gene Structure 5 exons, 4 introns  5 exons, 4 introns  
Gene SRD5A1 SRD5A2 
Chromosome 
Location 
5p15 2p23 
Size 259 amino acids, 29 
kDa 
254 amino acids, 28 kDa 
 
Tissue Distribution 
Liver, nongenital skin, 
prostate, brain, adipose 
tissue 
Prostate, epididymis, seminal 
vesicle, genital skin, uterus, Liver, 
breast, hair follicle, placenta, 
brain 
pH optima Neutral to basic Acidic or neutral  
Prostate Level Low High 
Substrate (T) affinity Low High 
 
Table 1-3 Comparison of human 5αR1 and 2 isoforms. 
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1.4.5.4.1.3.5αR3 
 
5αR3, encoded by SRD5A3, was identified  recently (Uemura et al. 2008) and its role is less 
clear, but thought to be more important in reducing non-steroidal substrates (Cantagrel et al. 
2010a). However, using an SRD5A3 construct, it is able to convert testosterone (Uemura et 
al. 2008) and androstenedione (Yamana et al. 2010) to their 5α-dihydro-metabolites. Its major 
role however is likely to be for N-linked glycosylation in post-transcription modification of 
proteins which presents with mutations in 5αR3 gene that result in a congenital disorder of 
glycosylation (CDG) (Kahrizi et al. 2011). 
 
1.4.5.4.2.5βR 
 
5βR gene (AKR1D1) is located on chromosome 7. AKR1D1 is also highly expressed in 
hepatocytes and its crystal structure has been determined (Faucher et al. 2008). AKR1D1 is 
able to metabolise both cortisol and cortisone and following 3α-HSD activity generates 5β-
tetrahydrocortisol (5βTHF) and 5β-tetrahydrocortisone (5βTHE). While 5αRs reduced 
testosterone to 5α-dihydrotestosterone, 5βR converts progesterone to 5β-pregnane-3,20-diol 
(Figure 1-26).  
Moreover, 5βR has a role in bile acid production and mutations in AKR1D1 gene lead to 
cholestatic liver disease in infants which can progress to liver failure (Lemonde et al. 2003). 
AKR1D1 knockout mice showed altered hepatic steroid with a 30±4% decrease in cortisone 
clearance and a 3.9±0.5-fold increase in the ratio of 5α-cortisone/cortisol metabolite 
generation, when compared to wildtype. In addition, bile acid concentrations were lower in 
AKR1D1 knockout male and female mice, with a dramatic change in male in comparison 
with wildtype (females: 310±67 pmol/mg (WT), 113±23 pmol/mg (knockout); male: 
61 
 
Chapter 1                                                                                                                                    General Introduction 
 
1164±626 pmol/mg (WT), 122±42 pmol/mg (knockout) p< 0.01, mean ± s.e). AKR1D1 
knockout mice have a sexually dimorphic metabolic phenotype, where female knockouts are 
protected from the metabolic consequences of a high fat diet with increased insulin sensitivity 
and improved glucose tolerance (Gathercole et al. 2015). These findings suggest that 
AKR1D1 inhibition could be beneficial in female patients with metabolic disease, although 
further work is needed to establish the mechanisms by which AKR1D1 regulates metabolism, 
and whether it has potential as a therapeutic target.  
 
 
 
Figure 1-26 The major metabolites of cortisone and cortisol and the enzymes involved 
catalysing the conversions. 5αR metabolises cortisol to 5α-dihyrocortisol with a following 
conversion to 5α-tetrahydrocortisol (5αTHF) by 3α-HSD. However, 5βR is able to metabolise 
both cortisol and cortisone and following 3α-HSD activity generates 5β-tetrahydrocortisol 
(5βTHF) and 5β-tetrahydrocortisone (5βTHE). 
 
 
1.5.Regulation of hepatic lipid metabolism by insulin, glucocorticoids 
and androgens  
 
Circulating lipids are important in cardiovascular disease (CVD); there is a strong association 
between elevated serum triglyceride and CVD (Sarwar et al. 2007). In addition, increased 
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level of total and LDL cholesterol is observed in the development of CVD. However, there is 
a strong inverse association between HDL cholesterol levels and CVD, and elevated total 
cholesterol/HDL cholesterol ratio has been used as a marker of severity of CVD (Platt et al. 
2015). Most of these lipids are produced and regulated within the liver. There are various 
transcriptional and post transcriptional factors, as well as hormones contributing to the 
regulation of hepatic lipogenesis. The liver X receptor (LXR) is an important transcriptional 
regulator by controlling the expression of lipogenic genes such as ACC, FAS and sterol 
regulatory element binding protein 1c (SREBP-1c) (Repa et al. 2000). SREBP-1c itself is a 
transcription factor which drives the expression of lipogenic genes involved in TAG synthesis 
and de novo lipogenesis (Kim et al. 1998).  
Post transcriptional regulation is also crucial, since phosphorylation of key lipogenic enzymes 
regulates their activity. In this thesis, I have focused on hormonal regulation of hepatic 
lipogenesis, in particular the role insulin, GCs and androgens and therefore the effect of these 
hormones upon lipogenesis is discussed in detail. 
 
1.5.1.Insulin and hepatic lipid metabolism  
 
Insulin increases de novo lipogenesis via several distinct pathways, in particular through the 
PI3K-dependent pathway, (PI3K/AKT/mTOR), which regulates lipogenic gene expression 
(ACC1 and FAS) by increasing SREBP-1c expression (Azzout-Marniche et al. 2000), and 
VLDL production (Savage and Semple 2010). In addition, insulin represses autophagy, which 
is a response to starvation, and leads to hepatic lipid degradation (Rautou et al. 2010). Overall 
therefore, insulin increases lipogenesis and decreases lipid degradation in hepatocytes.  
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Although the precise mechanisms are not clear, there is an association between hepatic 
steatosis and insulin resistance. This may be due to increased fatty acid concentrations 
available for esterification to TAG as a consequence of inadequate suppression of lipolysis of 
adipose tissue. Interestingly however, even in the insulin resistant state, the effect of insulin to 
augment lipogenesis is unexpectedly maintained and even enhanced by hyperinsulinemia 
whilst the fatty acid oxidation is decreased (Nagle et al. 2009).  
 
1.5.2.The effect of glucocorticoids on hepatic lipid metabolism and 
NAFLD 
 
GCs are important regulators of hepatic lipid metabolism genes including FASN and ACC1/2 
(Wang et al. 2012), promoting de novo lipogenesis and FFA usage and stimulating hepatic 
steatosis (Dolinsky et al. 2004;Norrheim et al. 1990). GCs also regulate fatty acid and 
cholesterol synthesis (Giudetti and Gnoni 1998) and HDL processing in hepatocytes 
(Bocharov et al. 1995), contributing to the lipid accumulation whilst reducing VLDL 
secretion. However, this decreased TAG secretion has not been consistent across all studies 
(Dolinsky et al. 2004). 
In human foetal hepatocytes, GCs cause a dose-dependent increase in cholesterol synthesis 
(Carr and Simpson 1984). Some studies suggest that GCs alone can increase lipid 
accumulation in hepatocytes (Dich et al. 1983;Mangiapane and Brindley 1986) while others 
have shown a synergistic relationship with insulin to augment lipid storage, by increasing 
synthesis and decreasing secretion (Amatruda et al. 1983;Mendoza-Figueroa et al. 1988).  
Rodent models have enhanced our understanding of the role of GCs in the pathogenesis of 
NAFLD. Rodents develop hepatic steatosis after being treated with corticosterone (D'Souza et 
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al. 2012;Morgan et al. 2014). The suggested mechanisms underpinning this were reduced 
TAG secretion, increased DGAT expression and FFA delivery to the circulation. In addition, 
GC excess in combination with a high fat diet was associated with fibrosis (D'Souza et al. 
2012). Increased CD36 expression has been reported following GC treatment, suggesting a 
potential magnitude to lipid accumulation within the liver (Morgan et al.  2014). Selective 
hepatic GR knockdown in mice ameliorates hepatic steatosis. These mice show reduced fat 
accumulation within the liver, decreasing fatty acid uptake and increasing ACC2 and CPT1 
expression (Lemke et al. 2008). 
In humans, the relationship between GCs and the pathogenesis of NAFLD has not been 
explored in detail. Patients with GCs excess (Cushing’s syndrome) develop NAFLD in up to 
20% of the cases, as measured using computerised tomography (Rockall et al. 2003). 
Furthermore, there is some evidence to suggest that patients with type 2 diabetes and NAFLD, 
may display sub-clinical hypercortisolism (Targher et al. 2005). Whilst activation of HPA 
axis has been reported in patients with NAFLD (Zoppini et al. 2004), larger epidemiological 
studies have shown no association between circulation cortisol levels and NAFLD (Hubel et 
al. 2015). These inconsistencies in these data may point towards a more tissue specific role of 
GCs in the pathogenesis of the NAFLD. 
 
1.5.3.The effect of androgens on hepatic lipid metabolism and 
NAFLD 
 
The role of androgens in the pathogenesis of metabolic disease remains controversial. There is 
evidence documenting an association between hypogonadism and NAFLD (Kim et al. 
2012;Volzke et al. 2010) with some evidence for improvement following androgen treatment 
(Haider et al. 2010;Hoyos et al. 2012). Assessing with CT imaging, obese men taking 
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testosterone for 18 weeks have demonstrated a significant decrease in hepatic fat (Hoyos et al. 
2012). However, a recent study using MRI has reported no effect of testosterone therapy on 
liver fat in older men with mobility limitation (Huang et al. 2013).  
Studying animal models, orchidectomised mice on a high fat diet increased hepatic fat when 
compared to controls. However, testosterone administration to these mice was able to 
ameliorate the hepatic steatosis (Senmaru et al. 2013). In addition, hepatic AR knockout mice 
on a high fat diet developed insulin resistance and hepatic steatosis. This observation was 
made in male but interestingly not in female mice (Lin et al. 2008). Adipose-specific AR 
knockout mice on high fat diet resemble human type 2 diabetes, with early insulin resistance 
and evolving insulin deficiency, and unlike liver-specific knockout mice there was no 
evidence of hepatic steatosis. In addition, compared to the liver-specific AR knockout mice, 
the nonesterified fatty acids (NEFA) levels were normal in Adipose-specific AR knockout 
mice; suggesting the observed insulin resistance is unlikely to be related to the spillover of the 
fatty acids to extra adipose organs and possibly via the dysregulation of insulin sensitising 
adipokines (McInnes et al. 2012b). 
Interestingly, women with hyperandrogenic polycystic ovary syndrome (PCOS) are 
predisposed to developing NAFLD (Jones et al. 2012). However, the prevalence of NAFLD is 
higher in white men compared to white women (Browning et al. 2004). This sex dimorphism 
in hepatic steatosis was shown to be due to the combination of the prolonged increase in de 
novo lipogenesis and lower dietary fatty acid oxidation in men compared to women which 
may induce fatty acid esterification and storage pathways, leading to a greater VLDL 
production or increased liver fat accumulation (Pramfalk et al. 2015). 
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Overall although androgens have been implicated in the pathogenesis of NAFLD, the exact 
role of testosterone in the molecular mechanism of steatosis remains controversial with 
conflicting data in the published literature. 
 
1.6.5αR and NAFLD 
1.6.1.5αR knockout  
 
Recently, the role of 5αRs in GC and androgen metabolism in the context of NAFLD and 
metabolic phenotype has been highlighted in studies using 5αR1 and 5αR2 knockout mice. 
Mice were fed normal chow or American lifestyle induced obesity syndrome (ALIOS) diet, a 
high fat high fructose diet generated hepatic steatosis and inflammation (Tetri et al. 2008), for 
6 or 12 months. Mice, lacking 5αR1 (but not 5αR2), developed greater hepatic steatosis 
compared to WT animals. In addition, at 12 months, 60% of mice fed on ALIOS diet 
developed hepatocellular carcinoma. However, only 20% of 5αR2 knockout mice and none of 
5αR1 knockout mice developed hepatocellular carcinoma, at 12 months. This suggests that 
mice lacking 5αR1 are prone to hepatic steatosis but protected from hepatocellular carcinoma. 
Mice do not express hepatic 5αR2 which might explain the conflicting data where 5αR1 
knockout mice develop hepatic steatosis but not 5αR2 knockout mice (Dowman et al. 2013).  
Additional studies on 5αR1 knockout mice indicate an approximate 80% reduction in 
glucocorticoid clearance compared to wildtype (Livingstone et al. 2014). Furthermore, on 
high fat diet feeding they develop greater weight gain, hyperinsulinaemia, hepatic steatosis 
and are more prone to hepatic fibrosis (Livingstone et al. 2015). 
 
67 
 
Chapter 1                                                                                                                                    General Introduction 
 
1.6.2.5αR as a therapeutic target 
 
There is a relationship between 5αR activity and metabolic phenotype, as measured by urinary 
steroid metabolites. 5αR activity increases with BMI and also with NAFLD but decreases 
with weight loss (Crowley et al. 2014;Konopelska et al. 2009;Tomlinson et al. 2008). In 
addition, increased 5αR activity has been reported in NASH but not in simple steatosis, 
suggesting differences in activity according to the stage of the disease (Ahmed et al. 2012). 
Liver biopsy studies have demonstrated conflicting data; 5αR2 mRNA expression level was 
reported to be increased in patients with NASH, but in other studies no changes were 
observed in hepatic 5αR1 and 2 expression levels across the spectrum of NAFLD. However, 
immunohistochemical staining demonstrated increased protein levels of 5αR1 but not 5αR2 as 
NAFLD develops (Dowman et al. 2013).  
Very recently, in a clinical study, dual inhibition of 5αR1 and 2 with dutasteride has been 
shown to be associated with decreased peripheral insulin sensitivity. However, specific effects 
on the liver were not examined (Upreti et al. 2014). In a recent study, healthy male volunteers 
were treated with finasteride or dutasteride for a period of three weeks, dutasteride treatment 
increased hepatic insulin resistance and the rate of hepatic de novo lipogenesis. However, 
finasteride was without effect; suggesting that either 5αR1, or dual 5αR1 and 2, inhibition is 
required for the observed increase in hepatic lipid accumulation (Hazlehurst et al. 2016). 
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1.7.Unanswered questions 
 
The rational of this work is based upon the phenotype of NAFLD. Glucocorticoids and 
androgens have both been implicated in the pathogenesis of NAFLD; androgen deficiency in 
males, androgen excess in females and glucocorticoid excess in both sexes are associated with 
NAFLD. However, the precise molecular mechanism underpinning hepatic lipid accumulation 
regulated by these steroid hormones, is not clear. Insulin enhances fat mass and it is clear that 
GCs induce insulin resistance. Thus, GC action upon global insulin sensitivity is likely to be 
the combination of metabolic events in different target organs. Previously within our group, 
the effect of GCs and insulin upon fat metabolism have been studied in adipose tissue and 
skeletal muscle. The metabolic effects of GCs on liver insulin sensitivity and lipid metabolism 
are complex but it is widely believed that GCs induce insulin resistance, studying mainly 
rodents (Guillaume-Gentil et al. 1993). However, studies in human liver models have not 
been performed.  
In addition, GCs and androgens are regulated at the pre-receptor level by A-ring reductases. 
There is an emerging role for overexpression of A-ring reductases as a therapeutic target in 
the treatment of metabolic diseases, in particular NAFLD. However, the effect of these 
enzymes upon hepatic lipid metabolism in human liver has not been stablished in detail and 
most studies used rodents. Therefore, there is a need to characterise A-ring reductases using 
liver human models and also to see if manipulation of these enzymes can alter the metabolic 
phenotype. 
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1.8.Aims 
 
• Define the impact of GCs upon lipid homeostasis and insulin sensitivity in human 
hepatocytes (Chapter ‘3’). 
 
• Characterise the impact of androgens upon lipid homeostasis and insulin sensitivity in 
human hepatocytes (Chapter ‘4’). 
 
• Determine the contribution of pre-receptor GC metabolism in the development of an 
unfavourable metabolic phenotype in human liver cultures of hepatocytes (Chapter 
‘5’).  
 
• Study if manipulation of pre-receptor GC metabolism can alter the metabolic 
phenotype (Chapter ‘5’). 
 
• Define putative mutations or polymorphisms through genetic sequencing of SRD5A1 
and 2 in patients with abnormal steroid metabolite ratios suggesting an altered 5αR 
activity (Chapter ‘6’). 
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Chapter 2 General Methods 
 
Methods specific to individual chapters are found in the methods sections of those chapters. 
Unless otherwise stated methods were carried out using Sigma -Aldrich Chemical Company 
(Pool, Dorset, UK) reagents and cell culture plastic ware from Corning (Artington, Surrey, 
UK). 
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2.1.Cell culture 
2.1.1.C3A  
2.1.1.1.Cell line 
 
C3A cells are a subclone of the hepatoma-derived HepG2 cell line (Parvez et al. 2011) which 
express the GC receptor but unlike HepG2 cells they lack 5αR2 expression and that is the 
reason they are the preferable model in this study. However, they lack IRS2 expression which 
was confirmed in this study, and therefore the Huh 7.5 cells were used as a more insulin 
sensitive cell line. In addition, Huh 7.5 and HepG2s carry a loss of function mutation, I148M, 
in PNPLA3 gene which is the best genetic predictor for NAFLD and increases TAG 
accumulation (Dutta 2015). C3As have not been checked for this gene but they are a subclone 
of HepG2s and most probably they represent the same mutation. The origin of C3A cells is 
the liver of a 15 year old Caucasian male, with hepatocellular carcinoma. Liver cells were first 
extracted and then immortalized by transfection host. One of the important characteristics of 
C3As is the ability to grow in low glucose media. This cell line was purchased from ATCC 
(Middlesex, UK) and cells were delivered frozen. 
 
2.1.1.2.Proliferation 
 
Cells were maintained in cell bind 25cm2 TC flasks in 5mL of MEM (PAA, Somerset, UK) 
supplemented with 1% L-Glutamine, 1% Penicillin/Streptomycin, 1% Mem non- essential 
amino acid and 10% Foetal Calf Serum (FCS) at 37oC in a humidified atmosphere of air with 
5% CO2. At 70% confluence cells were trypsinised and split 1 in 3 into fresh flasks. Prior to 
experiments, cells were trypsinised and subcultured into 24 well CellBind TC plates. Medium 
was replaced every two days and cells were cultured until 70% confluent (Figure2-1). 
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Figure 2-1 C3As morphology after day 2 (a) and 3 (b) of proliferation. 
 
 
The nutrient contests of MEM media is shown in table 2-1. The reason this media was chosen 
is the low glucose contents (1g/L) as higher glucose concentration can drive de novo 
lipogenesis (Table 2-1).   
 
Component  g/L Component g/L 
Amino Acids Inorganic Salts 
L-Arginine • HCl 
L-Cystine • 2HCl 
L-Glutamine 
L-Histidine • HCl • H2O 
L-Isoleucine 
L-Leucine 
L-Lysine • HCl 
L-Methionine 
L-Phenylalanine 
L-Threonine 
L-Tryptophan 
L-Tyrosine • 2Na • 2H2O 
L-Valine 
Choline Chloride 
Folic Acid 
myo-Inositol 
Niacinamide 
D-Pantothenic Acid (hemicalcium) 
Pyridoxal • HCl 
Riboflavin 
Thiamine • HCl 
0.126 
0.0313 
0.292 
0.042 
0.052 
0.052 
0.0725 
0.015 
0.032 
0.048 
0.01 
0.0519 
0.046 
0.001 
0.001 
0.002 
0.001 
0.001 
0.001 
0.0001 
0.001 
Calcium Chloride 
Magnesium Sulfate (anhydrous) 
Potassium Chloride 
Sodium Chloride 
Sodium Phosphate Monobasic 
(anhydrous) 
 
0.2 
0.09767 
0.4 
6.8 
0.122 
Other 
Glucose 
Phenol Red • Na 
1 
0.011 
Table 2-1 Detailed nutrient contents of MEM media, it is a low glucose media with glucose 
concentration of 1g/l. 
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2.1.1.3.Freezing down 
 
At 70% confluence, cells were trypsinised and centrifuged at 1500 g for 5 min. The pellet was 
resuspended in 1mL of freezing serum, FCS with 10% dimethyl sulfoxide (DMSO).  Cell 
mixture was aliquotted into 1.5mL cyrovials and slowly frozen at the rate of 1oC/ min in a 
cryofreezing chamber (Nalgene, Hereford, UK) at -80oC overnight. Cells were transferred to 
liquid nitrogen for long-term storage afterwards. 
 
2.1.2.Huh7.5  
2.1.2.1.Cell line 
 
Huh7.5 cells are well differentiated hepatoma-derived cell line that was taken from a male 
donor. These cells were a gift from the liver laboratories (IBR 5th floor, Clinical and 
experimental medicine department, University of Birmingham) and all experiments on 
Huh7.5 cells were carried out with the help of Dr. Reina Lim Teegan. Cells were cultured in 
MEM with 10% FCS and split into 24 well plates.  
 
2.1.2.2.Proliferation 
 
Cells were maintained in cell bind 25cm2 TC flasks in 5mL of MEM (PAA, Somerset, UK) 
supplemented with 1% L-Glutamine, 1% Penicillin/Streptomycin, 1% Mem non- essential 
amino acid and 10% Foetal Calf Serum FCS at 37oC in a humidified atmosphere of air with 
5% CO2. At 70% confluence cells were trypsinised and split 1 in 3 into fresh flasks. Prior to 
experiments, cells were trypsinised and subcultured into 24 well CellBind TC plates. Medium 
was replaced every two days and cells were cultured until 70% confluent. 
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2.2.Primary human hepatocytes 
 
Cryoplatable human hepatocytes were purchased from BioreclamationIVT Technologies 
(Baltimore, USA). Cryoplatable hepatocytes were isolated from whole livers not resections 
and the tissue was cryopreserved the same day to receive the highest quality hepatocytes. 
Each order was made considering the donor serology and phenotype provided by the 
company. Cells were delivered in a liquid nitrogen shipping container and transferred to 
liquid nitrogen on arrival. 
 
2.2.1.Thawing procedures 
 
Prior to thawing, InVitroGRO CP medium (BioreclamationIVT Technologies, Baltimore, 
USA) was pre-warmed to 37oC and supplemented with Torpedo Antibiotic mix (1mL per 
45mL CP medium). Primary hepatocyte vials were brought up on ice from liquid nitrogen 
storage. The vials were then placed in a 37oC water bath and shaken gently until the cells 
pulled away from the vial wall. Cells were then transferred to the pre-made CP medium and 
remaining cells in the vial were washed with 1mL of hepatocyte suspension. The thawing step 
was done in 90-120 seconds in order to get the best viability (approximately 70% healthy 
cells) and then this viability and also the cell count were measured using Trypan blue. The 
hepatocyte containing tube was inverted 3 times to resuspend the cells and the homogeneous 
suspension was gently plated by placing the pipet on the side of the wells. For seeding, the 
acceptable concentration for 24 and 12 well plates is 350,000 and 700,000 cells per well 
respectively, in order to reach 70% viability. BD BioCoat collagen I cell culture plates (BD 
Biosciences, New Jersey, USA) were only applied as advised by BioreclamationIVT. 
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2.2.2.Cell maintenance 
 
Cells were plated on collagen using InVitroGRO CP medium (BioreclamationIVT 
Technologies, Baltimore, USA) and after four hours this was replaced by InVitroGRO HI 
medium supplemented with Torpedo Antibiotic mix (1mL per 45mL HI medium). Cells were 
incubated at 37oC in a humidified atmosphere of air with 5% CO2 overnight. Having found 
many unattached cells in some primary cultures and following consultation with 
BioreclamationIVT, cells were kept in InVitroGRO CP medium for 18 hours and only were 
replaced with fresh CP medium if required (Figure 2-2). All the media were aspirated and 
replaced carefully to avoid disrupting cell monolayer.  
 
 
 
 
 
 
 
Figure 2-2 Primary human hepatocytes morphology after day 2. 
 
 
2.3.Protein extraction 
2.3.1.Principle 
 
In order to extract proteins, monolayer cells were lysed in buffer containing protease and 
phosphatase inhibitors, and detergent. This lysate was used to break the cell membranes and 
insoluble cell debris removed by centrifugation subsequently. 
76 
 
Chapter 2                                                                                                                                          General Methods 
 
2.3.2.Methods 
 
Cells were washed on ice with PBS and 100μl of RIPA buffer (1mM EDTA, 150mM NaCl, 
0.25% SDS, 1% NP40, 50mM Tris pH 7.4, supplemented with protease inhibitor (Roche, 
Sussex, UK) and phosphatase inhibitor (Thermofisher, Surrey, UK) was added per well of a 
24 well plate. Cells were scraped with a 1mL syringe plunger and lysate transferred into 
Eppendorf tubes and then incubated at -80ºC for 10 to 20 min. The lysates were thawed on ice 
and centrifuged at 12000 g for 15 min at 4oC. Finally the supernatants, containing soluble 
proteins, were transferred to new Eppendorf tubes and stored at -80oC. 
 
2.4.Measuring protein concentration 
2.4.1.Principle 
 
Total protein concentrations were measured using the BioRad RC DC protein assay (BioRad, 
Herts, UK). This colourmetric assay is based on the reaction of protein with an alkaline 
copper tartrate solution and then reduction of Folin reagent. This generates a reduced Folin 
species with a characteristic blue colour, with a maximum absorbance at 750nm and a 
minimum absorbance at 405nm.  
 
2.4.2.Methods 
 
Protein assays were carried out according to the manufacturer protocol (BioRad, Herts, UK) 
in a 96 well plate. To make protein standards, bovine serum albumin (BSA) was dissolved in 
RIPA buffer and then serially diluted to obtain the following concentrations: 0, 0.5, 1, 2, 4 
and 6 mg/mL. 5 µl of either sample or protein standards was added per well in duplicate. 
Subsequently, 20µl of solution A (alkaline copper tartrate solution) and 200µl of solution B 
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(Folin solution) were added per well. After incubation for 10min at room temperature the 
absorbance was read at 690nM on a vector3 1420 multilabel counter (PerkinElmer, Bucks, 
UK). 
 
2.5.Western blotting 
2.5.1.Principle 
 
This method is performed to measure the relative amounts of specific protein in a mixed 
protein sample. Prior to western blotting, protein samples are boiled to remove all proteins’ 
secondary and tertiary structures. Then proteins are separated by size using SDS-Page 
electrophoresis.  
After protein separation, they are transferred to a polyvinylidene difluoride (PVDF) or 
nitrocellulose membrane. This membrane is blocked using a solution containing a generic 
protein such as milk or BSA to prevent non-specific binding to the membrane and 
subsequently incubated with a primary antibody that binds specifically to the protein of 
interest. The membrane is then incubated with the secondary antibody which is conjugated to 
horseradish peroxidise (HRP) and directed against the primary antibody. HRP catalyses the 
oxidation of a luminal substrate producing blue light. This reaction is captured on a 
photographic film.  
 
2.5.2.Methods 
 
SDS-PAGE and protein transfer were performed in BioRad mini protein 3 apparatus (BioRad, 
Herts, UK). 10 to 40µg of protein was mixed with 5x loading buffer and boiled at 95ºC for 5 
min. Samples were run on a 8-12% gradient SDS-PAGE gel (BioRad, Herts, UK) at 200 V 
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for 1 h to 90 min. Precision Plus Protein Standard (BioRad, Herts, UK) was used as a marker. 
Protein samples were then transferred at 100v for 1h to a nitrocellulose membrane (GE 
Healthcare, Bucks, UK).  To check the efficiency of transfer, the membrane was incubated in 
Ponceau stain for 1min and rinsed with water until the protein bands observed.  
Membranes were blocked in 7mL of blocking buffer (PBS 0.1% Tween 5% Milk Powder) for 
1hr at room temperature and rinsed with washing buffer afterwards.  Primary antibody (Table 
2-2) was added to the membrane and incubated overnight at 4oC.After three washes with 
washing buffer (1 x PBS 0.1% Tween), membrane was incubated with secondary antibody 
(discussed in detail in section 3.3.5) for 1h at room temperature. Before the developing step, 
the membrane was washed 3X with washing buffer. Enhanced Chemiluminescence (ECL, GE 
Healthcare, Bucks, UK) was used for antibody detection. 0.5mL from both substrate A and B 
was mixed to reach a 1mL reaction mixture per membrane and applied on membrane for 2 
min. 
Finally, the membrane was exposed to photographic film (Perkin Elmer, Surrey, UK) in a 
dark room for 30sec to 1h. Films were developed on Compact X4 automatic film processor 
(Xograph Imaging Systems, Gloustershire, UK). 
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Table 2-2 List of antibodies used for western blot analysis. 
 
 
2.6.RNA extraction 
2.6.1.Principle 
 
To extract total RNA from a monolayer of cells or from tissue explants, Tri-Reagent was 
applied. Tri-Reagent contains phenol and guanidine thiocyanate which together can inhibit 
RNase activity. 
 
2.6.2.Methods 
 
After washing the cells on ice with PBS, 1 mL of Tri-Reagent was added per well of a 24 well 
plate and incubated at room temperature for 5 min. Cell lysates in Tri-Reagent were then 
transferred to Eppendorf tubes. 200 µl of chloroform was added per 1mL of reagent for each 
tube. Tubes were vigorously shaken for 10sec and incubated at room temperature for 15 min. 
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The mixture was centrifuged at 16000 g for 15 min at 4oC to separate the RNA in the aqueous 
phase from the DNA and protein at the interface. The aqueous phase was transferred to a new 
Eppendorf tube and 500 µL of isopropanol was added. The tubes were inverted 4 times and 
then incubated at room temperature for 15 min, and subsequently centrifuged at 16000 g for 
15 min.  
The supernatant was aspirated and the RNA pellet was washed with 75% ethanol, centrifuged, 
and aspirated again to remove the ethanol wash. The RNA pellet was air dried for 5 min, 
resuspended in 20 to 50µl of RNase free water and stored at -80oC. 
The quality of the RNA then assessed by electrophoresis on 1% agarose gel with 0.15 µg/mL 
GelRed (Cambridge biosciences LTD, Cambridge, UK). The intact RNA run on a gel will 
have two sharp, clear 18s and 28s rRNA bands which are visualised under UV light. The 28s 
rRNA band is approximately twice as intense as the 18s rRNA band in an intact RNA, and 
therefore, this 2/1 ratio (28s/18s) is a good indication of the high quality RNA. Degraded 
RNA will not present the 2/1 (28s/18s) ratio or will not have a sharp rRNA band and will 
have a smeared appearance. A very low molecular weight smear is a completely degraded 
RNA. All the samples were run beside Ambion’s RNA millennium markers (Thermofisher, 
Surrey, UK) to allow the size of any bands to be determined and also to check if the gel was 
run properly.  
The RNA concentration and purity is measured by NanoDrop ND-1000 UV-Vis 
Spectrophotometer (Thermofisher, Surrey, UK). All measurements were made using 1 µl of 
RNA with respect to a blank (nuclease free water). RNA has a maximum absorption at 260nm 
and its concentration is determined by the OD reading at 260nm. In addition to OD260, 
measurements should be taken at 280nm and 230nm. The OD260/OD280 ratio is an 
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indication of the protein contamination in the sample. Pure RNA has an OD260/OD280 ratio 
of 2.1. However, the RNA with the ratios in the range of 1.8 - 2.0 is considered acceptable. 
OD230 is an indicator of other contamination (such as ethanol used in RNA isolation method) 
and the ideal OD260/OD230 is greater than 1.5. 
 
2.7.Reverse Transcription (RT) 
2.7.1.Principle 
 
Reverse transcription (RT) is used to convert single stranded RNA into complementary DNA 
(cDNA). The extracted RNA is heated to denatured secondary structure and cooled 
subsequently to facilitate annealing of random hexomers to the RNA template. After 
annealing step, the RNA-bound primer is extended with the help of reverse transcriptase and 
RNase inhibitor to generate a complementary DNA copy of the RNA template. Finally, it is 
heated to a high temperature to inactivate reverse transcriptase which is also an end point for 
the reaction. This cDNA can then be used in a PCR reaction. 
 
2.7.2.Methods 
 
RT reactions were performed using Applied Biosystems Reverse Transcription Kit (Applied 
Biosystems, Warrington, UK). 1µg of RNA was diluted in nuclease free water to a final 
volume of 10µl, and 10µl of 2x RT master mix was added to this RNA dilution. To generate a 
2x RT master mix, components were added in the following order: 2 µl of 10x RT buffer, 
0.8µl of 25x dNTPs mix (100mM), 2µl of 10x RT Random primers, 1µl of Multiscribe 
reverse transcriptase, 1µl of RNase Inhibitor, and 3.2 µl of Nuclease free water. Samples were 
incubated at 25ºC for 10min followed by 37ºC for 120min, and then 85ºC for 5min to 
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denature the reverse transcriptase, using a thermal cycler (Applied Biosystems, Warrington, 
UK). 
 
2.8.Polymerase Chain Reaction 
2.8.1.Principle 
 
PCR is performed in order to amplify the specific region of DNA or cDNA using 
oligonucleotide primers which are complementary to the 3’ and 5’ ends of this region of 
interest. Double stranded DNA is heated with high temperature to denature and cooled 
subsequently to facilitate the primers annealing process. At the end, the temperature is 
increased so that Taq DNA polymerase can extend the oligonucleotides and produce the 
complementary DNA strands. 
 
2.8.2.Methods 
 
In a 10µl reaction the following components were added: MasterMix (final concentration 1x), 
forward and reverse primers (1 µM final concentration), and 100nM of DNA. In a thermal 
cycler (Biometra, Goettingen, Germany) samples were incubated at 94°C for 2min and then 
cycled 35 times at 94°C for 20 sec, 53.4 to 65°C for 20 sec, and 72°C for 30 sec. Samples 
were then incubated for 72°C for 5min. 
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2.9.Quantitative Polymerase Chain Reaction 
2.9.1.Principle 
 
Real-time PCR is used for detection of a PCR product while it accumulates during the PCR 
reaction using a fluorogenic probe. This probe is synthesised with a fluorescent reporter dye 
on its 5’and a quencher dye on its 3’end. Primers are complementary to the 5’ and 3’ ends of a 
region of interest and the oligonucleotide probe binds to the DNA template, downstream from 
one of the primer sites. Once the primer is extended, the probe is cleaved by the Taq DNA 
polymerase activity. The probe cleavage separates the reporter and the quencher dye which 
leads to an increase in the reporter dye signal. The removal of the probe from the template 
DNA is crucial for PCR process which allows primer extension until it reaches the end of the 
DNA. As the amount of reporter dye signal is increased in each cycle, the fluorescence 
intensity proportional to the amount of PCR product produced is augmented.  
The value at which the target sequence is detected called cycle threshold (Ct). As this 
technique is used for relative quantification, the ∆Ct (Ct of the target gene – Ct of the18s) 
values are calculated.  There is an inverse relationship between ∆Ct values and mRNA 
expression.  
 
2.9.2.Methods 
 
All real-time PCR experiments were carried out using Applied Biosystems reagents and gene 
expression assays (Warrington, UK) (list of primers used in the current study is shown in 
Table 2-3).  The 18s rRNA was used as control and all reactions were carried out in duplicate 
in 96-well plates (Applied Biosystems, Warrington, UK). The 18s rRNA contains forward 
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and reverse primers plus a labelled probe and has been used at a final concentration of 25mM 
each.  
 
 
Table 2-3 List of primers which are provided by Applied Biosystems. The information in this 
table is gathered from:  http://www.appliedbiosystems.com/absite/us/en/home/applications-
technologies/real-time-pcr.html. 
 
 
In all experiments, the following components were added per single reaction: 10 µl of 2x 
Master Mix, 1 µl of either 20x expression assay or 18s mixture, 100ng of cDNA and nuclease 
free water up to 20µl per well. Nuclease free water was added instead of cDNA to negative 
control wells. Plates were run on 7500 real-time PCR system (Applied Biosystems, 
Warrington, UK). All data were corrected to 18s. The validity of 18s as an internal control 
was confirmed by comparing 18s abundance in 4 experimental replicates after cortisol 
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treatment (cortisol 100, 250 and 1000nM vs. control) (Figure 2-3).  Ct values were used to 
determine ∆Ct (Ct of the target gene – Ct of the 18s), with a higher ∆Ct meaning lower gene 
expression. Where significant changes were found PCR data were also presented either as a 
fold change (2-difference in ∆CT) or arbitrary units (AU) (105*(2∆ct). 
Figure 2-3 The impact of cortisol treatment (100, 250 and 1000nM) on 18s abundance in 
four different experimental replicates in C3As.  The PCR data demonstrate that cortisol 
treatment has no impact on 18s values, validating its use as an internal housekeeping gene.  
2.10.De novo lipogenesis assay 
2.10.1.Principle 
De novo lipogenesis assay, also called Acetyl-CoA Carboxylase assay (ACC), is a multi-step 
assay. ACC is the rate-limiting enzyme in de novo lipogenesis with the role in carboxylation 
of acetyl-CoA to malonyl-CoA. The assay measures 1-[14C]-acetic acid incorporation into 
lipid, so any change in acetate incorporation is likely to reflect a change in ACC activity. 
Lipids are extracted from the cells and their radioactivity measured using scintillation 
counting. We actually measured the acetate incorporation to total lipid fraction which was 
used as a reflection of de novo lipogenesis. 
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2.10.2.Methods 
 
Prior to de novo lipogenesis assay, cells were incubated in a 24 well plate with 1mL of serum 
free medium.  0.12µCi/L 1-[14C]-acetic acid with cold sodium acetate to a final concentration 
of 10uM acetate was added to each well and the plate was incubated at 37ºC for 6h. Cells 
were then washed twice with 1mL of PBS and scraped in 250µl of PBS subsequently. Finally, 
the scraped cells were transferred into glass tubes. 
To extract the lipid fraction, 5mL of chloroform: methanol (2:1 by vol/vol) was added to each 
glass tube (Folch et al. 1957). The tubes were vortexed for 1min and 1mL of water was added. 
The glass tubes were vortexed again for 1 min and centrifuged at 3000 g for 10min until two 
phases were separated.  The upper phase was aspirated and the lower faction transferred to a 
5mL scintillation tube and evaporated until completely dry using a sample dryer in a fume 
cupboard. 5mL of scintillation cocktail was then added to each scintillation tube and samples 
were counted on the Liquid Scintillation Analyzer 2500 RT/AB (Packard, A Canberra 
Company, Oxfordshire, UK). No cells tube was used as a negative control. 
 
2.11.5αR2 overexpression 
 
In contrast to primary human hepatocytes, C3A 5αR2 expression is very low, and as a result 
they represent a good model to study the impact of 5αR2 transfection into the cell. The coding 
sequence of 5αR2 was cloned into the pcDNA3.1 vector (Invitrogen) by Dr Laura Gathercole 
in our lab and transiently transfected into C3A cells (Figure 2-4). 
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Figure 2-4 pcDNA3.1 vector (Picture is taken from Invitrogen-Thermo Fisher Scientific 
website;https://www.thermofisher.com/order/catalog/product/V79020)(a), schematic diagram 
of 5αR2 coding sequence (presented in red) cloned into the vector(presented in black)(b). 
 
 
2.11.1.C3A cell Transfection 
 
Prior to transfection, cells were seeded into a 24-well plate. Cells were ~60-70% confluent in 
order to obtain the most efficient transfection result. Transfection mixture was made up using 
1.5 µg of DNA diluted in 50 µL of OptiMEM serum free media (Invitrogen, Paisley, UK) and 
2 µL of Lipofectamine 2000 (Invitrogen, Paisley, UK) diluted in 50 µL of Optimem serum 
free media.  The mixtures were then incubated at room temperature for 5 mins. Subsequently, 
diluted DNA was combined with diluted Lipofectamine 2000, and finally after incubation at 
room temperature for 25 mins, 100 µL of complexes was added drop-wise to each well. The 
plates were rocked gently and left for incubation at 37ºC. 
Transfection duration was 48h and its efficiency was determined using a plasmid containing 
green fluorescence protein (GFP). Cells expressing GFP can be visualised under a 
fluorescence microscope and a representative image is shown in figure 5-2 (section 5.4.3.1). 
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Fluorescent and total cells were counted using an haemocytometer. The efficiency was 
presented as the % of fluorescent cells/total cells. Changes in 5αR2 mRNA expression level 
were confirmed by real-time PCR subsequently. 
 
2.12.Site Directed Mutagenesis (SDM) 
2.12.1.Principle 
 
Known mutations in SRD5A2 were made using Quikchange II site-directed mutagenesis kit 
(Agilent Technologies UK Limited, Cheshire, UK). This kit utilizes a double-strand DNA 
vector (containing the gene of interest) and a set of forward and reverse primers containing 
the desired mutation. These primers are designed to be complementary to opposite strands of 
the vector and are extended during temperature cycling using a high fidelity DNA 
polymerase. This generates a mutated plasmid from the parental DNA template. The parental 
DNA template is digested by DpnI, which specifically digests methylated and hemimethylated 
DNA. Finally the vector containing the desired mutation is transformed to competent cells 
(Figure 2-5). 
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Figure 2-5 Site directed mutagenesis (SDM) technique which has three major steps; mutant 
strand synthesis, DpnI designation of template, and transformation. Picture is taken from 
Quikchange (Agilent Technologies) website. 
 
 
2.12.2.Methods 
 
In a 50µl reaction the following components were added: 5μl of 10× reaction buffer, forward 
and reverse primers (125ng) 10ng of double-strand DNA template, 1μl of dNTP mix, 3μl of 
QuikSolution and ddH2O to a final volume of 50μl. In a thermal cycler (Biometra, 
Goettingen, Germany) samples were incubated at 95°C for 1min and then cycled 18 times at 
95°C for 50 sec, 53.4 to 60°C for 50 sec, and 68°C for 60 sec. Samples were then incubated 
for 68°C for 7min.  
1μl of DpnI was added to PCR Eppendorf, vortexed and incubated for 1 hour at 37°C. 1mL of 
ethanol (100%) was then added to each tube and incubated for 1hour at -80 °C. The mixture 
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was centrifuged at 16000 g for 20 min at 4oC and the supernatant aspirated. The DNA pellet 
was washed with 75% ethanol, centrifuged, and aspirated again to remove the ethanol wash. 
The DNA pellet was air dried for 10 min, resuspended in 10µl of RNase free water and stored 
at -80oC. Finally the DNA vector containing the desired mutation was transformed to XL10-
Gold ultracompetent cells. 
 
2.13.Gas/Liquid Chromatography-Mass Spectrometry (GC/LC-MS) 
 
As free steroids are polar compounds they should readily move from an aqueous to an organic 
environment.  This property allows for simple liquid-liquid extractions, this was historically 
done with dicholoromethane, However MTBE (methyl tert butyl ether) is now the solvent of 
choice. For conjugated steroids (steroid-sulphates or steroid-glucuronides) which are 
hydrophilic solid phase extraction is required to extract these from cell media or urine. 
After effective, efficient extraction of steroids positive identification is required using a 
sensitive, reproducible, accurate technique such as mass spectrometry (Krone et al. 2010). 
  
2.13.1.Chromatography 
 
There are two chromatographic techniques which can be linked to mass spectrometers to 
separate a steroid mixture into specific steroids; these are liquid chromatography and gas 
chromatography.    
Liquid chromatography (LC) permits separation of a mixture of liquid analytes into separate 
fractions.  This is achieved with the use of a column packed with a stationary phase (typically 
C18 and phenyl-hexyl) which retains the analytes. Steroids are retained on the column 
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stationary phase at differing degrees based on their polarity, increasing the polarity of the 
mobile phase elutes the steroids sequentially.  Typical mobile phases used in steroid analysis 
via LC/MS have one aqueous and one organic mobile phase such as water/methanol or 
water/acetonitrile.  
Gas chromatography (GC) permits separation of liquid analytes which are vaporised in the 
GC injector.  These gaseous steroids travel through the heated column and arrive at the mass 
spectrometer at different times due to differences in column liquid phase interaction. GC is 
used after chemical derivatisation of the steroids to increase the volatility and stability of the 
steroid. The derivatisation procedures involve addition of a trimethyl-silyl group which adds 
to any hydroxy group present on the steroid skeleton. Steroid specific gas chromatography 
columns have been produced; (5%-phenyl)-methylpolysiloxane columns such as the DB5 and 
the more specialised dimethylpolysiloxane stationary phase columns are widely used. 
 
2.13.2.Mass Spectrometry 
 
Mass Spectrometry in combination with either of these chromatographic separation 
procedures can be used to stablish a qualitative and quantitative profile of steroids within a 
sample.  After chromatographic separation the steroids sequentially enter the ionisation source 
of the mass spectrometer.   
The general operating principles of mass spectrometry are similar including four steps; 
ionisation, fragmentation, separation, and detection. The ionisation source vaporises and 
ionises the sample to produce gaseous ions.  There are many types of ionisation source 
including; electron ionisation (EI), chemical ionisation (CI), atmospheric pressure chemical 
ionisation (APCI), and electrospray ionisation (ESI). Fragmentation occurs where there is 
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excess internal energy more than is required to ionise the molecule. This energy can break the 
molecular bonds. Controlled fragmentation such as collision induced dissociation (CID) in an 
ion trap, allows structural information about a given molecule to be obtained. In addition, a 
mass analyser separates ions accurately using magnetic or an electrical field or a combination 
of both. Finally, a signal proportional to the ion signal (or count) is passed to a data system 
which processes this raw data into mass spectra and ion chromatograms.  
The specific methodology including the use of GC/LC-MS is detailed in related chapter ‘5’ 
(see section 5.3.7).  
 
2.14.Statistical analysis 
 
Data are presented as mean ± s.e. Normality tests were performed on all data. The tests were 
passed in all cases and therefore throughout the thesis, parametric statistical tests were used. 
One way ANOVA on ranks, was used to compare multiple treatments, doses or times. 
Tukey’s and Dunnett’s post-hoc analysis were used as follow-up tests to ANOVA. The 
Tukey’s test compares every mean with every other mean while the Dunnett’s test compares 
every mean to a control mean.  Statistical analysis on real-time PCR data was performed on 
mean ∆CT values ± s.e, unless otherwise stated. All analysis was performed using the 
Sigmastat 3.1 software (System Softwares, CA, USA). 
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3.1.Aims 
 
• To optimise the in vitro model for metabolic assessments in human hepatocytes 
• To define the impact of Glucocorticoids upon insulin sensitivity in human hepatocytes 
• To study the impact of Glucocorticoids on lipid metabolism in human hepatocytes 
 
3.2.Background  
 
The effects of GCs within the body, especially on the development of obesity and insulin 
resistance, are well described. These effects are exemplified in patients with circulating GC 
excess, Cushing’s syndrome. The most common observations in these patients are central 
obesity, hypertension, insulin resistance, type 2 diabetes and in 20% of cases, NAFLD 
(Shibli-Rahhal et al. 2006). Importantly, 1-2% of the population in United Kingdom and 
United States are taking prescribed GCs and their side effects create a significant health 
burden (Overman et al. 2013;Van Staa et al. 2000).  
Studies in both human and animal models have demonstrated that GCs induce whole body 
insulin resistance (Larsson and Ahren 1996;Zarkovic et al. 2008). However, the molecular 
mechanisms behind this have not been studied in detail. GC action upon global insulin 
sensitivity is likely to be the combination of metabolic events in different target organs. In 
adipose tissue, it has been suggested that GCs decrease insulin-stimulated glucose uptake 
(Sakoda et al. 2000). In contrast, there are some studies that have shown dose and time 
dependent increases in insulin sensitivity following GC treatment (Gathercole et al. 
2007;Tomlinson et al. 2010). These effects also persist after a long-term (7 days) GC 
administration (Gathercole et al. 2011a). Skeletal muscle is responsible for 80% of glucose 
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disposal in insulin-stimulated conditions (DeFronzo et al. 1981). This suggests that GCs in 
this tissue might play a role contributing to global insulin resistance. There are a number of 
studies that are in agreement with this; direct inhibition of insulin-stimulated glucose uptake 
by GCs in skeletal muscle has been demonstrated (Dimitriadis et al. 1997;Ruzzin et al. 2005). 
 The metabolic effects of GCs on liver insulin sensitivity and lipid metabolism are complex 
but it is widely believed that GCs induce insulin resistance. It has been shown that GCs 
decrease glucose usage and increase glucose output contributing to insulin resistance in 
rodents (Guillaume-Gentil, Assimacopoulos-Jeannet, & Jeanrenaud 1993). However, studies 
in human models have not been performed.  
As discussed in detail in section 1.3.4, insulin binding its receptor initiates a complex intra-
cellular cascade. In summary, the metabolic actions of insulin occur via the IRS, PI3Kinase 
axis (Giorgetti et al. 1993) which can result in activation of PKB/akt through S473 and T308 
phosphorylation (Hanada et al. 2004). This subsequently allows GLUT4 to translocate to the 
cell membrane and increase glucose uptake (Larance et al. 2005). 
There is a close link between intra-cellular lipid metabolism and the insulin signalling 
cascade. High plasma FFAs cause insulin resistance (Boden et al. 1991) and this is thought to 
be mediated by phosphorylation of Ser307 on IRS1 which is responsible for inhibition of IRS-
1 function (Yu et al. 2002). In addition, this insulin resistance impairs the interaction with the 
IR and  also targets IRS1 for proteasomal degradation (Sun et al. 1999).  
The interaction between GCs and the insulin signalling cascade and their effects on lipid 
metabolism have been studied in skeletal muscle and adipocytes. GCs enhance insulin action 
to drive lipid accumulation in human subcutaneous (sc) but not omental (om) adipose primary 
cultures (Gathercole et al. 2011b). However, in skeletal muscle, GCs induce insulin resistance 
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with an increase in lipogenesis in both murine and human cell lines and primary cultures 
(Morgan et al. 2013). 
There is evidence that GCs augment insulin action to promote lipid accumulation in rodent 
hepatocytes. Although dexamethasone alone did not have any effects on lipogenesis in rats, 
co-incubation with insulin increased lipogenesis (Amatruda et al. 1983). 
Defining the interaction between GCs, IR and lipid metabolism will contribute significantly to 
our understanding of the pathogenesis of NAFLD and hepatic insulin resistance and may lead 
to the identification of novel treatment targets.  Clinical studies have demonstrated a strong 
link between IR and NAFLD (Targher et al. 2006), but there is also evidence to implicate GC 
action. Liver specific GC receptor knockdown ameliorates hepatic steatosis in rodent models 
(Lemke et al. 2008) and liver-selective GR antagonism can improve carbohydrate signalling 
by reducing hepatic glucose production (Edgerton et al. 2006).  
We have therefore characterised the impact of cortisol upon the insulin signalling cascade and 
intra-cellular lipid metabolism using human tissues. We have used hepatocyte cell lines (C3A 
and Huh7.5) and also endorsed our findings in primary cultures of human hepatocytes.  
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3.3.Method 
3.3.1.C3A and Huh7.5 cell cultures and treatments 
C3A cells were cultured in MEM with 10% FCS and split into 24 well plates, as described in 
section 2.1.1.2. Before treatment, cells were fasted overnight in MEM without any 
supplements. Huh7.5 cells are well differentiated hepatoma-derived cell line that was derived 
from a male donor. These cells were a gift from the liver laboratories (IBR 5th floor, Clinical 
and experimental medicine department, University of Birmingham) and all experiments on 
Huh7.5 cells were carried out with the help of Dr. Reina Lim Teegan. Cells were cultured in 
MEM with 10% FCS and split into 24 well plates, as described in section 2.1.2.2. Before 
treatment, cells were fasted overnight in MEM without any supplements.  
Both C3As and Huh7.5s were treated with cortisol (dose range 100, 250, 1000nM) in order to 
accurately determine the response to GCs. In experiments investigating protein 
phosphorylation of the insulin signalling cascade, media was spiked with human insulin (dose 
range 1, 10, 20, 50 and 100nM) for the final 15 min of treatment (Figure 3-1). 
Figure 3-1 Cells were split into three 24 well plates, and fasted overnight before treatment. 
Cells were then treated with cortisol for 24h and finally harvested for RNA and protein 
extraction, and de novo lipogenesis assay. 
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3.3.2.Primary human hepatocytes cell culture and treatments 
Primary human hepatocytes were purchased from BioreclamationIVT Technologies 
(Baltimore, Maryland, United States). Access to the donors’ medical history was provided 
and the four most healthy donors (male n=4, age 54±14years, BMI 28.4±3 kg/m2, data are 
expressed as mean ± s.e) were chosen. Diabetic patients or those who had taken GC therapy, 
or any other related medications were excluded as were those with viral infection and high 
alcohol consumption (Appendix). Cells were cultured in InVitroGRO CP medium 
(BioreclamationIVT Technologies, Baltimore, USA) and seeded into 12 and 24 collagen 
coated well plates, as described in section 2.2.2. 
Before treatment, cells were fasted for 3 hours in Williams’ Medium E (detailed nutrient 
contents of media can be found at http://www.sigmaaldrich.com/life-science/cell-
culture/learning-center/media-formulations/williams.html) without any supplements. The 
glucose concentration is 2g/L in Williams’ Medium E compared to 1g/L in MEM, and 
therefore, media were corrected for glucose concentration. To define the impact of insulin and 
GCs, cells were treated with cortisol (dose range 100, 250, 1000nM) in the presence or 
absence of insulin (5nM, 24h). In all experiments investigating protein phosphorylation of 
insulin signalling cascade, media was spiked with human insulin (50nM) for the final 15 min 
of the treatment (Figure 3-2). 
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Figure 3-2 Primary hepatocytes were split into two 12 and one 24 well plates. Cells were 
fasted in William’s E medium for 3h and then treated with cortisol in presence and absence of 
insulin for 24 hours. Finally, cells were harvested for RNA and protein extraction, and de 
novo lipogenesis assay. 
3.3.3.RNA and Protein extraction  
After 24 hours of treatment, RNA was extracted (as described in section 2.6.2), from both 
C3As and primary hepatocytes, using Tri-Reagent. Protein was extracted (as described in 
section 2.3.2) from C3As, Huh7.5s and primary hepatocytes applying RIPA buffer. The 
extracted RNA and proteins were then used for Real-Time PCR and Western Blotting. 
3.3.4.Real-Time PCR 
The mRNA expression levels of insulin signalling (IRS1/2, AKT1/2) and lipid metabolism 
(ACC1/2, CPT1, DGAT2, GPAT, FAS) genes were determined using ABI-7500 PCR 
machine (Perkin-Elmer Applied Biosystems, Warrington, UK) as described in section 2.8.2.  
18s rRNA gene was used as a control in all reactions and all probes and primers were supplied 
by Applied Biosystem. 
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3.3.5.Western blotting 
 
In order to define insulin stimulation, the media from the cells (both in cell lines and primary 
hepatocytes) were spiked with insulin (explained in section 3.3.1, 3.3.2 and 3.3.3) and 
proteins were extracted.  
Western blot was performed on protein samples, as previously described in section 2.5.2. Anti 
PKB/AKT (anti total AKT) (Millipore, Hertfordshire, UK), anti phospho-AKT (Thr308) (Cell 
signalling technology, Danvers, MA, USA) and anti phospho-AKT (serine 473) (R&D 
Systems, Abingdon, UK) were used as primary antibodies.  Polyclonal Goat Anti-Rabbit 
Immunoglobulins (Dako, Glostrop, Denmark) were used as the secondary antibody and both 
primary and secondary antibodies were diluted 1/1000. All membranes were re-probed for β-
actin antibody (Abcam plc, Cambridge, UK) where the antibodies used at a dilution of 
1/5000. Bands were quantified by ImageJ software and expressed relative to β-actin to 
normalise for gel loading. 
 
3.3.6.Western blotting-separating ACC1/2 isoforms 
 
ACC is the rate-limiting enzyme in lipogenesis, converting acetyl CoA to malonyl-CoA. 
Although two isoforms of ACC (ACC1 and ACC2) contribute to this conversion, the 
malonyl-CoA produced by them impacts upon different metabolic pathways. The malonyl-
CoA generated by ACC1 is utilised for FFA synthesis whilst ACC2 is located on 
mitochondria surface and the malonyl-CoA formed by this isoform inhibits CPTI function 
inhibiting β-oxidation. Thus, separating these isoforms and studying them individually is 
informative (Ruderman et al. 1999). 
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These isoforms are encoded by different genes in man (Widmer et al. 1996) but share almost 
75% homology in amino acid sequence, and as a result are technically difficult to separate by 
western blotting. Therefore, specific changes were made to general method of western 
blotting described in section 2.5.2. Nupage Novex 3-8% Tris-acetate gel and Nupage Tris-
acetate SDS running buffer (Invitrogen, Paisley, UK), were used instead of 8-12% gradient 
SDS-PAGE gel running buffer (BioRad, Herts, UK). The blocking buffer was replaced with 
the Starting Block Blocking buffer (Pierce, Thermo Fisher Scientific, West Sussex, UK). 
Anti-phospho-AcCoA (Millipore, Watford, UK) and anti ACC (Avidin-HRP) (Sigma -
Aldrich Chemical Company, Pool, Dorset, UK)  were used as primary antibodies at the 
dilution of 1/1000. No secondary antibody was used for anti ACC (Avidin-HRP). Protein 
samples used for this western blot were isolated from primary human hepatocytes. 
Two isoforms of ACC were separated on the gel in both phospho and total ACC. (Figure 3-3). 
However, this was not sufficient for quantification, and therefore as with many reports in the 
published literature (Liu et al. 2014;Maslak et al. 2015), both isoforms combined in total were 
quantified.  
 
  
Figure 3-3 Separation of ACC1/2 isoforms in human hepatocytes using anti phospho and 
total ACC antibodies but this was not sufficient for quantification. 
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3.3.7.De novo lipogenesis assay 
 
In order to investigate the effect of GCs and insulin on lipid accumulation within liver at the 
functional level, de novo lipogenesis was determined by measuring 14C-acetate incorporation 
into cellular lipid (as described in 2.10.2). This assay was optimised in both C3As (50nM of 
insulin) (Figure 3-4) and primary cells (5nM of insulin) (Figure 3-5) to identify the optimal 
incubation time to achieve maximal insulin stimulated de novo lipogenesis. At baseline there 
were significant differences in de novo lipogenesis between preparations, in both the C3As 
and primary human hepatocyte models, however, the responses to treatment were consistent. 
Therefore, data are calculated as percentage change from untreated control.  
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Figure 3-4 Time dependent (1, 3, 6, 24, and 48h) preliminary de novo lipogenesis assays in 
C3A cells; it was identified that the optimal acetate incubation time to achieve the largest 
impact of insulin stimulation on de novo lipogenesis to be at the final 6h of the treatment. 
Insulin concentration=50nM, data are presented as 14C-acetate incorporation into lipid 
(%from control without insulin, mean ± s.e) of n=4 experiments and one way ANOVA with 
Tukey’s post-hoc analysis was applied using Sigmastat 3.1 to compare insulin stimulated 
treatments to no insulin treatments (*p<0.05 vs. no insulin). 
 
 
Figure 3-5 Time dependent (1, 3, 6, 24 and 48h) preliminary de novo lipogenesis assays in 
primary hepatocytes; it was identified that the optimal acetate incubation time to achieve the 
largest impact of insulin stimulation on de novo lipogenesis to be at the final 6h of the 
treatment. Insulin concentration=5nM, data are presented as 14C-acetate incorporation into 
lipid (% from control without insulin, mean ± s.e) of n=7 experiments and one way ANOVA 
with Tukey’s post-hoc analysis was applied using Sigmastat 3.1 to compare insulin stimulated 
treatments to no insulin treatments  (*p<0.05 vs. no insulin). 
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In both C3As and primary cultures, insulin had its most marked effect at 6h. Therefore, we 
opted that for the final 6h of treatment with steroid hormones, 0.12µCi/L 1-[14C]-acetic acid 
with cold sodium acetate to a final concentration of 10uM acetate would be added to each 
well to quantify the relative contribution of  de novo lipogenesis to total lipid synthesis within 
the cells. The lipid content of the cells was recovered in chloroform: methanol (2:1 by 
vol/vol) (Folch et al. 1957) and radioactivity was measured by scintillation counting as 
described in section 2.10.2. 
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3.4.Results 
3.4.1.GC regulation of insulin signalling in C3As and primary 
hepatocytes 
3.4.1.1.Gene expression  
 
IRS1 and AKT1/2 were all expressed in C3A cells but IRS2 was not expressed. Cortisol pre-
treatment did not alter the expression of insulin signalling genes significantly (Table 3-1). 
Since these cells do not express IRS2, performing the same experiment on an alternative cell 
line or/and primary cultures of human hepatocytes was justified.  
 
Gene Control Cortisol (250 nM) P Value 
AKT1 15.20 ± 0.60 15.14 ± 0.50 NS 
AKT2 16.30 ± 0.35 16.14 ± 0.42 NS 
IRS1 17.98 ± 1.09 17.60 ± 1.05 NS 
IRS2 Not detected   
 
Table 3-1 mRNA expression of insulin signalling genes in C3As in response to cortisol (F, 
250nM for 24h) treatment. Data are expressed as mean ΔCt values ± s.e of n=7 experiments 
and Student’s t-tests were applied using Sigmastat 3.1 to compare cortisol treatment to 
control. 
 
 
IRS1/2, INS, and AKT1/2 were all expressed in primary cultures. However, neither cortisol 
nor insulin pre-treatment altered the expression of insulin signalling genes significantly (Table 
3-2). Although gene transcription was not altered by GCs, this does not represent the major 
regulatory step in insulin signalling, as most gene products are heavily post transcriptionally 
modified. Therefore, looking at protein expression and functional activity is warranted. 
 
 
 
106 
 
Chapter 3             Impact of GCs upon insulin signalling cascade and lipid metabolism 
a) 
Gene Control F100(nM) F250(nM) F1000(nM) P Value 
AKT1 15.67 ± 0.44 16.06 ± 0.57 15.29 ± 0.59 15.48 ± 0.54 NS 
AKT2 16.40 ± 0.43 16.27± 0.54 15.24 ± 0.41 15.47± 0.35 NS 
INS 15.34 ± 0.58 15.15 ± 0.65 14.98 ± 1.07 14.63 ± 0.56 NS 
IRS1 16.45 ± 0.53 16.68 ± 0.74 15.73 ± 1.06 15.32 ± 0.24 NS 
IRS2 14.90 ± 0.56 15.03 ± 0.58 14.62 ± 0.84 14.40 ± 0.44 NS 
b) 
Gene Ins(5nM) F100(nM)+Ins F250(nM)+Ins F1000(nM)+Ins P Value 
AKT1  15.47 ± 0.51    14.83 ± 0.42    14.65 ± 0.25   15.56 ± 0.21 NS 
AKT2  15.32 ± 0.49    15.31± 0.41    14.63 ± 0.25   15.08± 0.37 NS 
INS  15.31 ± 0.77   15.02 ± 0.41    14.34 ± 0.42   14.54 ± 0.45 NS 
IRS1  16.53 ± 0.60   15.67 ± 0.18    15.01 ± 0.55   15.19 ± 0.52 NS 
IRS2  14.92 ± 0.54   14.48 ± 0.19    13.93 ± 0.68   14.51 ± 0.50     NS 
Table 3-2 mRNA expression of insulin signalling genes in primary hepatocytes in response to 
cortisol (F, dose range 100, 250, 1000nM for 24h) treatment alone (a) and co-incubation with 
insulin (5nM for 24h) (b). INS=Insulin, IRS=Insulin receptor, data are expressed as mean 
ΔCt values ± s.e of n=4 experiments and one way ANOVA with Dunnett’s post-hoc analysis 
was applied using Sigmastat 3.1 to compare multiple cortisol treatments to control (a) and 
multiple cortisol with insulin treatments to insulin alone (b).  
3.4.1.2.Protein expression 
3.4.1.2.1.Insulin signalling 
In order to determine whether the C3A cell line is a good model to study the insulin signalling 
cascade, activating T308 and S473 phosphorylation of AKT, and total AKT protein 
expression levels were measured in response to brief insulin stimulation (15min).  We 
observed no significant changes in phosphorylation of AKT residues T308 and S473, 
consistent with a lack of insulin stimulation. Total AKT expression did not change (Figure 
3-6). The lack of insulin response was also endorsed from our preliminary model optimisation 
studies examining 14C-acetate incorporation into lipid (Figure 3-4). 
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Figure 3-6 No insulin stimulation was detected in C3As using anti phospho-AKT T308 and 
S473. Total AKT protein expression remained unchanged. These are representative western 
blots of n=4 experiments and insulin dose range was 1, 10, 20, 50, and 100nM for 15min. 
 
 
In order to identify a cell line that was more insulin responsive and therefore more 
representative of the in vivo situation, experiments were repeated in Huh7.5 cells. Insulin 
stimulated PKB/akt phosphorylation (S437) in Huh7.5 cells, in a dose-dependent manner 
without having any effect on total PKB/akt levels (Figure 3-7). 
 
                            
Figure 3-7 Insulin (dose range 10 and 100 nM for 15mins) pre-treatment increases insulin 
stimulated  PKB/akt (S473) phosphorylation in a dose dependent manner in Huh 7.5 cells 
without changing total PKB/akt. These are representative western blots of n=4 experiments. 
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3.4.1.2.2. GCs and insulin signalling  
 
To determine the interaction between GC and insulin signalling and to investigate whether 
cortisol may regulate of insulin sensitivity in human hepatocytes, PKB/akt phosphorylation 
was measured in Huh7.5 cells. Cortisol did not change insulin stimulated PKB/akt 
phosphorylation (S473) or total PKB/akt protein expression (Figure 3-8).  
 
                
Figure 3-8 Cortisol does not affect insulin-stimulated PKB/akt (S473) phosphorylation or 
total PKB/akt protein expression in Huh 7.5 cells. These are representative western blots of 
n=3 experiments. Abbreviations: Ins, insulin (50nM for 15mins); F, cortisol (dose range 100, 
250, 1000nM for 24h). 
 
 
Although Huh7.5s were insulin sensitive, we observed no changes with cortisol pre-treatment 
and as an hepatoma cell line, they may not be representative of human hepatocyes. Therefore, 
the same experiment was performed in primary cultures of human hepatocytes. 
PKB/akt phosphorylation was measured in human hepatocytes after cortisol pre-treatment 
with an insulin spike (50nM). In contrast to our observations in cell lines, cortisol increased 
insulin-stimulated PKB/akt phosphorylation (S473) in a dose-dependent manner as quantified 
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by ImageJ software and expressed relative to β-actin as an internal control. Total PKB/akt 
protein expression remained unchanged (Figure 3-9). 
 
 
Figure 3-9 Cortisol induces a dose-dependent increase in insulin stimulated PKB/akt 
phosphorylation without alternation in total PKB/akt in primary cultures. Data presented are 
the mean ± s.e of n=4 experiments with representative western blots inserted above. Bands 
are quantified relative to β-actin as internal loading control and one way ANOVA with 
Dunnett’s post-hoc analysis  was applied using Sigmastat3.1 to compare multiple cortisol 
treatments to control (*p<0.05 vs. control). Abbreviations: Ins, insulin (50nM for 15mins); F, 
cortisol (dose range 100, 250, 1000nM for 24h). 
 
 
3.4.2.GC regulation of lipid homeostasis in C3As and primary 
hepatocytes 
3.4.2.1.Gene expression 
 
ACC1/2, CPT1, DGAT2, GPAT, and FAS were all expressed in C3A cells (Table 3-3). 
Among the key genes involved in lipid metabolism, cortisol pre-treatment increased mRNA 
expression of ACC2 (0.005±0.003 (control) vs. 0.008±0.004 (cortisol), mean arbitrary unit 
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values ± s.e, p<0.05) and FAS (0.071±0.007 (control) vs. 0.110±0.019 (cortisol), mean 
arbitrary unit values ± s.e, p<0.05), Figure 3-10, but not ACC1, diacyly glycerol acyl 
transferase 2 (DGAT2) and glycerol phosphate acyl transferase (GPAT). 
 
Gene Control Cortisol (250 nM) P Value 
ACC1 16.53 ± 0.63 16.22 ± 0.61      NS 
ACC2 21.04 ± 1.78 20.58 ± 1.89 P<0.05 
Cpt1A 17.34 ± 0.71 17.16 ± 0.60 NS 
FAS 14.20 ± 0.53 13.89 ± 0.59 P<0.05 
DGAT2 12.97 ± 0.52 12.88 ± 0.05 NS 
GPAT 18.10±0.22 18.01±0.17 NS 
 
Table 3-3 mRNA expression of lipid metabolism genes in C3As in response to cortisol (F, 
250nM for 24h) treatment. Data are expressed as mean ΔCt values ± s.e of n=7 experiments 
and Student’s t-tests were applied using Sigmastat 3.1 to compare cortisol treatment to 
control. 
 
  
 
 
Figure 3-10 Cortisol (250nM for 24h) increases mRNA expression of ACC2 and FAS in C3A 
cells. Data are the mean values from n=7 experiments and expressed as mean arbitrary unit 
values ± s.e. Student’s t-tests were applied using Sigmastat 3.1 to compare cortisol treatment 
to control (*p<0.05 vs. control). 
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ACC1/2, CPT1, DGAT2 and FAS were all expressed in primary cultures. However, neither 
cortisol nor insulin pre-treatment altered the expression of lipid metabolism genes 
significantly (Table 3-4).  
a) 
Gene Control F100(nM) F250(nM) F1000(nM) P Value 
ACC1 16.93 ± 0.48 17.43 ± 0.35 17.01 ± 0.81 16.68 ± 0.21 NS 
ACC2 18.23 ± 0.78 18.02 ± 0.73 17.74 ± 0.83 17.57 ± 0.79 NS 
Cpt1A 15.06 ± 0.31 15.22 ± 0.36 14.61 ± 0.64 14.77 ± 0.28 NS 
FAS 15.99 ± 0.20 16.04 ± 0.33 15.69 ± 0.37 15.37± 0.40 NS 
DGAT2 15.50 ± 0.61 15.71 ± 0.58 15.46 ± 0.43 16.27 ± 0.18 NS 
 
b) 
Gene Ins(5nM) F100(nM)+Ins F250(nM)+Ins F1000(nM)+Ins P Value 
ACC1  16.57 ± 0.45   16.05 ± 0.41    15.77 ± 0.29   16.07 ± 0.45 NS 
ACC2  18.17 ± 0.90   17.58 ± 0.94    17.21 ± 0.94   17.44 ± 0.83 NS 
Cpt1A  15.49 ± 0.44   14.50 ± 0.34    14.09 ± 0.21   14.69 ± 0.47 NS 
FAS  15.57 ± 0.32   15.37 ± 0.35    14.97 ± 0.35   15.34± 0.39 NS 
DGAT2  15.54 ± 0.62   15.25 ± 0.89    14.92 ± 0.50   15.28 ± 0.85 NS 
 
Table 3-4 mRNA expression of lipid metabolism genes in primary cultures of human 
hepatocytes in response to cortisol (F, dose range 100, 250, 1000nM for 24h) treatment alone  
(a) and co-incubation with insulin (5nM, 24h) (b). Data are expressed as mean ΔCt values ± 
s.e of n=4 experiments and one way ANOVA with Dunnett’s post-hoc analysis was applied 
using Sigmastat 3.1 to compare multiple cortisol treatments to control (a) and multiple 
cortisol with insulin treatments to insulin alone (b).   
 
 
3.4.2.2.Protein expression 
 
In order to investigate the mechanisms underpinning the impact of cortisol upon lipogenesis 
at the protein level, western blotting was performed using anti-phospho and total ACC 
antibodies. ACC1 and ACC2 activities are regulated by phosphorylation at inhibitory residues 
serine-79 and serine-218, respectively, mediated through and AMPK-dependent pathway 
(Morgan et al. 2013). Pre-treatment with cortisol did not result in changes in total ACC 
protein expression. In addition, cortisol did not regulate phosphorylation at ser-79/218 
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residue. However, insulin decreased ser-79/218 phosphorylation, which would predict 
increased functional lipogenic activity (Figure 3-11).  
 
 
Figure 3-11 There is no convincing effect of cortisol (F, dose range 100, 250, 1000nM for 
24h) but insulin (5nM for 15mins) decreased the inhibitory phosphorylation in primary 
cultures of human hepatocytes and this would be predicted to increase lipogenesis. No effect 
was observed with total ACC levels. These are representative western blots of n=4 
experiments. 
 
 
3.4.2.3.De novo lipogenesis in C3As, Huh7.5s and primary human 
hepatocyte cultures 
 
Cortisol decreased lipogenesis in a dose dependent manner in C3A cells (85.6 6.6% [100nM], 
73.5 7.9% [250nM], 55.04 5.6% [1000nM] vs. control (100%), p<0.05, mean ± s.e) (Figure 
3-12). 
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.   
Figure 3-12 Cortisol decreases de novo lipogenesis in a dose dependent manner in C3As. 
Data are presented as 14C-acetate incorporation into lipid (% from control, mean ± s.e) of 
n=7 experiments. One way ANOVA test with Dunnett’s post-hoc analysis was applied using 
Sigmastat 3.1 to compare multiple cortisol treatments to control (*p<0.05 vs. control), and 
ANOVA test with Tukey’s post-hoc analysis was used to compare multiple cortisol treatment 
(†p<0.05 vs. cortisol 100nM and §p<0.05 vs. cortisol 250nM). Cortisol dose range= 100, 
250, 1000nM for 24h  
 
 
To study the effect of insulin on lipogenesis and also to identify the optimal insulin 
concentration to achieve maximal insulin stimulated lipogenesis, C3As were treated with 
insulin (dose range 20, 40, 60, 80nM). No significant insulin stimulation lipogenesis was 
identified in C3As (Figure 3-13). 
 
 
Figure 3-13 No significant insulin stimulation lipogenesis was observed in C3A cells. Data 
are presented as 14C-acetate incorporation into lipid (% from control, mean ± s.e) of n=4 
experiments and one way ANOVA with Dunnett’s post-hoc analysis was applied using 
Sigmastat 3.1 to compare multiple insulin treatments to control. Insulin concentrations= 20, 
40, 60 and 80nM for 24h. 
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In the absence of cortisol, and consistent with the data presented on the insulin signalling 
cascade protein expression, insulin (50nM) had no effect upon lipogenesis (114.9±12.4% vs. 
control (100%), p=NS). Interestingly, when C3A cells were pre-treated with cortisol (250nM, 
24h), the stimulatory effect of insulin upon lipogenesis was augmented (mean % increase in 
lipogenesis following insulin, 14.9±12.4% (control) vs. 38.2±12.3% (cortisol), p<0.05, mean 
± s.e) (Figure 3-14). 
 
 
Figure 3-14  In C3As insulin (50nM for 24h) alone increases lipogenesis modestly but not 
significantly. However, in presence of cortisol (250nM for24h)  this reaches statistical 
significance. Data are presented as 14C-acetate incorporation into lipid (% from control, 
mean ± s.e) of n=7 experiments and Student’s t-tests were applied using Sigmastat 3.1 to 
compare cortisol treatment in presence of insulin to cortisol alone (*p<0.05 vs. cortisol). 
 
 
Based on gene and protein expression studies, Huh7.5 cells were more insulin sensitive 
compared to C3As and were used as an alternative cell line to explore the effect of GCs and 
insulin on liver lipogenesis. However, no significant changes were observed in lipogenesis 
after pre-treatment with cortisol (Figure 3-15). 
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Figure 3-15 De  novo lipogenesis remained unchanged after cortisol (dose range 100, 250, 
1000nM for 24h) pre-treatment in Huh7.5 cells. Data are presented as 14C-acetate 
incorporation into lipid (% from control, mean ± s.e) of n=4 experiments and one way 
ANOVA with Dunnett’s post-hoc analysis was applied using Sigmastat 3.1 to compare 
multiple cortisol treatments to control. 
 
 
3.4.2.4.De novo lipogenesis in primary cultures 
 
Significant insulin stimulation of lipogenesis was observed in primary human heaptocye 
cultures compared to our observations in C3A cells (Figure 3-16).  
 
 
Figure 3-16 Insulin (5nM, 24h) stimulates lipogenesis significantly in primary cultures 
compared to C3A cell line. Data are presented as percentage, however, the actual counts 
differ between primary and C3A cells. Therefore, the purpose of this graph is solely to 
compare the insulin sensitivity. Data are presented as 14C-acetate incorporation into lipid (% 
from control, mean ± s.e) of n=4 experiments and Student’s t-tests were applied using 
Sigmastat 3.1 to compare insulin treatment to control (*p<0.05 vs. control). 
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Endorsing our findings in C3As, in the absence of insulin, cortisol caused a dose-dependent 
decrease in lipogenesis in human primary cultures (97.7% [100nM], 85.1% [250nM], 67.08% 
[1000nM] vs. control (100%), p<0.05, mean ± s.e). However, co-incubation with insulin 
(5nM) was able to reverse the effects of cortisol (130.3% [INS + 100nM cortisol] vs. 97.7% 
[100nM cortisol]; 139.9% [INS + 250nM cortisol] vs. 85.1% [250nM cortisol]; 152.37% [INS 
+ 1000nM cortisol] vs. 67.08% [1000nM cortisol], p<0.05, mean ± s.e). This data from de 
novo lipogenesis assay was in consistent with our observation at ACC protein expression 
level as inactivating phosphorylation of ACC was decreased following incubation with 
insulin.  
Interestingly, the ability of insulin to stimulate lipogenesis was augmented at the highest 
doses of cortisol and this stimulatory effect of insulin upon lipogenesis was augmented in a 
dose dependent manner (130.3% [INS + 100nM cortisol], 139.9% [INS + 250nM cortisol], 
152.37% [INS + 1000nM cortisol] vs. Insulin (127.8%), p<0.05, mean ± s.e) (Figure 3-17). 
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Figure 3-17 Cortisol decreases de novo lipogenesis in a dose dependent manner in primary 
hepatocyte. However, co-incubation with insulin (5nM for24h) was able to reverse the 
cortisol effects. Data are presented as 14C-acetate incorporation into lipid (% from control, 
mean ± s.e) of n=4 experiments.one way ANOVA with Dunnett’s post-hoc analysis was 
applied using Sigmastat 3.1 to compare multiple cortisol treatments to control (*p<0.05vs. 
control), and ANOVA with Tukey’s post-hoc analysis was used to compare cortisol in 
presence of insulin treatments to cortisol alone ( p<0.05vs. cortisol). Cortisol dose range= 
100, 250, 1000nM for 24h 
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3.5.Discussion 
 
The specific interaction between GCs and insulin in liver has not been fully examined and 
studies have mainly been performed in rodent cell lines (Saad et al. 1995;Wang et al. 1995).  
Few studies used human models and no studies have been performed on primary cultures of 
isolated human hepatocytes. In our study, experiments have been performed on a novel 
human cell line, C3A, and findings endorsed in primary cultures of human hepatocytes. C3A 
cells are a sub clone of the hepatoma-derived HepG2 cell line (Parvez, Purcell, & Emerson 
2011) and express the GC receptor. 
In rodent hepatocytes (Foa hepatoma cells), GCs alone increased IRS1 expression in liver. 
However, when cells were treated with GC in combination with insulin, the effect of insulin 
to decrease IRS1 levels dominated (Saad, Folli, & Kahn 1995). In the C3A cell line, we were 
unable to detect any significant insulin stimulation as measured by AKT phosphorylation sites 
(T308 and S473). Subsequently, no changes were observed in expression of insulin signalling 
pathway genes in GC pre-treated cells. In addition, we have now shown that C3A cells do not 
express IRS2, underpinning a lack of insulin response. Importantly, IRS2 (compared to IRS1) 
is thought to be more crucial in determining insulin resistance in mouse liver (Kido et al. 
2000;Previs et al. 2000). Therefore, our observations in C3A cells could either be explained 
by species specificity (human vs. mouse) or simply by a lack of insulin response. 
Huh 7.5s were used as an alternative, potentially more insulin sensitive cell line, but again no 
significant changes were observed after GC treatment. Therefore, we carried out definitive 
insulin signalling experiments in primary human hepatocytes. Although we were not able to 
detect any significant effects of GCs on insulin signalling at mRNA expression level, GC 
exposure increased insulin stimulated PKB/akt phosphorylation at S473 suggesting increased 
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insulin sensitivity. Whilst this in vitro observation may appear to conflict with widely held 
beliefs about GCs causing global insulin resistance, we and others have previously reported 
insulin sensitisation of human adipocytes by GCs (Gathercole et al. 2007; Tomlinson et al. 
2010). However, the in vivo situation is more complex and clinical studies may point towards 
GCs causing hepatic insulin resistance (Hazlehurst et al. 2013). This highlights the 
importance of extrapolating with caution in vitro observations into the clinical setting.  
GCs have been widely reported to drive lipogenesis and limit β-oxidation which may 
contribute to lipid accumulation (Amatruda et al. 1983;Mangiapane and Brindley 1986). 
Selective hepatic GR knockdown in mice reduces fat accumulation within the liver, 
decreasing fatty acid uptake and increasing ACC2 and CPT1 expression (Lemke et al. 2008). 
In vitro studies in cultured rat hepatocytes have also suggested that GCs promote VLDL 
secretion (Wang, McLeod, Yao, & Brindley 1995).  
Our data have examined the effects of GC alone and in combination with insulin using 
primary and human cell lines. In the C3A cells, cortisol alone increased mRNA expression of 
ACC2 and FAS but not ACC1, diacyly glycerol acyl transferase 2 (DGAT2) and glycerol 
phosphate acyl transferase (GPAT). However, cortisol alone decreased de novo lipogenesis in 
a dose dependent manner in C3As probably reflecting rate-limiting, post-transcriptional 
regulation.  
In primary human hepatocyte cultures, no significant changes in lipogenic gene expression 
were observed with GC pre-treatment. However, GCs in isolation were able to decrease 
lipogenesis consistent with our C3A cell data in agreement with adipose tissue (Gathercole et 
al.2011b). Our data therefore suggest that in the fasting state (in the absence of insulin) within 
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liver, the elevated GC to insulin ratio will result in a net inhibitory effect upon local 
lipogenesis. 
In many situations, GC and insulin have opposing actions, but the specific interaction of GC 
and insulin signalling in hepatocytes remains controversial with conflicting data in the 
published literature (Caro and Amatruda 1982;Klein et al. 2002;Kosaki and Webster 
1993;Olefsky et al. 1975). However, there is some evidence showing that GC may potentiate 
the action of insulin to promote lipogenesis within hepatocytes (Amatruda, Danahy, & Chang 
1983). In addition, mice treated with corticosterone increased hepatic triglyceride which was 
confirmed by histology, quantitative TAG assay and serum free fatty acid levels (Morgan et 
al. 2014).  
Interestingly, when C3A cells were treated with GC in combination with insulin, the effect of 
insulin to induce an increase in lipogenesis was augmented. This stimulatory effect of insulin 
upon lipogenesis was also enhanced in a dose dependent manner in an identical experiment in 
primary human hepatocytes in which it was paralleled by a decrease in ser-79/218 
phosphorylation of ACC. This raises the possibility that in the physiological fed state, when 
insulin to GC ratio is elevated, insulin and GC act synergistically promoting lipid storage. Our 
data on GC impact on insulin action upon increasing hepatic lipogenesis is consistent with the 
published data (Berthiaume et al. 2007;Hazlehurst et al. 2013;Wang et al. 2004) on 
subcutaneous adipose tissue. Overall therefore, we propose, that this reflects the function of 
liver to mobilize lipid during fasting and to store lipid in the fed state (Figure 3-18).  
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Figure 3-18 GC decreases de novo lipogenesis in the absence of insulin (fasted state) in all 
three insulin target tissues. However in the presence of insulin (fed state) GC decreases 
lipogenesis in muscle with an increase in liver and adipose tissue. 
 
 
In summary, my data have added to the concept of tissue specific response of metabolic target 
tissues to glucocorticoids and insulin. We determined that the concept of GCs to induce 
‘global’ insulin resistance might reflect inhibition of insulin action in skeletal muscle, with 
insulin sensitivity in adipose tissue and potentially the liver. Accordingly, GCs decrease 
lipogenesis in muscle (Morgan et al. 2013) and increase it in adipose tissue (Gathercole et al. 
2011a) and hepatocytes in the fed (high insulin) state (Hazlehurst et al. 2013). This may help 
explain the increased fat mass, obesity and hepatic steatosis observed in state of GC excess 
where GCs and insulin can act synergistically to drive lipid accumulation. 
However, the in vitro data that we have generated in primary cultures and cell lines need to be 
tested in clinical studies. Such studies that have been performed within the group have begun 
to suggest that GCs may cause hepatic insulin resistance (alongside skeletal muscle insulin 
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resistance and adipose insulin sensitisation) (Hazlehurst et al. 2013) and this reflects the 
relative simplicity of cell culture models as opposed to complex in vivo physiology. 
One of the challenges of this study was using the right model; C3As were not highly insulin 
sensitive and Huh7.5 did not respond to GC treatments. However, all the experiments were 
also carried out in primary cultures which are significantly insulin sensitive. Primary cultures 
are expensive, and therefore, we were not able to perform further functional assays such as β-
oxidation to have a better understanding of GCs effects on hepatic lipid metabolism. The 
optimisation of western blotting on separation of ACC1 and 2 isoforms was not successful, 
and therefore, the western blotting was carried out using total ACC. Basal de novo lipogenesis 
were significantly lower in primary hepatocytes compared to C3As. This may represent 
differences in cell origin, C3As are an hepatocellular carcinoma cell line and cancer cells have 
higher rates of lipogenesis (Swinnen et al. 2006). Two different media were used for culturing 
the primary hepatocytes and C3A cells which may contribute to differences in baseline levels 
of lipogenesis. However, cells were fasted in serum free media and corrected for the glucose 
levels (initial glucose levels in MEM and Williams’ E media are 1 and 2g/L, respectively- 
these media were glucose only without any fatty acids supplementation). These factors can 
impact on both basal lipogenesis and the response to stimuli, however the response to 
treatment was similar in each of the models.  
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4.1.Aims 
 
• To optimise an in vitro model for metabolic assessments in human hepatocytes 
• To define the impact of androgens upon insulin sensitivity in human hepatocytes and 
to compare effects in hepatocytes from male and female donors 
• To study the impact of androgens on lipid metabolism in human hepatocytes and to 
compare effects in hepatocytes from male and female donors 
 
4.2.Background  
 
Low testosterone is reported to be associated with increased body fat, obesity, type 2 diabetes 
and insulin resistance (Wang et al. 2011). However, the effect of testosterone on hepatic liver 
metabolism has not been studied in detail. Vozke et al. (2010) reported that low testosterone 
was associated with hepatic steatosis. Moreover, hepatic AR knockout mice fed a high fat diet 
have improved insulin resistance and hepatic steatosis. However, testosterone levels were not 
measured in this study (Lin et al. 2008). Interestingly, DHT has been predicted to have an 
opposing action with increased hepatic Stearoyl-CoA desaturase1 (SCD1), a rate-limiting step 
in monounsaturated fatty acid synthesis (Moverare-Skrtic et al. 2006). Conversely, women 
with hyperandrogenic polycystic ovary syndrome (PCOS) are predisposed to developing 
NAFLD that appears to be independent of insulin resistance or obesity (Jones et al. 2012).  
Moreover, testosterone can have different pathways of action; conversion to DHT or binding 
directly to AR, conversion to 17β-estradiol via the action of aromatase and subsequent 
activation of the ER, and through non-genomic mechanisms (discussed in detail in section 
1.4.1.2).  
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Ultimately, the relationship between hepatic steatosis and testosterone concentrations remains 
controversial with conflicting data in the published literature. Therefore, the interaction 
between insulin and androgen in hepatic lipid metabolism needs further investigations. 
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4.3.Method 
4.3.1.C3A cell culture and treatments 
 
C3A cells were cultured in MEM with 10% FCS and split into 24 well plates, as described in 
section 2.1.1.2. Before treatment, cells were fasted overnight in serum free MEM without any 
supplements. C3As were treated with testosterone (dose range 5, 50nM) and DHT (10nM) in 
order to accurately determine the response to androgens. 
 
4.3.2.Primary human hepatocytes cell culture and treatments 
 
Primary human hepatocytes were purchased from BioreclamationIVT Technologies 
(Baltimore, Maryland, United States). Access to the donors’ medical history was provided 
and the 8 most healthy donors (male: n=4, age 54±14years, BMI 28.4±3 kg/m2; female: n=4, 
age 56±4.7years, BMI 23.98±3.1 kg/m2, data are expressed as mean ± s.e) were chosen. 
Diabetic patients or those who had taken GC therapy, or any other related medications were 
excluded as were those with viral infection and high alcohol consumption (Appendix). Cells 
were cultured in InVitroGRO CP medium (BioreclamationIVT Technologies, Baltimore, 
USA) and seeded into 12 and 24 collagen coated well plates, as described in section 2.2.2. 
Before treatment, cells were fasted for 3 hours in Williams’ Medium E without any 
supplements. To define the impact of insulin and androgens, cells were treated with 
testosterone (dose range 5, 50nM) and DHT (10nM) in the presence or absence of insulin 
(5nM, 24h). 
 
 
127 
 
Chapter 4     Impact of androgens on hepatic insulin sensitivity and lipid metabolism comparing male and female hepatocytes 
4.3.3.RNA extraction  
After 24 hours of treatment, RNA was extracted as described in section 2.6.2, from both 
C3As and primary hepatocytes, using Tri-Reagent. The extracted RNA was then used for 
Real-Time PCR. 
4.3.4.Real-Time PCR 
The mRNA expression levels of insulin signalling (IRS1/2, AKT1/2) and lipid metabolism 
(ACC1/2, CPT1, DGAT2, GPAT, FAS) genes were determined using ABI-7500 PCR 
machine (Perkin-Elmer Applied Biosystems, Warrington, UK) as described in section 
2.8.2.18s rRNA gene was used as a control in all reactions and all probes and primers were 
supplied by Applied Biosystem. 
4.3.5.AR overexpression 
In contrast to primary human hepatocytes, AR expression is very low in C3As, and therefore 
the coding sequence of AR was cloned into the pcDNA3.1 vector (Invitrogen, Paisley, UK) 
by Dr Silvia Parajes in our lab and transiently transfected into C3A cells with a help of a 
master’s student, Nikolaos Nikolaou, as described in section 2.11.1. Cells were then treated 
with and without testosterone (50nM) and DHT (10nM) for the final 6h of transfection. The 
transfection efficiency was determined using a plasmid containing green fluorescence protein 
(GFP).  
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4.3.6.De novo lipogenesis assay 
 
In order to investigate the effect of androgens and insulin on lipid accumulation within liver at 
a functional level, de novo lipogenesis was determined by measuring 14C-acetate 
incorporation into cellular lipid. This assay was optimised in both C3As (50nM of insulin) 
and primary cells (5nM of insulin) to identify the optimal incubation time to achieve maximal 
insulin stimulated de novo lipogenesis. As described previously (chapter 3 section 3.3.6), in 
both C3As and primary cultures, insulin had its most marked effect at 6h. Based on this 
optimization, for the final 6h of treatment with steroid hormones, 0.12µCi/L 1-[14C]-acetic 
acid with cold sodium acetate to a final concentration of 10uM acetate was added to each well 
to quantify the relative contribution of de novo lipogenesis to total lipid synthesis within the 
cells. The lipid content of the cells was recovered in chloroform: methanol (2:1 by vol/vol) 
(Folch et al. 1957) and radioactivity was measured by scintillation counting as described in 
section 2.10.2. 
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4.4.Results 
4.4.1.Optimising the in vitro model by comparing the gene profiles 
 
In order to choose the most appropriate model to study the effect of androgens upon lipid 
metabolism and insulin sensitivity in liver, gene expression profiles were compared between 
available liver cell lines and primary hepatocytes. Interestingly, only primary hepatocytes 
expressed the AR, and therefore, primary hepatocytes represent the best model (Table 4-1). 
However, C3As represent a good model for AR overexpression study as they do not express 
AR gene and also are a less expensive model compared to primary cultures. In addition, 
choosing C3As as the cell line model would give us the ability to compare the effect of GCs 
and androgens on hepatic lipogenesis as the main cell line used in our GC studies was C3As. 
Therefore, we started our experiments using C3As and then carried out the experiments in 
primary cultures. 
 
 
Table 4-1 Gene expression profiles were compared between Primary Hepatocytes, HepG2, 
Huh7.5 and C3A cell lines. Primary hepatocytes are the only model that expresses mRNA 
encoding AR. Data are expressed as ΔCt values. 
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4.4.2. Androgen regulation of insulin signalling in C3As 
4.4.2.1.Gene expression  
 
Testosterone pre-treatment did not alter the expression of insulin signalling genes and among 
steroid hormone metabolizing and signalling genes, only GR expression level was increased 
significantly (Table 4-2 and Figure 4-1).  
 
    Gene Control Testosterone (50 
nM) 
P 
Value 
GR 16.46 ± 0.40 15.80 ± 0.47 P<0.05 
5αR1 17.07 ± 0.79 16.90 ± 0.89 NS 
5α33 14.14 ± 0.65 13.76 ± 0.90 NS 
5βR 16.40 ± 0.43 15.97± 0.60 NS 
H6PDH 15.09 ± 0.47 14.88 ± 0.61 NS 
AKT1 15.20 ± 0.60 15.17 ± 0.53 NS 
AKT2 16.30 ± 0.35 16.03 ± 0.53 NS 
IRS1 17.98 ± 1.09 17.61 ± 0.95 NS 
 
Table 4-2 mRNA expression of pre-receptor regulation and insulin signalling genes in C3As 
in response to testosterone (50nM, 24h) treatment. Data are expressed as mean ΔCt values ± 
s.e of n=5 experiments and Student’s t-tests were applied using Sigmastat 3.1 to compare 
testosterone treatment to control. 
.            
 
Figure 4-1 Testosterone (50nM, 24h) increases mRNA expression of GR in C3As. Data are 
the mean values from n=7 experiments and expressed as mean arbitrary unit values ± s.e). 
Student’s t-test was applied using Sigmastat 3.1 to compare testosterone treatment to control 
(*p<0.05 vs. control). 
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4.4.3.Androgen regulation of lipid homeostasis in C3As and primary 
hepatocytes 
4.4.3.1.Gene expression in C3As 
 
No significant changes were identified in lipid metabolism gene expression after testosterone 
(50nM) pre-treatment (Table 4-3). 
 
Gene Control Testosterone (50 nM) P 
Value 
ACC1 16.53 ± 0.63 16.28 ± 0.64 NS 
ACC2 21.04 ± 1.78 20.70 ± 1.82 NS 
Cpt1A 17.34 ± 0.71 17.16 ± 0.65 NS 
FAS 14.20 ± 0.53 14.15 ± 0.70 NS 
 
 Table 4-3 mRNA expression of lipid metabolism genes in C3As in response to testosterone 
(50nM, 24h) treatment. Data are expressed as mean ΔCt values ± s.e of n=5 experiments and 
Student’s t-test were applied using Sigmastat 3.1 to compare testosterone treatment to 
control.    
 
 
4.4.4.De novo lipogenesis assay in C3As 
 
AR overexpression was confirmed by real-time PCR (30.04 ± 0.018AU AR vs. 0.02 ± 
0.003AU control, p<0.05). Both testosterone and DHT treatment increased basal de novo 
lipogenesis (124.9 ± 6.2% [50nM testosterone], 128.1 ± 4.7% [10nM DHT] vs. 100% control 
of n=4, p<0.05 mean ± s.e). Even in the absence of testosterone or DHT, AR overexpression 
alone caused a significant increases in 1-[14C]-acetate incorporation into lipid (202.7±10.8% 
AR vs. 100% control [vector only] of n=4, p<0.05, mean ± s.e). Treatment with either 
testosterone or DHT did not further enhance lipid accumulation (209.6 ±16.5%% [50nM 
testosterone], 224.6 ± 8.6% [10nM DHT] vs. 202.7±10.8% (control), mean ± s.e, p<0.05) 
(Figure 4-2). 
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Figure 4-2 Androgen receptor (AR) overexpression alone, and in the presence of 
T=testosterone (50nM, 24h) or DHT (10nM, 24h) increases de novo lipogenesis in C3As. 
However, neither T (50nM, 24h) nor DHT (10nM, 24h) further enhanced de novo lipogenesis 
on AR overexpressed C3A cells. Data are presented as 14C-acetate incorporation into lipid 
(dpm, mean ± s.e) of n=4 experiment and one way ANOVA with Dunnett’s post-hoc analysis  
was applied using Sigmastat 3.1 to compare testosterone and DHT treatments to control 
(*p<0.05 vs. control). 
 
 
4.4.5.De novo lipogenesis assay in primary hepatocytes 
 
Insulin stimulation of lipogenesis was observed in primary cultures (153.92 ± 18.77 % [INS] 
vs. control (100%), 133.27 ± 4.4% [INS + 5nM testosterone] vs. 102.08 ± 12.32% [5nM 
testosterone], 181.31 ± 22.23% [INS + 10nM DHT] vs. 123.76 ± 13.72% [10nM DHT], (5nM 
insulin) of n=4, p<0.05, mean ± s.e). However, there were no significant changes in de novo 
lipogenesis following testosterone or DHT treatment in primary cultures from male donors 
(Figure 4-3).   
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Figure 4-3 In primary cultures of male donors, testosterone (5 and 50nM, 24h) nor DHT 
(10nM, 24h) have any effect on de novo lipogenesis. However, insulin sensitivity is confirmed 
again in primary hepatocytes. Insulin concentration=5nM, data are presented as 14C-acetate 
incorporation into lipid (% from control, mean ± s.e) of n=4 experiment and one way ANOVA 
with Tukey’s post-hoc analysis was applied using Sigmastat 3.1 to compare insulin stimulated 
treatments to no insulin treatments (*p<0.05 vs. no insulin).  
 
 
In contrast, in samples from female donors, testosterone increased lipogenesis (139.66 ± 
17.63% [5nM testosterone] vs. 100% (control) of n=4, p<0.05, mean ± s.e) and this 
stimulatory effect of testosterone upon de novo lipogenesis was augmented in the presence of 
insulin (153.89 ± 18.74% [INS + 5nM testosterone] vs. 100% (control) of n=4, p<0.05, mean 
± s.e). Interestingly, DHT decreased lipogenesis in hepatocytes from female donors only 
(100% (control) vs. 61.38 ± 10.42% [10nM DHT] of n=4, p<0.05, mean ± s.e) (Figure 4-4). 
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Figure 4-4 In primary cultures of female donors, testosterone at 5nM (for 24h) increased de 
novo lipogenesis and this stimulatory effect was augmented in presence of insulin (5nM for 
24h). However, DHT (10nM) decreased de novo lipogenesis compared to control. Data are 
presented as 14C-acetate incorporation into lipid (% from control, mean ± s.e) of n=4 
experiment and one way ANOVA with Dunnett’s post-hoc analysis was applied using 
Sigmastat 3.1 to compare multiple treatments with control (*p<0.05 vs. control no insulin). 
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4.5.Discussion 
 
In this study, we have shown that androgens are able to increase lipid accumulation within 
C3A cells and in primary cultures of human hepatocytes from female, but not male donors. 
Cross-sectional clinical studies have shown that low testosterone concentrations are 
associated with increased hepatic steatosis in men (Kim et al. 2012;Volzke et al. 2010) and 
are consistent with findings in rodent models suggesting that DHT treatment can decrease 
hepatic lipid accumulation.  In contrast, women with polycystic ovarian syndrome (PCOS), a 
condition characterised by androgen excess as well as insulin resistance, are at an increased 
risk of developing NAFLD although the precise contribution of each of these processes 
(insulin resistance and androgen excess) to the development of NALFD remains unclear 
(Jones et al. 2012;Markou et al. 2010).  
Although in vitro cell models are not able to replicate all the processes that contribute to the 
development of NAFLD in vivo, in C3A cells, high doses of testosterone (50nM), and DHT 
increased de novo lipogenesis. However, lipogenic gene expression changes were not 
mirrored the de novo lipogenesis assay as no significant changes were observed after 
testosterone (50nM) pre-treatment suggesting that post-transcriptional modification of 
enzyme activity may be important.  
Interestingly, in primary cultures, we observed sexually dimorphic effects. In cells derived 
from male donors, androgen treatment failed to have a significant impact upon lipogenesis, 
however in female samples, 5nM testosterone increased de novo lipogenesis. It is interesting 
to note that DHT did not alter lipogenesis in hepatocytes from male donors, but decreased 
lipogenesis in female hepatocytes. The mechanisms underpinning this observation and the 
physiological relevance (the concentrations of DHT used far exceed those seen in the female 
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circulation) are not clear. The discrepancy between the effects of androgens on C3A cells and 
in primary cultures may reflect origin of C3A cells from human hepatoma (and the well 
described impact of androgens upon their pathogenesis) (Kalra et al. 2008) and this serves to 
emphasize the important of endorsing in vitro observations in additional models including 
human primary cultures.  
Differential tissue-specific effects are also well described. In prostate cells, androgens also 
increase de novo lipogenesis (Moon et al. 2011;Swinnen et al. 1997) whilst in adipose tissue, 
they inhibit pre-adipocyte differentiation and adipogenesis (Chazenbalk et al. 2013;Singh et 
al. 2006). 
Enhancing androgen action through androgen receptor overexpression increased de novo 
lipogenesis providing further evidence as to the potent ability of this pathway to regulate lipid 
accumulation. Interestingly, we observed no additional effects of providing additional AR 
ligand, perhaps suggesting maximal stimulation with receptor overexpression alone. 
Furthermore, AR overexpression alone in the absence of ligand was able to increase 
lipogenesis. While, it is possible that this may reflect existing intracellular androgen 
availability, ligand-independent activation of the AR remains plausible. This has been 
identified as a potential mechanism that might be crucial in regulating cell growth in the 
context of malignancy (Chung et al. 2014) notably in prostate cancer (Kasina and Macoska 
2012) although the precise mechanisms that underpin ligand-independent AR activation 
remain unclear.  
Importantly, not all actions of androgens upon the liver may be mediated by classical AR 
signalling. AR-independent regulation of lipogenesis in the liver has been observed in 
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testicular feminized mice that lack a functional androgen receptor, with a reduction in 
lipogenesis following testosterone treatment (Kelly et al. 2014). 
One of the limitations of the study was that no hepatic cell line expressed AR. However, 
C3As were transfected with AR and primary cultures were used as an alternative model. 
Primary cultures are expensive, and therefore, we were not able to perform further functional 
assays such as β-oxidation to have a better understanding of androgens effects on hepatic lipid 
metabolism. In addition, there are other sex hormones such as oestrogen which is involved in 
lipid metabolism and also the ratio between testosterone and this hormone might also play a 
role in lipid accumulation. Tamoxifen, which is a selective oestrogen receptor modulator and 
it is widely used in treatment of oestrogen- responsive breast cancer, induces the development 
of NAFLD as its frequent side effect (Murata et al. 2000). In a study using orchidectomised 
rats on high fat diet, they showed that estradiol and DHT can separately decrease lipid 
accumulation in zone 3 and 1 respectively. However, when these rats were treated with 
estradiol and DHT together, they observed an additive positive effect on normalising impaired 
fat accumulation in all three zones of their livers (Zhang et al. 2013). We only studied 
testosterone and DHT effect on lipid metabolism and did not study the effect of oestrogen 
which is a limitation of this study and might be one of the reasons for the observed sexually 
dimorphic responses from primary cultures on androgens and lipid metabolism in female 
donors compared to males 
.  
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5.1.Aims 
 
• To determine the contribution of pre-receptor GC metabolism (through the activity of 
the A-ring reductases) to control GC availability in liver cell models 
• To define the impact of manipulation of pre-receptor GC metabolism to alter 
metabolic phenotype (lipid homeostasis) in human liver cell models 
 
5.2.Background  
 
The effects of GCs within the body especially on the development of obesity and insulin 
resistance are well described. This is exemplified by patients with excessive circulating GC, 
Cushing’s syndrome. The most common observations in these patients are central obesity, 
hypertension, insulin resistance and in some cases type-2-diabetes (T2D) (Van Staa et al. 
2000). In patients with simple obesity and insulin resistance, circulating cortisol is not 
increased (Fraser et al. 1999). However, intracellular GC metabolism, especially in insulin 
target tissues (including liver, adipose tissue, and muscle) is an important regulatory step.  
The 11β-HSD1 isoform predominates in liver and adipose tissue, and therefore amplifying 
local GC effects (Tomlinson et al. 2004). Non-selective inhibitors of 11β-HSD type 1 and 2 
(carbenoxolone), increased insulin sensitivity in T2D and improved hepatic insulin sensitivity 
in human (Andrews et al. 2003;Walker et al. 1995). Moreover, selective inhibition of 11β-
HSD1 decreased local GC and improved insulin sensitivity in muscle (Alberts et al. 
2002;Alberts et al. 2003). As 11β-HSD1 has been considered as a therapeutic target, A-ring 
reductases might be as important with the opposite action of cortisol clearance. 
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We have shown that increased global 5αR activity is associated with impaired glucose 
tolerance and may be a future predictor of metabolic disease (Crowley et al. 2014;Tomlinson 
et al. 2008). The lack of SRD5A2 expression in the mouse liver (contrasting with human 
liver) has limited the interpretation of data from SRD5A2 knock out mice (Dowman et al. 
2013) and has highlighted the importance of the use of human models. There are no in vitro 
data using human cells that have begun to explore the mechanisms that might be responsible 
for the observations seen in rodent models or in clinical studies. The translational importance 
of this not only relates to enhancing our understanding of the pathogenesis of NAFLD, but 
also to the widespread use of SRD5A2 inhibitors including the selective SRD5A2 inhibitor, 
finasteride, and the non-selective (SRD5A1 and 2) inhibitor, dutasteride. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
141 
 
Chapter 5                    Pre-receptor metabolism of GCs as a regulator of metabolic phenotype in human liver 
5.3.Method 
5.3.1.C3A cell culture and treatments 
 
C3A cells were cultured in MEM with 10% FCS and split into 24 well plates, as described in 
section 2.1.1.2. Before treatment, cells were fasted overnight in MEM without any 
supplements. C3As were treated with testosterone (50nM) and cortisol (dose range 250, 500, 
1000nM) in order to accurately determine the pre-receptor GC response. 
 
5.3.2.Primary human hepatocytes cell culture and treatments 
 
Primary human hepatocytes were purchased from BioreclamationIVT Technologies 
(Baltimore, Maryland, United States). Access to the donors’ medical history was provided 
and the 4 most healthy donors (male: n=4, age 54±14years, BMI 28.4±3 kg/m2, data are 
expressed as mean ± s.e) were chosen. Diabetic patients or those who had taken GC therapy, 
or any other related medications were excluded as were those with viral infection and high 
alcohol consumption (Appendix). Cells were cultured in InVitroGRO CP medium 
(BioreclamationIVT Technologies, Baltimore, USA) and seeded into 12 and 24 collagen 
coated well plates, as described in section 2.2.2. 
Before treatment, cells were fasted for 3 hours in Williams’ Medium E without any 
supplements. To define the impact of 5αR inhibitors, cells were treated with cortisol (250nM), 
finasteride (500nM) and dutasteride (500nM) alone and in combination with 250nM of 
cortisol. 250 nM is a physiological concentration of cortisol and the higher does for cortisol 
was not used as the aim of this experiment was to test if finasteride and dutasteride can 
enhance the effect of cortisol. In addition, it is not entirely clear if finasteride and dutasteride 
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are competitive or uncompetitive inhibitors, therefore, 500nM which is twofold excess 
concentration of these inhibitors (compared to cortisol concentration of 250nM) was used. 
 
5.3.3.RNA extraction  
 
After 24 hours of treatment, RNA was extracted (as described in section 2.6.2), from both 
C3As and primary hepatocytes, using Tri-Reagent. The extracted RNA was then used for 
Real-Time PCR. 
 
5.3.4.Real-Time PCR 
 
The mRNA expression levels of pre-receptor regulation (GR, SRD5A1 and 3, H6PDH), 
insulin signalling (IRS1/2, AKT1/2) and lipid metabolism (ACC1/2, CPT1, DGAT2, GPAT, 
FAS) genes were determined using ABI-7500 PCR machine (Perkin-Elmer Applied 
Biosystems, Warrington, UK) as described in section 2.8.2. 
18s rRNA gene was used as a control in all reactions and all probes and primers were supplied 
by Applied Biosystem. 
 
5.3.5.SRD5A2 overexpression 
 
In contrast to primary human hepatocytes, SRD5A2 expression is very low in C3As, and 
therefore the coding sequence of SRD5A2 was cloned into the pcDNA3.1 vector (Invitrogen, 
Paisley, UK) by Dr Laura Gathercole in our lab and transiently transfected into C3A cells as 
described in section 2.11.1. C3As were then treated with and without testosterone (50nM) and 
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cortisol (dose range 250, 500, 1000nM) for the final 24h of transfection. The transfection 
efficiency was determined using a plasmid containing green fluorescence protein (GFP).  
 
5.3.6.Site directed mutagenesis (SDM) 
 
The R246Q mutant was inserted by site directed mutagenesis into the SDR5A2 cDNA using 
the Quikchange II site-directed mutagenesis kit (Agilent Technologies UK Limited, Cheshire, 
UK) as per the manufactures guidance (described in section 2.12.2). Sequencing was then 
performed to confirm if the correct mutation had been made. The R246Q mutant was 
transiently transfected into C3A cells as described in section 2.11.1. C3As were then treated 
with and without testosterone (50nM) and cortisol (dose range 250, 500, 1000nM) for the 
final 24h of transfection. The transfection efficiency was determined using a plasmid 
containing green fluorescence protein (GFP). 
 
5.3.7.Gas and Liquid chromatography/Mass spectrometry (GC/MS 
and LC/MS) 
 
Cortisol was measured by gas chromatography mass spectrometry (GC-MS). The method was 
adapted from a historic in house method using for more than 20 years (Arlt et al. 2011). 
Cortisol was extracted from cell media after addition of the internal standard cortisol-d4 
(which is labelled with deuterium residues that allows specific ion detection). Briefly, 
transfected cells were incubated with 200nM of cortisol for 24 hours. One mL of media was 
collected, extracted by solid-phase extraction (SPE) and the samples were derivatised 
overnight to form methyloxime trimethylsilylethers. The final derivative was dissolved in 55 
μL cyclohexane, which was transferred to an autosampler vial for gas chromatography/mass 
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spectrometry (GC/MS) analysis. An Agilent 5973 instrument (www.agilent.com) was used in 
a selected ion monitoring mode. Cortisol was positively identified by comparison to an 
authentic reference standard that gave a double peak at approximately 25.7 min, monitored 
ion was cortisol 605 and cortisol-d4 609 was used as an internal control. 
5αR activity was measured using liquid chromatography/mass spectrometry (LC/MS). 
Briefly, cells were incubated with 100nM T for 30 minutes. Media was removed and 
transferred into glass tubes. Five milliliters dichloromethane was added to each tube, vortexed 
for 30 seconds, and then centrifuged for 10 minutes at 1500 g. The aqueous phase was 
removed and the steroid-containing organic solvent phase evaporated in air to dryness. The 
steroid extract was analyzed using LC-MS/MS (Xevo TQ mass spectrometer combined with 
an acquity uPLC system) with an electro-spray ionisation source in positive ion mode. Steroid 
hormones were eluted from a BEH C18 2.1 × 50 mm 1.7 μm column using a methanol/water 
gradient system, solvent A was water 0.1% formic acid, and B was methanol 0.1% formic 
acid. The flow rate was 0.6 mL/min and starting conditions were 45% B increasing linearly to 
75% B over 5 minutes. Steroid hormones were positively identified by comparison of 
retention times and mass transitions to steroid standards. Retention time, mass transitions 
quantifier ion (qualifier ion) testosterone 2.8min, 289>97 (289>109), testosterone-d3 2.7min, 
292>109 (292>97), DHT 3.0min, 291>255, (291>159), DHT-d3 3.0min 294>258, (294>159). 
Testosterone-d3 and DHT-d3 were used as internal standard. 
All the samples for GC, LC/MS were prepared by a master’s student, Nikolaos Nikolaou, and 
the data were analysed by Dr Angela Taylor. 
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5.3.8.De novo lipogenesis assay 
 
In order to investigate the effect of pre-receptor GC metabolism, 5αRs, on lipid accumulation 
within liver at the functional level, de novo lipogenesis rates were determined by measuring 
14C-acetate incorporation into cellular lipid. This assay was optimised in both C3As (50nM of 
insulin) and primary cells (5nM of insulin) to identify the optimal incubation time to achieve 
maximal insulin stimulated de novo lipogenesis. As optimised previously (chapter 3 section 
3.3.6), in both C3As and primary cultures, insulin had its most marked effect at 6h. Therefore, 
we opted that for the final 6h of treatment with steroid hormones, 0.12µCi/L 1-[14C]-acetic 
acid with cold sodium acetate to a final concentration of 10uM acetate would be added to 
each well to quantify the relative contribution of de novo lipogenesis to total lipid synthesis 
within the cells. The lipid content of the cells was recovered in chloroform: methanol (2:1 by 
vol/vol) (Folch et al. 1957) and radioactivity was measured by scintillation counting as 
described in section 2.10.2. 
. 
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5.4.Results 
5.4.1.Pre-receptor enzyme expression in primary human 
hepatocytes and liver cell lines 
5.4.1.1.mRNA expression 
 
In order to choose the most appropriate model to study the effect of pre-receptor GC 
metabolism upon lipid metabolism and insulin sensitivity in liver, gene expression profiles 
were compared between available liver cell lines and primary hepatocytes. C3A cells and 
primary hepatocytes expressed the least and the most SRD5A2 respectively, and therefore, 
representing good in vitro models for this study (Table 5-1).  
 
 
Table 5-1 Gene expression profiles were compared between Hepatcytes, HepG2, Huh7.5 and 
C3A cell lines. SRD5A2 expressed the least and the most in C3As and primary hepatocytes 
respectively. Therefore, C3As and primary hepatocytes were used for overexpression and 
chemical inhibition of SRD5A2 respectively. Data are expressed as ΔCt values. 
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5.4.2. Regulation of pre-receptor modifying enzymes by GCs, 
androgens in C3A cells  
5.4.2.1.mRNA expression  
 
To determine the contribution of pre-receptor GC metabolism to GC and androgen 
metabolism in liver cell line, gene expressions were measured after GC and testosterone 
treatment. GC was without effect (Table 5-2) and testosterone pre-treatment only increased 
GR expression level significantly (Table 5-2 and Figure 5-1).  
 
a) 
    Gene Control Cortisol (250 nM) P 
Value 
GR 16.46 ± 0.40 16.03 ± 0.26    NS 
5αR1 17.07 ± 0.79 16.88 ± 0.84 NS 
5αR3 14.14 ± 0.65 13.95 ± 0.64 NS 
5βR 16.40 ± 0.43 16.27± 0.54 NS 
H6PDH 15.09 ± 0.47 14.88 ± 0.51 NS 
b) 
    Gene Control Testosterone (50 
nM) 
P 
Value 
GR 16.46 ± 0.40 15.80 ± 0.47 P<0.05 
5αR1 17.07 ± 0.79 16.90 ± 0.89 NS 
5αR3 14.14 ± 0.65 13.76 ± 0.90 NS 
5βR 16.40 ± 0.43 15.97± 0.60 NS 
H6PDH 15.09 ± 0.47 14.88 ± 0.61 NS 
 
Table 5-2 mRNA expression of pre-receptor regulation genes in C3As in response to cortisol 
(250nM, 24h) (a) and testosterone (50nM, 24h) treatment (b). Only testosterone (50nM, 24h) 
increases mRNA expression of GR. Data are expressed as mean ΔCt values ± s.e of n=5 
experiments and Student’s t-tests were applied using Sigmastat 3.1 to compare cortisol and 
testosterone treatments to their controls.       
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Figure 5-1 Testosterone (50nM, 24h) increases mRNA expression of GR in C3As. Data are 
the mean values from n=7 experiments and expressed as mean arbitrary unit values ± s.e. 
Student’s t-test was applied using Sigmastat 3.1 to compare testosterone treatment to control 
(*p<0.05 vs. control). 
 
 
5.4.3.Modulation of SRD5A2 expression and activity  
5.4.3.1.Transfection 
 
An acceptable (approximately 70%) transfection efficiency of SRD5A2 in C3As was 
observed by using a plasmid containing green fluorescence protein (GFP) (Figure 5-2). 
 
 
 
 
 
 
 
 
Figure 5-2 70% SRD5A2 transfection efficiency in C3As was observed using a plasmid 
containing green fluorescence protein (GFP). 
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5.4.3.1.1.mRNA expression  
 
More than 1000-fold increase was observed in the mRNA expression level of SRD5A2 in 
C3A transfected cells compared to control (vector only) cells (SRD5A2:1000-Fold 3.8 ± 0.2 
[Transfected] vs. 13.8 ± 0.3 [vector only], mean ∆Ct values ± s.e) (Figure 5-3). 
 
a) 
 
 
 
b) 
 
Figure 5-3 5αR2 overexpression was confirmed by Real-time PCR (a). Increased 5αR2 
expression was observed following transfection into C3A cells compared to vector. There is a 
very low endogenous level of 5αR2 expression in vector only cells but it is not absent, and 
therefore, it is not a true negative control (b). Data presented are mean ± s.e of n=3 
experiments and Student’s t-test was applied using Sigmastat 3.1 to compare 5αR2 
overexpression to vector (*p<0.05 vs. vector). 
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5.4.3.1.2.Enzymatic activity 
 
Functional activity was confirmed through increased DHT generation following incubation 
with testosterone (DHT: 7.5±0.2 [vector] vs. 126.4±14.7nM [SRD5A2], initial testosterone 
concentration=100nM, mean ± s.e, p<0.05) (Figure 5-4) and clearance of cortisol (77nM 
[SRD5A2] vs. 130nM [vector], initial cortisol concentration=200nM, p<0.05, mean ± s.e) 
(Figure 5-5) as measured by LC/MS and GC/MS respectively. The mutant SRD5A2 
construct, R246Q, was without activity. Conversion of testosterone to DHT was similar to 
that observed in the vector only transfection control (DHT: 7.5±0.2 [vector] vs. 9.2±0.8 nM 
[SRD5A2- R246Q], p<0.05, mean ± s.e) (Figure 5-4).  
 
Figure 5-4 Transfection of wild-type 5αR2 (in contrast to the mutant R246Q construct) in 
C3As is associated with increased dihydrotestosterone [DHT] generation from testosterone 
(100nM). Data presented are mean ± s.e of n=3 experiments and pcDNA3.1is the vector. One 
way ANOVA with Dunnett’s post-hoc analysis was applied using Sigmastat 3.1 to compare 
the wild-type 5αR2 and the mutant R246Q construct to vector (*p<0.05 vs. vector). 
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Figure 5-5 Transfection of wild-type 5αR2 (in contrast to the mutant R246Q construct) in 
C3As is associated with increased cortisol (200nM) clearance. Data presented are mean ± s.e 
of n=3 experiments and pcDNA3.1is the vector. Student’s t-test was applied using Sigmastat 
3.1 to compare the cortisol clearance between 5αR2 overexpression and vector (*p<0.05 vs. 
vector). 
 
 
5.4.3.1.3.Functional impact of modulation of pre-receptor GC 
metabolism upon de novo lipogenesis in human hepatocytes 
5.4.3.1.3.1.Genetic manipulation in C3A cells 
 
As observed previously, cortisol decreased de novo lipogenesis in a dose dependent manner in 
C3A cells transfected with the vector construct alone. In the absence of cortisol, SRD5A2 
overexpression had no effect. However, in the presence of cortisol, SRD5A2 restored 
lipogenesis to levels observed in untreated controls (82.5% [100nM cortisol] vs. 103.3% 
[SRD5A2+100nM cortisol], 71.01% [250nM cortisol] vs. 109.4% [SRD5A2+250nM 
cortisol], 61.9% [1000nM cortisol] vs. 103.8% [SRD5A2+1000nM cortisol], p<0.05, mean ± 
s.e), control=100%) (Figure 5-6). 
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Figure 5-6 In C3A cells, the decrease in lipogenesis associated with increasing doses of 
cortisol was abolished in cells transfected with wild-type 5αR2. Data are presented as 14C-
acetate incorporation into lipid (% from control, mean ± s.e) of n=5 experiment. One way 
ANOVA with Dunnett’s post-hoc analysiswas applied using Sigmastat 3.1 to compare 
multiple cortisol treatments to control (*p<0.05 vs. control), and ANOVA with Tukey’s post-
hoc analysis was used to compare cortisol in presence of insulin treatments to cortisol alone 
( p<0.05 vs. cortisol). Cortisol dose range= 100, 250, 1000nM for 24h  
  
 
Complementary experiments using the R246Q SRD5A2 construct that is devoid of functional 
activity did not alter cortisol mediated suppression of de novo lipogenesis (Figure 5-7) 
 
Figure 5-7 Transfection of mutant R246Q 5αR2 did not affect the ability of cortisol to supress 
lipogenesis. Data are presented as 14C-acetate incorporation into lipid (% from control, mean 
± s.e) of n=3 experiment and one way ANOVA with Dunnett’s post-hoc analysis was applied 
using Sigmastat 3.1 to compare multiple treatments with control (*p<0.05 vs. control). 
Cortisol dose range= 100, 250, 1000nM for 24h  
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5.4.3.2.Pharmacological manipulation of 5αR activity in primary 
human hepatocytes 
5.4.3.2.1.De novo lipogenesis assay 
 
To further endorse these findings, experiments were undertaken using pharmacological 
inhibitors of 5αR isoforms in primary cultures of human hepatocytes. Primary cultures of 
hepatocytes are a better model to use for inhibitors study as they express high levels of both 
5αR1 and 2, and therefore can potentially help to identify which isoform is most important. 
On their own the inhibitors, finasteride or dutasteride, were without effect. However, 
consistent with our transfection studies, both finasteride (selective SRD5A2 inhibitor) and 
dutasteride (nonselective SRD5A1 and 2 inhibitor) augmented the action of cortisol to 
suppress de novo lipogenesis (88.3±5.3% [cortisol 250nM] vs. 76.9±5.2% [cortisol 
250nM+finasteride 500nM], p<0.05 and 66.3±5.9% [cortisol 250nM+dutasteride 500nM], 
p<0.01, mean ± s.e) (Figure 5-8). 
 
Figure 5-8 In primary cultures of human hepatocytes, pharmacological inhibition of 5αRs 
with either the selective (finasteride, 500nM) or nonselective inhibitor (dutasteride, 500nM), 
augments the action of cortisol (250nM) to suppress lipogenesis. Data are presented as 14C-
acetate incorporation into lipid (% from control, mean ± s.e) of n=4 experiment and one way 
ANOVA with Dunnett’s post-hoc analysis was applied using Sigmastat 3.1 to compare 
multiple treatments to control (*p<0.05, **p<0.01 vs. control) and ANOVA with Tukey’s  
post-hoc analysis was used to compare multiple treatments to cortisol(§ P<0 .05, §§ P<0 .01 
vs. cortisol). 
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5.5.Discussion 
 
A-ring reductases have a dual action, inactivating cortisol to dihydrocortisol with a 
subsequent conversion to tetrahydrocortisol, and activating testosterone to DHT. However, 
the ability of testosterone to regulate lipid metabolism does not appear to be dependent upon 
the presence of SRD5A2. The C3A cell line expresses SRD5A2 at a low level, and yet both 
testosterone and DHT were able to stimulate lipogenesis to a similar extent as discussed in 
chapter 4 (section 4.4.4). Our experiments therefore focused on the role of SRD5A2 to 
regulate the effects of GCs upon liver metabolism. 
We have successfully overexpressed SRD5A2 in C3As. In control cells (vector only) cortisol 
decreased lipogenesis in a dose dependent manner as we have previously described in chapter 
3 (section3.4.2.3). 5αR2 transfected cells were able to overcome and recover the inhibitory 
action of cortisol upon lipogenesis. Thus, selective (finasteride) and non-selective 
(dutasteride) inhibition of hepatic 5αR2 decreased lipogenesis in human liver. This was in 
contrast with the published data using animal models which suggest 5αRs (mainly focused on 
5αR1) activity increase susceptibility to development of fatty liver (Livingstone et al. 2009). 
However, 5αR2 activity has not been studied in human cell line in the published literature. 
While genetic ablation of SRD5A1 in rodent models increases lipid accumulation and 
fibrosis, the precise mechanisms that underpin this are not clear (Dowman et al. 
2013;Livingstone et al. 2015). In a recently published clinical study, nonselective 
5αRinhibition with dutasteride was associated with peripheral insulin resistance and it has 
been suggested that this may reflect a specific role for SRD5A1 in skeletal muscle (Upreti et 
al. 2014). The precise impact upon liver fat accumulation could not be determined as pre and 
post intervention assessment of hepatic lipid content was not performed. 
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In the presence of insulin, cortisol and insulin act synergistically to increase lipid 
accumulation in primary human hepatocytes (as described in chapter 3 section 3.4.2.4). 5αR 
inhibitors decrease cortisol clearance and therefore enhance cortisol action to act 
synergistically with insulin (probably in the fed, postprandial state) to drive lipid 
accumulation. We have clinical evidence to suggest that this might be the case as healthy 
male volunteers increased liver fat associated with elevated rates of de novo lipogenesis after 
dutasteride treatment (Hazlehurst et al. 2016) and this also seems to be endorsed from 
findings in the rodent 5αR1 knockout mice who develop increased hepatic lipid accumulation 
(Dowman et.al 2013). 
As obesity, diabetes and the metabolic syndrome are rising within population in western 
countries, NAFLD becomes an increasingly important cause of morbidity and mortality. 
Current treatments principally reduce cardiovascular risks and improve metabolic variables. 
The most effective treatment, for those with NAFLD who have advanced liver fibrosis, is 
weight-reducing surgery. However, there is not yet a highly effective therapy for these 
patients and few liver-specific therapies are available (Dowman et al. 2011). Hence, 
modulation of  hepatic 11bHSD1 and the A-ring reductases may represent a novel therapy for 
patients with NAFLD (Dowman et al. 2010). 
Although it is been reported that increased hepatic 5αR activity has been demonstrated in 
patients with IR and NAFLD (Konopelska et al. 2009), the actual role of each isoform and 
their contribution to the regulation of hepatic lipogenesis is not clear. However, we have 
demonstrated a novel role for 5αR2 in human hepatocytes which if overexpressed can be used 
as an attractive therapeutic target for patients with IR and NAFLD. This has also important 
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implications to the large numbers of patients with prostate-related disease prescribed 5αR 
inhibitors.  
We have shown that 5αR inhibitors decrease cortisol clearance and we have hypothesised that 
they might enhance cortisol action, and therefore, enhanced cortisol availability could then act 
synergistically with insulin to drive lipid accumulation. However, one of the limitations of 
this study is that we have not tested this hypothesis due to the lack of time. Therefore, 
experiments including co-incubation of cells treated with 5αR inhibitors with both cortisol 
and insulin should be planned in future studies. In addition, there is no specific 5αR1 inhibitor 
available, and therefore, it has not been used in this study.  
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6.1.Aims 
 
• To define putative mutations or polymorphisms through genetic sequencing of 
SRD5A1 and 2 in patients with abnormal steroid metabolite ratios suggestive of 
reduced 5αR activity. 
 
6.2.Background  
 
5α1, 2, and 3 enzymes are encoded by SRD5A1, 2, and 3 genes. Each gene has 5 exons. More 
than 40 mutations have been reported in all five exons of SRD5A2 (Cheon 2011). However, 
mutations in 5αR1 have not been described yet. Recently mutations have been identified in 
SRD5A3 resulting in a new type of congenital disorder of glycosylation (CDG) (Cantagrel et 
al. 2010). SRD5A3 probably does not have a major role in androgens or GC metabolism. 
Only recently, SRD5A3 was discovered to metabolise testosterone to DHT (Uemura et al. 
2008), however no similar catalytic activities have been found for GCs (Nixon, Upreti, & 
Andrew 2012). 
5αR2 converts testosterone into DHT in the external genitalia. Absent or reduced function of 
this enzyme causes 46XY DSD (disorder of sexual development). Most affected 46XY 
individuals with this condition as a result of mutations in 5αR2, have ambiguous external 
genitalia with a clitoral-like phallus and some have micropenis. They are usually raised as 
females although they are genetically males (Chan et al. 2009). The main biochemical feature 
of this syndrome is an elevated testosterone to DHT ratio with elevated plasma testosterone 
levels with low DHT levels (Zhu and Sun 2005). The DHT/T ratio therefore is an indicator of 
5αR activity and interestingly this demonstrates significant heritability and in male twin 
studies this has been estimated to be around 42% (Meikle et al. 1986). Patients with 5αR2 
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mutations also have defects in cortisol metabolism consistent with the role of 5αR2 to inactive 
and clear cortisol. Urinary steroid profile in these patients has shown decreased 5αTHF (Can 
et al. 1998).  
We have identified 9 individuals (referred to them as patient in this report) with abnormal A-
ring reductase activity based on urinary GC/MS analysis. Urinary steroid metabolite ratios 
indicative of 5αR activity were >2 standard deviations lower than the mean from our 
normative cohort of > 50 individuals. All patients are on no medication that could explain the 
abnormality and we therefore hypothesised that genetic defects in either SRD5A1 or 2 might 
underpin these observations. Importantly whilst mutations in 5αR2 are well described, to date, 
no mutations have been identified in 5αR1 and therefore we questioned whether the urinary 
steroid metabolite phenotype in these patients might represent the first description of genetic 
defect in 5αR1.  
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6.3.Method 
6.3.1.GC/MS 
 
Briefly, steroids and their conjugates were extracted from urine samples via solid phase 
extraction. Samples were deconjugated and then derivatised to form methyloxime-
trimethylsilylethers (MOTMS). The final derivative was dissolved in 55ul cyclohexane and 
analysed by GC/MS as described in detail by (Arlt et al. 2011) and also explained in section 
5.3.7. All the samples for GC/MS were prepared by a master’s student, Nikolaos Nikolaou, 
and the data were analysed by Dr Angela Taylor. 
 
6.3.2.DNA extraction from patients’ blood samples  
 
After taking the blood from patients with abnormal A-ring reductase activity in clinic, DNA 
was extracted from all blood samples using the DNA blood maxi kit (50) (Qiagen, 
Dusseldorf, Germany). 
 
6.3.3.Designing primers for A-ring reductases 
 
The total number of 20 reverse and forward primers for all 10 exons of these 2 genes 
(SRD5A1 and 2) were designed using NCBI and Primer3 online websites (Figure 6-1). Oligo 
calc software was also applied to check the melting temperature, potential hairpin formation 
and self-complementarity of each primer. These primers were synthesised by Alta bioscience 
(University of Birmingham, Birmingham, UK). 
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Figure 6-1 Genomic locations of designed primers. Primers were designed using NCBI, 
Primer3 online websites (http://bioinfo.ut.ee/primer3-0.4.0/), and Oligo calc software. These 
primers were synthesised by Alta bioscience (University of Birmingham, Birmingham, UK). 
 
 
6.3.4.Optimising the primers by PCR 
 
In order to define the best annealing temperature, all the primers were optimised in a range of 
8 different temperatures (53.4 to 65°C). In a 10µl reaction the following components were 
added: MasterMix (final concentration 1x), forward and reverse primers (10 µM), and 100nM 
of DNA (for optimising the primers a control DNA was used trying not to waste the patients’ 
DNA). In a thermal cycler (Biometra, Goettingen, Germany) samples were incubated at 94°C 
for 2min and then cycled 35 times at 94°C for 20 sec, 53.4 to 65°C for 20 sec and 72°C for 30 
sec. Samples were then incubated for 72°C for 5min. 
The DNA products were then assessed by electrophoresis on 1% agarose gel with 0.15 µg/mL 
GelRed (Cambridge biosciences LTD, Cambridge, UK) and visualised by GeneSnap software 
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subsequently. The annealing temperature which gave the cleanest band was chosen for each 
exon. Optimising of one exon from each gene is chosen to be shown as an example in Figure 
6-2. 
 
 
 
 
 
 
 
 
Figure 6-2 Optimising of exon 1 of each SRD5As in a range of 8 different temperatures (53.4 
to 65ᵒC) using electrophoresis on 1% agarose gel, best annealing temperatures are shown by 
arrows. 
 
 
6.3.5.Sequencing 
 
When the primers were optimised, the actual PCR was carried out on control DNA and later 
on patients’ DNA, using the specific annealing temperature for each exon. The DNA products 
were then assessed by electrophoresis on 1% agarose gel with 0.15 µg/mL GelRed 
(Cambridge biosciences LTD, Cambridge, UK) and visualised under UV light. The DNA 
bands were purified from the gel using DNA mini kit (Qiagen, West Sussex, UK). For 
preparing a 10µl reaction for each PCR product sample to take for sequencing, each primer 
(reverse or forward) was added separately to the other components in the following order: 
Nuclease Free Water (final concentration 1x), forward or reverse primer (3.2pM), and 10nM 
of DNA.  
SRD5A2
Exon 1
434bp
SRD5A1
Exon 1
397bp
53.4- 54.9- 56.6- 58.9- 60- 61- 63.5- 65
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Finally the samples were sent for sequencing. The sequencing of DNA was performed using 
an automated ABI 377 sequencer in the Functional Genomic Laboratory at the University of 
Birmingham, Plasmid to Profile sequencing (Birmingham, UK) and CLC DNA workbench 
software  was used for further analyses of the obtained sequences. 
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6.4.Results 
6.4.1.Patient identification 
6.4.1.1. Urine analysis 
9 patients (named in alphabetical order; A to I in this report) with abnormal A-ring reductase 
activity based on urinary GC/MS analysis have been identified (Table 6-1). These patients 
have altered urinary steroid profiles with low level of 5α-reduced metabolites. The normal 
mean 5αTHF/THF ratio is 0.89±0.32 in men and 0.67±0.33 in women while the mean 
5αTHF/THF ratio in men and women of this research are 0.22±0.11 and 0.13±0.03 
respectively (mean ± s.e). This indicates that 5αR activity in patients were approximately >2 
standard deviations lower than the mean from our normative cohort of > 50 individuals and it 
is possible that this may reflect genetic defect in SRD5A1 and/or 2. There is a degree of 
variability in both 5αTHF and THF, as also seen in a study on 101 obese patients (Tomlinson 
et al. 2008). This may reflect variability of how complete the 24h urine collection is. In the 
current study, urine samples were a spot sample, and therefore, it is not possible to quantify 
24h production rates for individual metabolites but allows us to compare metabolite ratios. 
(Figure 6-3).  
Table 6-1 Urinary steroid metabolite analysis from all the 9 individual patients (A to I). The 
5αTHF/THF ratio is a marker of 5αR activity.  Data are presented in nM, F=Female, 
M=Male. 
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Figure 6-3 The 5αTHF/THF ratio is a marker of 5αR activity. The 5aTHF/THF ratio in men 
and women of these patients (shown in red) are almost two fold lower than normal mean 
5aTHF/THF ratio in men (blue) and in women (purple). Data are presented as mean ± s.e.
6.4.1.2.Sequencing analysis 
6.4.1.2.1.5αR2 
All 5 exons of SRD5A2 have been sequenced and the results are summarised below 
Table 6-2). No polymorphisms were identified in patients A, B, C, F or H. 
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        Patient ALLELE1 ALLELE2 REGION DBSNP      AA      AA       AA      AA
COORDINATE ALLELE1ALLELE2 COORDIN CODON
D C G coding rs523349 Leu Val CG
E C G coding rs523349 Leu Val CG
E G A coding rs9282858 Ala Thr GA
E G A UTR3 rs28383082 GA
G C G coding rs523349 Leu Val GG
I C G coding rs523349 Leu Val CG
I G A coding rs9282858 Ala Thr GA
 
Table 6-2 Polymorphisms identified in SRD5A2 in UTR3 and coding regions of patients D, E, 
G and I. No polymorphisms were identified in patients A, B, C, F or H. The sequencing of 
DNA was performed by the Functional Genomic Laboratory at the University of Birmingham, 
Plasmid to Profile sequencing (Birmingham, UK) and data were analysed using CLC DNA 
workbench software. 
 
 
In addition, no polymorphisms were found in exon 2, 3 or 4 of SRD5A2 in patients D, E, G or 
I. However, in exon 1, in four patients (D, G, E and I) a substitution of valine for leucine at 
codon 89 (Figure 6-4a) was observed (L89V). In addition, in two of these patients (E and I) 
with L89V, A49T (a substitution of threonine for alanine at codon 49) (Figure 6-4b) 
polymorphism was identified in the same exon. L89V and A49T variants are not novel and 
have been identified previously. 
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Figure 6-4 DNA sequence chromatograph from patient E indicating; a) C to G transversion 
resulting in a leucine (L) for valine (V) amino acid substitution at codon 89 (L89V) 
polymorphism, b) G to A transversion resulting in a threonine for alanine amino acid 
substitution at codon 49 (A49T) polymorphism.  Data were analysed using CLC DNA 
workbench software. 
a) 
b) 
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6.4.1.2.2.5αR1 
 
5αR1 sequencing analysis was performed by Beckman Coulter Genomics Inc. (Danvers, MA, 
US) and Whole Genome Amplification (WGA) was performed prior to sequencing. 
 
 
Table 6-3 Polymorphisms identified in SRD5A1. There are three coding sequence changes but 
they do not cause amino acid changes.  In patient G and A (highlighted rows), SNPs with low 
allele frequencies were identified. In patient G and A the SNP is located in intron1/exon2 
boundary, and intron 3 respectively. Data were generated by Beckman Coulter Genomics Inc. 
(Danvers, MA, US).   
 
 
Although no exonic mutation was identified in SRD5A1 of these patients, several intronic and 
3’UTR single nucleotide polymorphisms (SNPs) were found. The identified SNPs were 
checked with NCBI SNPs and hapmap databases for their allele frequencies. Two SNPs were 
identified with low allele frequencies (lower than 0.01) which are highlighted in Table 6-3. 
rs186093099 A>C, C= 0.003 AC heterozygote in patient G (Figure 6-5) 
rs168713       A>G G= 0.15  GG homozygote= 0.012 in patient A 
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Figure 6-5 DNA sequence chromatograph from patient G indicating an A to C nucleotide 
substitution in rs186093099 polymorphism. Data were analysed using CLC DNA workbench 
software. 
 
 
6.4.1.3.Splice variants in 5αR1 
 
In order to examine whether these SNPs could change the splicing sites, NetGene2 software 
was used. This program takes the sequence file (only in FASTA) and predicts intronic splice 
sites in the human genome. No changes in splicing sites were observed comparing rs168713 
with the wild type sequence. However, changing nucleotide A to C in (rs186093099) was 
predicted to increase the potency of a splice site located at intron1/exon2 boundary (0.82 
[rs186093099] compared to 0.19 wild-type).  
The predicted effect of increased potency at this splice site, is that exon 2 may be retained in 
the mature mRNA. Studying the NCBI SNPs database, the SRD5A1 gene has different 
splicing variants, with and without exon 2. Therefore we hypothesised that this SNP predicts a 
longer splice variant containing exon 2 (Figure 6-6) and that this could potentially impact 
upon enzyme activity. 
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Figure 6-6 SRD5A1 gene has 2 splice variants (longer splice variant with 5 exons shown by 
black arrow and a shorter one with 4 exons indicated with blue arrow). The polymorphism in 
our patient makes the longer splice (5 exons) more potent and this may explain the metabolic 
phenotype.   
 
 
To test the hypothesis that the presence of this SNP may alter the relative proportion of the 
long and short splice variants (and that this in turn may translate to an alteration in 5αR1 
function), a set of primers were designed to amplify SRD5A1 splice variants comparing 
patients (with abnormal urinary steroid metabolite ratios) and controls (normal urinary steroid 
profiles). cDNA from human muscle tissue, obtained following skeletal muscle biopsy 
performed for a different clinical study (Hassan-Smith et al. 2015), was used for both patients 
and controls. SRD5A1 is highly expressed in human liver and therefore human primary 
hepatocyte cDNA was also used as a positive control.  
Conventional PCR analysis demonstrated a decreased abundance of the short splice variant in 
the patients compared to controls, suggesting that the polymorphism may enhance the 
expression of the long splice variant (Figure 6-7). 
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Figure 6-7 Conventional PCR analysis demonstrates a reduced amount of the short splice 
variant in patient with the rs186093099 SNP (red arrow) in comparison with controls (green 
arrow).cDNA from muscle was used for both patients and controls. 
 
 
In order to quantify the preliminary observations made using conventional PCR, semi-
quantitative real-time PCR was undertaken using an Applied bio-system assay on demand 
which amplifies only the long isoform. Despite the results from the conventional PCR, there 
was no significant difference between expression levels of the long splice variant in patients 
compared to controls (∆CT of longer isoform expression; patient 18.18 vs controls; 17.27, 
17.81, 19.19, 17.47). Thus, we were unable to confirm our hypothesis that greater 
incorporation of exon 2 in individuals with rs186093099 polymorphism.  
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
Chapter 6                                        Molecular characterisation of patients with abnormal A-ring reductase activity 
 
6.5.Discussion 
 
Our results from this chapter have not revealed any exonic mutations in SRD5A1 or SDR5A2 
that might explain the abnormal urinary steroid metabolite ratios that we observed in these 
patients. However, we did observe L89V and A49T polymorphisms in exon 1 of SRD5A2; 
four patients were identified with L89V from which two were also carrying A49T. 
These two polymorphisms have been reported in the published literature and have been 
widely investigated in association with prostate cancer (Pearce et al. 2002). An increased 
DHT level is associated with increased prostate cancer risk (Gann et al. 1996;Ross et al. 
1992), as it binds to the AR and modulating cell division in the prostate (Coffey 1993) and 
therefore 5αR activity is important in determining the prostate cancer risk. In an in vivo study 
in 102 Asian individuals, they studied L89V polymorphism. They measured serum DHT 
concentrations and when they correlated this data with the patients’ genotype, they found out 
that patients with VV genotype had the highest serum DHT while the patients with LL 
genotype had the lowest. They showed that in in patients with LL genotype the enzyme 
activity is reduced to 30% suggesting that the VV genotype is associated with higher enzyme 
activity (Makridakis et al. 1997). This suggests that L89V polymorphism is associated with 
increased prostate cancer risk through increasing 5αR activity. 
In addition, in experiments where the A49T SNP in SRD5A2 has been overexpressed in 
mammalian COS cells, a 5-fold increase in enzyme activity was observed compared to the 
wild type (Makridakis et al. 1999). However, studying 449 Finnish patients with prostate 
cancer; no significant differences were observed in A49T prevalence when compared to 
controls (Mononen et al. 2001). This is in contrast in what has been reported in African-
American, Hispanic (Makridakis et al. 1999) and Caucasians (Jaffe et al. 2000) where the 
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patients with prostate cancer had higher A49T prevalence when compared to the same ethnic 
controls. This, together with the in vitro data, suggest that A49T might be a race related 
genetic risk factor for prostate cancer and also SRD5A2 enzyme activity. In our study, L89V 
and A49T were identified in Caucasian patients with low level of 5α-reduced metabolites and 
therefore, based on literature, there might be no association between found polymorphisms 
and the reduced enzyme activity. 
Despite being unable to identify any exonic mutations in SRD5A1, we identified a 
polymorphism within the intron1/exon2 boundary (rs186093099). In silico, this 
polymorphism was predicted to strengthen the intron1/exon2 splice site. A more potent splice 
site suggests increased incorporation of exon 2, however we were unable to confirm this by 
PCR. This suggests that SRD5A1 has different splicing variants in population which is not 
associated with observed reduced enzyme activity and metabolic readouts.  
To date, no mutation has been reported in SRD5A1. However several polymorphisms have 
been associated with progression of prostate cancer; rs518673 and rs166050 in SRD5A1 
(Audet-Walsh et al. 2011). SRD5A1 rs248793 was associated with increased DHT/T ratio 
affecting the circulating androgens level (Ellis et al. 2005). In addition, in a cross-sectional 
study, an association between SRD5A1 rs248800 and increased risk of hepatitis C related 
liver disease in male was observed (White et al. 2014). Although we were unable to find an 
association between SRD5A1 (rs186093099) and the altered urinary steroid profiles, the 
expanded polymorphism and mutation data base of SRD5A genes has enhanced our 
understanding of the regulation of 5αR1 expression, in particular the different splicing 
variants. These different splicing variants, short and long isoforms, might have different 
activities for which to be proved further studies are needed. 
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Although we were unable to find a genetic regulation to explain the altered urinary steroid 
profiles in these patients, this observed 5αR different activity might be regulated post-
transcriptionally. We know that obesity and insulin resistance are associated with increased 
5αR activity and that this decreases with weight loss and 5αR activity predicts adverse 
phenotype in the future (Tomlinson et al. 2008), and therefore we hypothesized that these 
individuals might be protected from this. 
In addition, it is known that SNPs can cause structural variation and suggest mRNA structure 
dependent mechanism by which SNPs can generate allele specific biological consequences. 
Our data present the contribution of SNPs to structural diversity of mRNA and suggest a 
significant role for the SNPs by affecting mRNA structure, and eventually biological function 
(Shen et al. 1999). The known SNPs we found in SRD5A2 (L89V and A49T) are both 
missense variants as also mentioned on Ensembl website. Using both SIFT and PolyPhen 
software which predict the effect of SNPs on protein function, L89V variant has a tolerated 
and benign effect on protein function. However, A49T variant demonstrates a deleterious and 
possibly damaging effect. Both SNPs had a negative effect on the ability of the enzyme to 
bind to the testosterone substrate (Russell and Wilson 1994) and L89V decreased the affinity 
for the NADPH cofactor. The enzyme with A49T has a high Vmax when compared to the 
normal enzyme due to the change from small size and hydrophobic alanine to medium size 
and polar threonine (Makridakis et al. 1999). This provides insight into mechanisms of human 
phenotypic variation and helps studies of disease susceptibility and drug response.  
The low number of patients and also amount of samples were the limitations of this study. 
After sequencing of SRD5A2 in all patients in our lab, due to the low amount of samples left 
we decided to use the Beckman Coulter Genomics Inc. (Danvers, MA, US) to sequence the 
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SRD5A1 gene. Using this company, very low amount of cDNA from patients was used as the 
Whole Genome Amplification (WGA) was performed prior to sequencing. However, 
sequencing of SRD5A2 in our lab was beneficial to learn new techniques (DNA extraction 
from blood, designing and optimising primers, and sequencing) and also to use several 
software such as Oligo calc to design primers and CLC DNA workbench to analyse the 
sequencing data.  
Although we based this study on the 5αTHF/THF ratio obtained from urinary GC/MS 
analysis, studying the actual 5αTHF and THF levels are also important as increased 
5αTHF/THF ratio can be a result of decreased 5αRs activity or increased 5βR activity. 
However, we have not sequenced the 5βR in these patients due to the lack of cDNA samples 
available and that is one of the limitations of this study. Moreover, studying the actual values 
of these metabolites is important. There is a degree of variability in both 5αTHF and THF 
values.  In order to quantify an absolute change in production rate, of either 5α or 5β-reduced 
metabolites, a 24h urine collection is needed. In the current study we compared relative ratios 
of 5α or 5β-reduced metabolites in spot urines, therefore, they reflect a measure of A-ring 
reductase activity which could be due to altered 5α or 5βR activity.  
In addition, the different splicing variants (short and long SRD5A1) may have different 
activities. However, the short and long SRD5A1 constructs has not been generated due to the 
lack of time and should be planned in future studies. 
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Increased de novo lipogenesis is associated with metabolic disease and in particular with 
NAFLD (Kawano and Cohen 2013). Patients with NAFLD have increased levels of FAS, 
ACC1 and SREBP1c, and the contribution of de novo lipogenesis to the accumulated TAG is 
increased to 26% (Donnelly et al. 2005). Furthermore, de novo lipogenesis generates saturated 
fatty acids, predominantly palmitate, and patients with NAFLD have increased saturated fatty 
acid levels and in particular palmitate (Kotronen et al. 2009a; Sanders and Griffin, 2016). 
Saturated fatty acids are also known as  ‘bad’ fat (Alkhouri et al. 2009); studies show an 
association between increased saturated fatty acids, in particular palmitic acid, and insulin 
resistance (Kotronen et al. 2009b). Therefore, the focus of the current study was on de novo 
lipogenesis and how steroid hormones can affect this pathway. 
The impact of GCs to regulate carbohydrate metabolism in particular gluconeogenesis in the 
fasting state is well described. However, their impact on lipid metabolism remains relatively 
poorly understood in human models. We have previously shown in adipose and skeletal 
muscle that GCs decrease lipogenesis in the absence of insulin consistent with their role to 
mobilize fuel in the fasting state (Gathercole et al. 2007;Morgan et al. 2013). In the fed state, 
however, GCs and insulin act synergistically to drive lipid accumulation. Studies performed 
in rodent hepatocytes have demonstrated this relationship (Amatruda et al. 1983) and we have 
now shown this in primary cultures of human hepatocytes. 
In our in vitro model, the ability of GCs to enhance the ability of insulin to drive lipogenesis 
was associated with increased activation of the insulin signalling cascade as demonstrated by 
increased phosphorylation of PKB/akt, similar to our published observations in human 
adipose tissue (Gathercole et al. 2007;Hazlehurst et al. 2013). Although augmentation of 
insulin action by GCs has been observed in rodent hepatocytes (Amatruda, Danahy, & Chang 
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1983), these in vitro data may not be reflective of more complex in vivo physiology. Clinical 
studies that have administered GCs have shown evidence of increased hepatic insulin 
resistance in most cases (Petersons et al. 2013) (Figure 7-1).  
 
 
 
Figure 7-1 Tissue specific GC action to regulate lipid metabolism and insulin action. GCs 
induce insulin resistance in skeletal muscle and insulin sensitivity in adipose tissue. We have 
described insulin sensitisation by GCs in human hepatocytes and this may lead to increased 
lipid accumulation (as in adipose tissue) in the fed state. This may represent an important 
mechanism in the development of the Cushing’s phenotype and its associated adverse 
metabolic features. 
 
 
Low testosterone concentrations are associated with increased hepatic steatosis in men (Kim 
et al. 2012;Volzke et al. 2010) but women with polycystic ovarian syndrome (PCOS) are 
reported to be at an increased risk of developing NAFLD (Jones et al. 2012;Markou et al. 
2010). We have shown that androgens are able to increase lipid accumulation within C3A 
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cells and in primary cultures of human hepatocytes from female, but not male donors. The 
observed sexually dimorphic effects in primary cultures may suggest the different 
mechanisms behind androgens and lipid metabolism in females compared to men.  
As data from male primary cultures did not confirm the C3As data, this highlights the 
important of endorsing in vitro observations in additional models including human primary 
cultures. Data from male primary cultures might suggest that androgens have less impact on 
NAFLD phenotype when compared to GCs. This is in agreement with in vivo data from our 
group showing that liver gene expression profile in 5αR1 knockout mice overlap with those 
induced by GCs rather than androgens (Dowman et al. 2013). Others have recently 
demonstrated impaired hepatic metabolic clearance of corticosterone in 5αR1 knockout mice 
but persistence of the effect of finasteride in gonadectomised rats and therefore suggested that 
GC excess is likely to be the mechanism underpinning the observed hepatic steatosis in this 
model (Livingstone et al. 2015). 
There is now an emerging role for the 5αR isoforms in the regulation of metabolic phenotype. 
The ability of testosterone to regulate lipid metabolism does not appear to be dependent upon 
the presence of SRD5A2. The C3A cell line does not express SRD5A2, and yet both 
Testosterone and DHT were able to stimulate lipogenesis to a similar extent. Our experiments 
therefore focused on the role of SRD5A2 to regulate the effects of GCs upon liver 
metabolism.  
In rodent modelsSRD5A1 deletion increases lipid accumulation and promotes fibrosis, the 
precise mechanisms that underpin this are not clear (Dowman et al. 2013;Livingstone et al. 
2015). Nonselective 5αR inhibition with dutasteride was associated with peripheral insulin 
resistance. This may reflect a specific role for SRD5A1 in skeletal muscle, however, pre and 
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post intervention assessments of hepatic lipid content were not performed. Therefore, the 
precise impact upon liver fat accumulation could not be determined (Upreti et al. 2014). In a 
recently published clinical study, dutasteride (but not finasteride) treatment increased hepatic 
insulin resistance and the rate of hepatic de novo lipogenesis. Therefore, the observed increase 
in hepatic lipid accumulation might be due to either 5αR1, or dual 5αR1 and 2, inhibition 
(Hazlehurst et al. 2016). 
The role of SRD5A2 in clearing cortisol is well stablished through the examination of urinary 
steroid metabolite profiles in patients with proven SRD5A2 mutations (Peterson et al. 1985). 
Detailed metabolic studies in patients with mutations SRD5A2, have not been performed. In 
our study, we demonstrated that 5αR2 transfected liver cells were able to overcome and 
recover the inhibitory action of cortisol upon lipogenesis. This was in agreement with the 
published data suggesting; increasing 5αR activity is associated with an adverse metabolic 
phenotype (Tomlinson et al. 2008;Tsilchorozidou et al. 2003). This may reflect a 
compensatory mechanism to clear active GCs, in particular from the liver in an attempt to 
protect it from lipid accumulation. With more severe liver disease, 5αR activity decreases and 
this may increase GC exposure and may serve and a local anti-inflammatory measure to try to 
limit the progression of non-alcoholic steatohepatitis, fibrosis and scarring (Ahmed et al. 
2012).  
In addition, we have shown that 5αR inhibitors (both finasteride and dutasteride) augment the 
effect of cortisol on decreasing lipogenesis. Previously, we described that cortisol and insulin 
act synergistically to increase lipid accumulation and therefore we suggest that 5αR inhibitors 
enhance cortisol action to act synergistically with insulin (probably in the fed, postprandial 
state) to drive lipid accumulation. This also seems to be endorsed from findings in the rodent 
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5αR1 knockout mice who develop increased lipid accumulation (Dowman et.al 2013) (Figure 
7-2). 
 
 
Figure 7-2 GCs acting in isolation decrease lipogenesis but enhance insulin-stimulated 
lipogenesis. We discovered that 5αR overexpression ameliorates the effects of cortisol upon 
lipid metabolism but chemical inhibition of 5αR augments the actions of cortisol. This may 
suggests that in presence of insulin, 5αR inhibitors enhance cortisol action to act 
synergistically with insulin to drive lipid accumulation. This finding has potentially 
significant implications for patients taking finasteride and dutasteride. 
 
 
We identified 9 patients with low levels of 5α-reduced metabolites, based on urinary GC/MS 
analysis, which we hypothesised to be as a result of altered 5αRs activity. Therefore, we 
sequenced SRD5A1 and 2 in these patients but did not find any polymorphisms explaining the 
abnormal steroid profile. However, the expanded polymorphism and mutation data base of 
SRD5A genes has enhanced our understanding of the regulation of 5αR1 expression, in 
particular the different splicing variants. 
In conclusion, we have demonstrated the potent actions of androgens and GCs to regulate 
lipid metabolism in human hepatocytes in vitro and shown that pre-receptor regulation 
through that expression and activity of SRD5A2 is able to modify their action. This has 
important implications not only in terms of predisposing individuals to the development of 
hepatic steatosis, but also to the large numbers of patients prescribed 5αR inhibitors. While 
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the role of these compounds in the treatment of prostate-related disease is stablished, the long-
term metabolic consequences of these medications have not been assessed. 
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Comparing our in vitro model with translational clinical studies, we observed fundamental 
differences in response of insulin sensitivity to GC treatment between primary hepatocytes in 
vitro and in human liver physiology in vivo. Within the research group we have shown no 
increase in hepatic insulin sensitivity in healthy volunteers treated with GCs in a clinical study  
(Hazlehurst et al. 2013). However, our in vitro data had suggested that GCs enhance insulin 
sensitivity in primary hepatocytes. Possible explanations for this difference might include the 
organ/cell isolation system or the fact that in vitro single treatments are being tested (rather 
than trying to replicate the complex hormonal environment that is seen in vivo).Access to 
human model systems to translate laboratory-based findings is therefore crucially important.  
In our laboratory-based studies, cells were treated with GCs for 24h and it is possible that 
prolonged administration of GCs might have differing effects. These incubations were not 
performed, but would provide additional valuable data. Importantly, this may then more 
closely  mimic  patients with variety range of inflammatory conditions such as rheumatoid 
arthritis and asthma whom receive prolong synthetic GC treatment (Wei et al. 2004). 
In addition, in order to fully understand the dynamic impact of GC upon lipid homeostasis 
further functional assays such as β-oxidation should be performed on hepatocytes. To perform 
this assay, cells can be incubated with a tritiated fatty acid tracer and the amount of tritiated 
water, released during oxidation measured (specific activity measured using scintillation 
counting). 
In chapter 5, we have shown that 5αR inhibitors decrease cortisol clearance and we have 
hypothesised that they might enhance cortisol action. It is possible therefore that enhanced 
cortisol availability could then act synergistically with insulin to drive lipid accumulation. 
Additional experiments would therefore include co-incubation of cells treated with 5αR 
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inhibitors with both cortisol and insulin. We would anticipate that 5αR inhibitors would 
significantly enhance the synergistic actions of cortisol combined with insulin. 
For complete characterisation of 5αRs, further in vivo studies including overexpression in 
rodents and inhibition of 5αRs in humans are warranted. Future experiments would include 
liver specific overexpression of 5αR isoforms in rodent models. These transgenic models are 
then would be given dietary or GC treatments in order to see if 5αRs can reverse the effect of 
GC and ameliorate their hepatic lipid profile. These rodent studies could be extended into the 
clinical setting through translational studies. The clinical effect of 5αR inhibitors on hepatic 
lipid metabolism and insulin sensitivity could be assessed in healthy volunteers taking 
glucocorticoids alone or taking glucocorticoids in addition to 5αR inhibitors. As local GC 
availability increases (as a consequence of 5αRs inhibition), we might expect to see a 
worsening of metabolic hepatic phenotype. We would predict that individuals taking both 
GCs and 5αR inhibitors, the phenotype would be worsen in comparison to those taking GCs 
alone.  
Additional future studies could look at long-term consequences of finasteride and dutatseride 
prescriptions. These drugs are widely prescribed and it is possible that these drugs may have 
an adverse impact upon liver fat accumulation and this may translate to an adverse clinical 
outcome. Currently there are no published data that examined the long-term cardiovascular 
outcome in patients taking these drugs. 
In order to try to identify the cause of the abnormal urinary ratios, studied in chapter 6, 
experiments investigating the regulation of short and long 5αR1 isoforms could be 
undertaken. These different splicing variants may have different activities and therefore to test 
this hypothesis, short and long SRD5A1 constructs could be generated. These constructs 
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would then be expressed in cells and their enzymatic activity in the presence of GCs/androgen 
measured. 
Whilst it is known that GCs and androgens are involved in the development of NAFLD, they 
may also have a role in regulating the inflammatory component of the disease. Therefore, in 
future studies we will also investigate the impact of GCs and androgens on inflammation and 
inflammatory pathways in both our animal and in vitro models.  
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Appendix
 
 
_________________Carolyn Watt_____________________ 
Caution: This product was prepared from fresh human tissue.  Treat all products containing human-derived materials as potentially infectious, as no 
known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. 
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures. 
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt 
PLATEABLE CRYOPRESERVED MALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: M00995-P 
Lot Number: QOQ Storage Conditions: below -150ºC (vapour phase of liquid 
nitrogen freezer) 
Test Results: 
Specification Result 
>70% post-thaw viability by trypan blue exclusion 92 % 
? 5 million viable cells 6.27 million viable cells 
? 2 PC/VC ratio after 48 hours with 25 μM rifampin 6.09 
CYP3A4: basal rate of formation of 6?-hydroxytestosterone at day 5 1.06 pmol/106 cells/min 
? 2 PC/VC ratio after 48 hours with 50 μM omeprazole 13.1 
CYP1A2: basal rate of formation of acetaminophen at day 5 0.500 pmol/106 cells/min 
PC/VC ratio after 48 hours with 1 mM phenobarbital 4.23 
CYP2B6: basal rate of formation of hydroxybuproprion at day 5 0.113 pmol/106 cells/min 
? 0.1 OD MTT value at day 5 0.226 OD 
>70% confluent monolayer at day 5 84 % 
Lot Characterization Results: 
Assay Result 
ECOD: total rate of formation of 7-HC and metabolites 78.0 pmol/106 cells/min 
UGT/ST: 
rate of formation of 7-hydroxycoumarin glucuronide 390 pmol/106 cells/min 
rate of formation of 7-hydroxycoumarin sulfate 71.8 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 78.5 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 20.5 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 33.2 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin 1.82 pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 48.1 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 28.1 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 25.0 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available** 
Donor Demographics, as reported to Celsis | In Vitro Technologies: 
Age: 66 Race: C Cause of death: CVA Height: 67" Weight: 84 Kg 
Social history:  ETOH: 2 drinks/day, Tobacco: 1ppd x 50yrs, no drug use 
Medical history:  HTN x less than 5 yrs, adenocarcinoma in lung discovered after death 
Confluence – Day 5 
Serology: 
EBV Not reported Hepatitis B Negative 
RPR Negative Hepatitis C Negative
CMV Negative HIV Negative
????????
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_____________Carolyn Watt_______________________________ 
Caution: This product was prepared from fresh human tissue.  Treat all products containing human-derived materials as potentially infectious, as no 
known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. 
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures. 
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt 
PLATEABLE CRYOPRESERVED MALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: M00995-P 
Lot Number: OHO Storage Conditions: below -150ºC (vapour phase of  liquid 
nitrogen freezer) 
Test Results: 
Specification Result 
>70% post-thaw viability by trypan blue exclusion 86 % 
? 5 million viable cells 6.69 million viable cells 
? 2 PC/VC ratio after 48 hours with 25 μM rifampin 4.25 
? 2 PC/VC ratio after 48 hours with 50 μM omeprazole 21.6 
PC/VC ratio after 48 hours with 1 mM phenobarbital 6.45 
? 0.1 OD MTT value at day 5 0.337 OD 
>70% confluent monolayer at day 5 98 % 
Lot Characterization Results: 
Assay Result 
ECOD: total rate of formation of 7-HC and metabolites 172 pmol/106 cells/min 
UGT/ST: 
rate of formation of 7-hydroxycoumarin glucuronide 427 pmol/106 cells/min 
rate of formation of 7-hydroxycoumarin sulfate 20.4 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 49.2 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 143 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 95.4 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin 85.2 pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 27.7 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 24.3 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 170 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available** 
Donor Demographics, as reported to Celsis | In Vitro Technologies: 
Age: 28 Race: C Cause of death: Head Trauma; 2nd 
to GSW 
Height: 173cm Weight: 85 Kg 
Social history: 
No ETOH or Tobacco; smoked marijuana 
  Confluence – Day 5 
Medical history: 
No medical issues/problems in provided history 
Serology: 
EBV Positive
CMV Positive
RPR Negative
Hepatitis B Negative 
Hepatitis C Negative 
HIV Negative
????????
?93
PLATEABLE CRYOPRESERVED MALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: M00995-P
Lot Number: CPQ Storage Conditions: below -150ºC (vapour phase of  liquid
nitrogen freezer) 
Test Results:
Specification Result
>70% post-thaw viability by trypan blue exclusion   93  % 
? 5 million viable cells 11.4  million viable cells
? 2 PC/VC ratio after 48 hours with 25 ?M rifampin 13.1
? 2 PC/VC ratio after 48 hours with 50 ?M omeprazole 18.1
PC/VC ratio after 48 hours with 1 mM phenobarbital 4.00
? 0.1 OD MTT value at day 5 0.242 OD
>70% confluent monolayer at day 5   93 %
Lot Characterization Results:
Assay Result
ECOD: total rate of formation of 7-HC and metabolites 78.0 pmol/106 cells/min 
UGT/ST:
rate of formation of 7-hydroxycoumarin glucuronide 440 pmol/106 cells/min 
 rate of formation of 7-hydroxycoumarin sulfate 41.0 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 18.0 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 105 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 36.4 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin 17.8 pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 32.1 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 49.9 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 95.2 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available**
Donor Demographics, as reported to Celsis | In Vitro Technologies:
Age: 31 Race: C Cause of death: Head Trauma; 2nd 
to MVA 
Height: 73" Weight:??196lb
Social history: 
No alcohol use; Tobacco: 1-1.5 ppd x 15yrs, chewed tobacco; Drugs: Smokes crack, cocaine and marijuana 
Medical history: 
No medical history, no meds. 
Serology: 
EBV Not Reported
CMV Negative 
RPR Positive
Hepatitis B Negative 
Hepatitis C Negative 
HIV Negative
_________Carolyn Watt________________________________
Caution: This product was prepared from fresh human tissue.  Treat al
known test methods can offer assurance that products derived from hu
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures.
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt
l products containing human-derived materials as potentially infectious, as no 
man tissues will not transmit infectious agents. 
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Caution: This product was prepared from fresh human tissue.  Treat all products containing human-derived materials as potentially infectious, as no 
known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. 
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures. 
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt 
PLATEABLE CRYOPRESERVED MALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: M00995-P 
Lot Number: YOW Storage Conditions: below -150ºC (vapour phase of  liquid 
nitrogen freezer) 
Test Results: 
Specification Result 
>70% post-thaw viability by trypan blue exclusion 92 % 
? 5 million viable cells 7.41 million viable cells 
? 2 PC/VC ratio after 48 hours with 25 μM rifampin 10.2 
? 2 PC/VC ratio after 48 hours with 50 μM omeprazole 15.8 
PC/VC ratio after 48 hours with 1 mM phenobarbital 11.3 
? 0.1 OD MTT value at day 5 0.171 OD 
>70% confluent monolayer at day 5 87 % 
Lot Characterization Results: 
Assay Result 
ECOD: total rate of formation of 7-HC and metabolites 82.3 pmol/106 cells/min 
UGT/ST: 
rate of formation of 7-hydroxycoumarin glucuronide 448 pmol/106 cells/min 
rate of formation of 7-hydroxycoumarin sulfate 47.4 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 12.5 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 19.9 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 20.4 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin BQL pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 14.7 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 36.2 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 3.56 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available** 
Donor Demographics, as reported to Celsis | In Vitro Technologies: 
Age: 78 Race: C Cause of death: Stroke Height: 72" Weight: 76 Kg 
Social history: 
ETOH: 3 cans of beer/wk; Tobacco: 1ppd x 15yrs - quit 40yrs ago 
  Confluence – Day 5 
Medical history: 
Lupus, OA.  No meds. 
Serology: 
EBV Not reported
CMV Positive
RPR Negative
Hepatitis B Negative 
Hepatitis C Negative 
HIV Negative
????????
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 Carolyn Watt___________________ 
Caution: This product was prepared from fresh human tissue.  Treat all products containing human-derived materials as potentially infectious, as no 
known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. 
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures. 
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt 
PLATEABLE CRYOPRESERVED FEMALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: F00995-P 
Lot Number: TLQ Storage Conditions: below -150ºC (vapour phase of liquid 
nitrogen freezer) 
Test Results: 
Specification Result 
>70% post-thaw viability by trypan blue exclusion 80 % 
? 5 million viable cells 6.39 million viable cells 
? 2 PC/VC ratio after 48 hours with 25 μM rifampin 3.83 
? 2 PC/VC ratio after 48 hours with 50 μM omeprazole 9.62 
PC/VC ratio after 48 hours with 1 mM phenobarbital 2.00 
? 0.1 OD MTT value at day 5 0.290 OD 
>70% confluent monolayer at day 5 93 % 
Lot Characterization Results: 
Assay Result 
ECOD: total rate of formation of 7-HC and metabolites 183 pmol/106 cells/min 
UGT/ST: 
rate of formation of 7-hydroxycoumarin glucuronide 448 pmol/106 cells/min 
rate of formation of 7-hydroxycoumarin sulfate 42.9 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 33.1 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 119 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 59.6 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin 68.9 pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 30.5 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 19.5 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 99.1 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available** 
Donor Demographics, as reported to Celsis | In Vitro Technologies: 
Age: 52 Race: C Cause of death: Anoxia; 2nd to 
Cardiac Arrest 
Height: 5'2" Weight: 48.2Kg 
Social history: 
No ETOH; Tobacco: 2ppd x 35yrs, Marijuana daily 
Medical history: 
COPD  Confluence – Day 5 
Serology: 
EBV Positive
RPR Negative
CMV Positive
Hepatitis B Negative 
Hepatitis C Negative 
HIV Negative
????????
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Caution: This product was prepared from fresh human tissue.  Treat all products containing human-derived materials as potentially infectious, as no 
known test methods can offer assurance that products derived from human tissues will not transmit infectious agents. 
These products are for research use only.  Do not use in animals or humans.  These products have not been approved for any diagnostic or clinical 
procedures. 
1450 South Rolling Road  Baltimore, MD 21227 Toll Free 888.488.3232 Fax 410.455.1245 www.celsis.com/ivt 
PLATEABLE CRYOPRESERVED FEMALE HUMAN HEPATOCYTES 
PRODUCT NUMBER: F00995-P 
Lot Number: GNA Storage Conditions: below -150ºC (vapour phase of liquid 
nitrogen freezer) 
Test Results: 
Specification Result 
>70% post-thaw viability by trypan blue exclusion 83 % 
? 5 million viable cells 7.26 million viable cells 
? 2 PC/VC ratio after 48 hours with 25 μM rifampin 4.24 
CYP3A4: basal rate of formation of 6?-hydroxytestosterone at day 5 26.4 pmol/106 cells/min 
? 2 PC/VC ratio after 48 hours with 50 μM omeprazole 18.7 
CYP1A2: basal rate of formation of acetaminophen at day 5 1.53 pmol/106 cells/min 
PC/VC ratio after 48 hours with 1 mM phenobarbital 3.89 
CYP2B6: basal rate of formation of hydroxybuproprion at day 5 0.908 pmol/106 cells/min 
? 0.1 OD MTT value at day 5 0.241 OD 
>70% confluent monolayer at day 5 85 % 
Lot Characterization Results: 
Assay Result 
ECOD: total rate of formation of 7-HC and metabolites 173 pmol/106 cells/min 
UGT/ST: 
rate of formation of 7-hydroxycoumarin glucuronide 473 pmol/106 cells/min 
rate of formation of 7-hydroxycoumarin sulfate 99.9 pmol/106 cells/min 
CYP1A2: rate of formation of acetaminophen 71.5 pmol/106 cells/min 
CYP2A6: total rate of formation of 7-HC and metabolites 131 pmol/106 cells/min 
CYP2C9: rate of formation of 4?-methylhydroxytolbutamide 36.8 pmol/106 cells/min 
CYP2C19: rate of formation of 4?-hydroxymephenytoin 27.4 pmol/106 cells/min 
CYP2D6: rate of formation of dextrorphan 19.9 pmol/106 cells/min 
CYP2E1: rate of formation of 6-hydroxychlorzoxazone 16.9 pmol/106 cells/min 
CYP3A4: rate of formation of 6?-hydroxytestosterone 62.0 pmol/106 cells/min 
2
**genotyping data will be provided on the Celsis website as the data are made available** 
Donor Demographics, as reported to Celsis | In Vitro Technologies: 
Age: 71 Race: C Cause of death: CVA Height: 66" Weight: 49 Kg 
Social history:  ETOH: Wine daily x 50yrs, Tobacco: 2ppd x 56yrs, Drugs: Heroine (IVDA), Marijuana, and Cocaine in 
1960's/70's 
Medical history:  Sepsis 1 month ago, aneurysm 5 years ago, HTN for 15 years non compliant, seizures, COPD for 20 years, 
circulatory problems, bilateral forearm rash, blocked vessels to lower legs, colitis for 40 years, benign laryngeal polyp, lower back 
pain for 5 years, DM.  Medication: Dilantin, HTN  
 Confluence – Day 5
Serology: 
EBV Not reported Hepatitis B Negative 
RPR Negative Hepatitis C Negative
CMV Positive HIV Negative
????????
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Glucocorticoids and androgens have both been implicated in the pathogenesis of non-alcoholic
fatty liver disease (NAFLD); androgen deficiency in males, androgen excess in females and gluco-
corticoid excess in both sexes are associated with NAFLD. Glucocorticoid and androgen action are
regulated at a pre-receptor level by the enzyme 5-reductase type 2 (SRD5A2) that inactivates
glucocorticoids to their dihydrometabolites and converts testosterone to dihydrotestosterone
(DHT).Wehavethereforeexploredtheroleofandrogensandglucocorticoidsandtheirmetabolism
by SRD5A2 upon lipid homeostasis in human hepatocytes.
In both primary human hepatocytes and human hepatoma cell lines, glucocorticoids decreased de
novo lipogenesis in adose-dependentmanner.Whilst androgen treatment (testosteroneandDHT)
increased lipogenesis in cell lines and in primary cultures of human hepatocytes from female
donors, it was without effect in primary hepatocyte cultures from men. SRD5A2 over-expression
reduced theeffectsof cortisol to suppress lipogenesis andthiseffectwas lost followingtransfection
with an inactive mutant construct. Conversely, pharmacological inhibition using the 5-reductase
inhibitors finasteride and dutasteride, augmented cortisol action.
We have demonstrated thatmanipulation of 5-reductase type 2 activity can regulate lipogenesis
in human hepatocytes in vitro. This may have significant clinical implications for those patients
prescribed 5-reductase inhibitors, in particular augmenting the actions of glucocorticoids to
modulate hepatic lipid flux.
The global epidemic of obesity and type 2 diabetes istightly linked to the increasing prevalence of nonalco-
holic fatty liver disease (NAFLD) which contributes sig-
nificantly to increased morbidity and mortality (1). The
potent role of glucocorticoids (GC) tomodulatemetabolic
phenotype is exemplified in patients with GC excess,
Cushing’s syndrome, and many of these patients develop
NAFLD (2). However, in most patients with metabolic
disease andNAFLD, circulatingGC levels are not elevated
(3). At a tissue-specific level, notably within the liver, GCs
are cleared by a series of enzymes including the A-ring
reductases (5-reductase type 1 (SRD5A1) and 2
(SRD5A2) and5-reductase). 5-reductase exists as 2 iso-
forms (SRD5A1 and 2), both have 5 exons and 4 introns,
but share less than 50% homology and both isoforms are
expressed in human liver (4); SRD5A1 alone is expressed
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in?mouse?liver.?SRD5A2?is?believed?to?be?the?major?isoform?
in?clearing?cortisol?in?human?studies?(5),?however,?there?is?
an?emerging?role?for?SRD5A1?in?the?pathogenesis?of?met-
abolic?disease.?We,?and?others,?have?shown?that?in?a?rodent?
model,? genetic? ablation?of? SRD5A1? increase? lipid? accu-
mulation?in?the?liver?and?the?severity?of?NAFLD?(6,?7).
The?role?of?androgens?in?the?pathogenesis?of?metabolic?
disease? remains? controversial.? There? is? evidence? docu-
menting?an?association?between?hypogonadism?and?NA-
FLD?(8,?9)?with?some?evidence?for?improvement?following?
androgen?treatment?(10,?11).?SRD5A2?has?an?established?
role?in?the?conversion?of?testosterone?to?dihydrotestoster-
one?(DHT)?and?genetic?mutations?lead?to?46XY?DSD?(Dis-
order?of?Sex?Development).?While?DHT?is?a?more?potent?
activator? of? the? androgen? receptor? (AR),? testosterone?
binds?and?activates?the?AR.?We?have?shown?that?increased?
global?5-reductase? activity? is? associated?with? impaired?
glucose?tolerance?and?may?be?a?future?predictor?of?meta-
bolic?disease?(12,?13).?The?lack?of?SRD5A2?expression?in?
the?mouse?liver?(contrasting?with?human?liver)?has?limited?
the?interpretation?of?data?from?SRD5A2?knock?out?mice?
(7)?and?has?highlighted?the?importance?of?the?use?of?human?
models.?The?translational?importance?of?this?not?only?re-
lates?to?enhancing?our?understanding?of?the?pathogenesis?
of?NAFLD,?but? also? to? the?widespread?use?of? SRD5A2?
inhibitors? including? the? selective,?SRD5A2? inhibitor,?Fi-
nasteride,?and?the?nonselective?(SRD5A1?and?2)?inhibitor,?
Dutasteride.
Lipid?accumulation?within?hepatocytes?is?the?first?step?
in? the?development?of?NAFLD,?and? in? some? individuals?
can?progress? through? inflammation? (NASH),? to? fibrosis?
and? eventual? cirrhosis.? There? are?multiple?mechanisms?
that? contribute? to? lipid? accumulation? in? vivo? including?
re-esterification?of?free?fatty?acids?(FFA)?delivered?princi-
pally?from?intra-abdominal?tissue?depots,?de?novo?synthe-
sis?of?triacylglycerol?from?acetyl?CoA?(de?novo?lipogenesis,?
DNL)?as?well?as?limitation?of?-oxidation?and?lipid?export?
and? secretion.?While? FFA? delivery? is? believed? to? be? the?
most? important?process? in? the?development?of?NAFLD,?
the?contribution?of?DNL?increases?significantly?in?patients?
with?NAFLD? (14).?The? rate-limiting? step? in?DNL? is? the?
carboxylation? of? acetyl?CoA? to?malonyl-CoA? by? acetyl?
CoA?carboxylase?(ACC)?which?is?subsequently?converted?
by?a?multistep?reaction?to?palmitate?by?fatty?acid?synthase?
(FAS).?There?are?two?isoforms?of?ACC?(ACC1?and?ACC2);?
in? lipogenic? tissues?ACC1? predominates? and? is? the? key?
regulatory?step?of?fatty?acid?synthesis.?ACC2?is?localized?
to? the?mitochondrial?membrane,? and? its? role? is? to? limit?
-oxidation? through?malonyl-CoA?mediated? inhibition?of?
carnitine?palmitoyl?transferase?I?(CPT?I).
Although?it?is?not?possible?to?replicate?all?the?processes?
that?contribute? to? the?development?of?NAFLD?using? in
vitro?systems,?using?established?cellular?models,?we?have?
tested?the?hypothesis?that?SRD5A2?represents?an? impor-
tant?regulator?of?the?metabolic?actions?of?androgens?and?
GCs? to? modulate? lipid? homeostasis? within? human?
hepatocytes.
Materials?and?Methods
C3A?and?primary?human?hepatocyte?culture
The?C3A? human? hepatocyte? cell? line?was? purchased? from?
LGC?Standards?(ATCC?-?CRL-10?741,?Middlesex,?UK),?and?cul-
tured?in?Eagle’s?Minimum?Essential?Medium?(EMEM)?contain-
ing?10%?fetal?calf?serum?and?glutamine/penicillin/streptococcus.?
Cells?were?seeded?in?24-well?plates?and?at?70%–80%?confluence?
were? incubated?with?control?media?with?or?without?hormonal?
treatments.?The?precise?conditions?for?individual?experiments?is?
detailed?in?the?results?section.?All?reagents?were?supplied?by?Sig-
ma-Aldrich?(Dorset,?UK)?unless?otherwise?stated.
Primary?human?hepatocytes?were?purchased? from?Celsis? In?
Vitro?Technologies?(Baltimore,?Maryland,?US).?All?donors?were?
healthy,? nondiabetic,? none? consumed? alcohol? above? recom-
mended?limits?(female??14?U/wk,?male??21?U/wk),?none?were?
taking? regular?medications?and?all?had?negative?viral?hepatitis?
serology?(male:?n??4,?age?54??14years,?BMI?28.4??3.3?kg/m2;?
female:?n??4,?age?56??4.7years,?BMI?23.98??3.1?kg/m2).?Cells?
were? cultured? overnight? in?Williams’?Medium? E?without? any?
supplements?before?being? treated?with?GCs?or?androgens.?For?
insulin?signaling?studies,?media?was?spiked?with?insulin?15-min-
utes?prior? to? cell?harvest? as?described? above.?Lipogenesis?was?
measured?by? the?uptake?of?1-[14C]-acetate? into? the? lipid?com-
ponent?(see?below)
RNA?extraction?and?Reverse?Transcription
Total?RNA?was?extracted?from?tissue?and?cells?using?the?Tri-
Reagent?system.?RNA?integrity?was?assessed?by?electrophoresis?
on?1%?agarose?gel.?Concentration?was?determined?spectropho-
tometrically? at? OD260. I n a 5 0 l? volume,? 500ng? of? total?
RNA?was? incubated?with? 250uM? random? hexamers,? 500uM?
dNTPs,? 20U? RNase? inhibitor,? 63U? Multiscribe? reverse?
transcriptase,? 5.5?mM? MgCl? and? 1? x? reaction? buffer.? The?
reverse? transcription? reaction? was? carried? out? at? 25°C? for?
10min,?48°C?for?30min?and? then? the? reaction?was? terminated?
by?heating?to?95°C?for?5min.
Real-Time?PCR
mRNA? levels?were?determined?using?an?ABI?7500?sequence?
detection? system? (Perkin-Elmer? Applied? Biosystems,? War-
rington,?UK).?Reactions?were? performed? in? 10l? volumes? on?
96-well?plates? in? reaction?buffer?containing?2?x?TaqMan?Uni-
versal?PCR?Master?mix? (Applied?Biosystems,?Foster?City,?CA,?
USA).?All?primers?and?probes?were?supplied?by?applied?biosys-
tems?‘assay?on?demand’?(Applied?Biosystems)?and?reactions?nor-
malized?against?the?house?keeping?gene?18S?rRNA,?provided?as?
a?preoptimized?control?probe.?All?target?genes?were?labeled?with?
FAM?and?the?housekeeping?gene?with?VIC.?The?reaction?condi-
tions?were?as? follows:?95°C? for?10-minutes,? then?40? cycles?of?
95°C?for?15-seconds?and?60°C?for?1min.
Data?were?obtained?as?ct?values?(ctcycle?number?at?which?
logarithmic?PCR?plots?cross?a?calculated?threshold?line)?and?used
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to determine ct values (ct (ct of the target gene) – (ct of the
housekeepinggene).Datawere expressedas arbitraryunits using
the following transformation [expression  1000*(2
-ct) arbi-
trary units (AU)].
Protein extraction and Immunoblotting
Total protein was extracted from cells using RIPA buffer (50
mM Tris pH 7.4, 1% NP40, 0.25% sodium deoxycholate, 150
mM NaCl, 1 mM EDTA, 1 mM PMSF and protease inhibitor
cocktail (Roche, Lewes, UK) dissolved in 10 mL of distilled wa-
ter) and freeze thawing. Protein concentrations were measured
using a commercially available assay (Bio-RadLaboratories Inc.,
Hercules, CA). 15 g of protein was resolved on a 12.5% SDS
PAGE gel and transferred onto nitrocellulose membrane, Hy-
bond ECL (GE Healthcare, Chalfont St Giles, UK). Primary
(PKB/akt, Biosource, Nivelles, Belgium and anti phosphoPKB/
akt (serine 473), R&D Systems, Abingdon, UK) and secondary
antibodies (Dako, Glostrop, UK) used at a dilution of 1/1000.
Membranes were reprobed for -Actin. Primary and secondary
antibodies were used at a dilution of 1/5000 (Abcam plc, Cam-
bridge, UK). For antibody characteristics see Supplemental Ta-
ble 1. Bands were quantified with Genesnap by Syngene (Cam-
bridge, UK) and expressed relative to-actin to normalize for gel
loading.
De novo lipogenesis (DNL)
DNL was measured by the uptake of 1-[14C] -acetate into the
lipid component of hepatocytes as has been described previously
(15).Cells were cultured in a 24-well plate, washed 3 times with
serum free media and then incubated with 500l of serum free
media with 4.44kBq/L 1-[14C]-acetic acid with cold sodium ac-
etate to a final concentration of 10 M acetate and treated with
or without insulin (0.5ng/ml). The cells were incubated at 37°C
for6-hours.After incubationactivitywas terminatedbywashing
the cells 3 times with cold PBS and scraping into 250l of PBS.
The lipid fractionwas recovered in Folch solvent, the solventwas
evaporated and the radioactivity retained in the cellular lipidwas
determined by scintillation counting and expressed as disinte-
grations per minute (dpm)/well. To account for variability be-
tween experimental replicates, data are presented as percentage
change from control.
-oxidation
Rates of -oxidation were measured by the conversion of
[3H]-palmitate to 3H2O. Cells were cultured in a 24-well plates
and were washed 3 times with serum free media. Cells were then
incubated with 300l of low glucose serum free media with
4.44kBq/L [3H]-palmitic acidwith cold palmitate to a final con-
centration of 10 M. The cells were incubated at 37°C for
24hours. After incubation medium was recovered and precipi-
tated with an equal volume of 10% tricholoroacetic acid. The
aqueous component of the supernatants was extracted with 2:1
choloform methanol solution. Radioactivity was determined by
scintillation counting, expressed as disintegrations per minute
(dpm)/well and finally calculated as percentage change from
control.
Transfection studies
The Androgen receptor (AR) and SRD5A2 cDNAs were
cloned into the pcDNA3.1 vector (Invitrogen, Paisley, UK) and
transiently transfected into C3A cells. Prior to transfection, cells
were seeded into a 24-well plate. Cells were 60%-70% con-
fluent in order to obtain the most efficient transfection results.
Transfectionmixture comprised 1.5g ofDNAdiluted in 50L
of OptiMEM serum free media (Invitrogen, UK) and 2 L of
Lipofectamine 2000 (Invitrogen, Paisley,UK) diluted in 50Lof
Optimem serum free media. 100L of transfection mixture was
added drop-wise to eachwell. The plates were rocked gently and
left for incubationat37°C.Transfectiondurationwas48hand its
efficiency was determined by applying a plasmid containing the
Green Fluorescent Protein (GFP) gene. Changes in AR and
SRD5A2 mRNA expression level were confirmed by real-time
PCR.
Site directed mutagenesis
TheR246Qmutant was inserted by site directedmutagenesis
into the SDR5A2 cDNA using the Quikchange II site-directed
mutagenesis kit (Agilent Technologies UK Limited, Cheshire,
UK) as per the manufactures guidance. In a 50l reaction the
following components were added: 5l of 10 reaction buffer,
forward and reverse primers (125ng) 10ng of double-strand
DNA template, 1l of dNTP mix, 3l of QuikSolution and
ddH2O to a final volume of 50l. Using a thermal cycler (Bi-
ometra, Göttingen, Germany) samples were incubated at 95°C
for 1min and then cycled 18 times at 95°C for 50 seconds, 53.4
to 60°C for 50 seconds, and 68°C for 60 seconds. Samples were
then incubated for 68°C for 7min. 1l ofDpnIwas added toPCR
reaction, vortexed and incubated for 1 hour at 37°C. 1ml of
ethanol (100%) was then added to each tube and incubated for
1hour at –80°C. The mixture was centrifuged at 16 000 XG for
20 minutes at 4°C and the supernatant aspirated. The DNA
pellet was washed with 75% ethanol, centrifuged, aspirated, air
dried for 10 minutes, resuspended in 10l of RNase free water.
Finally, the DNA vector containing the R246Q mutation was
transformed to XL10-Gold ultracompetent cells.
Gas and Liquid chromatography/Mass
spectrometry (GC/MS and LC/MS)
Cortisol was extracted from cell media after addition of the
internal standard cortisol-d4. Briefly, transfected cells were in-
cubated with 200 nM of cortisol for 24h. 1ml of media was
collected, extracted by SPE and the samples were derivatized
overnight to form methyloxime-trimethylsilylethers (MO-
TMS). The final derivative was dissolved in 55ul cyclohexane,
which was transferred to an autosampler vial for GC/MS anal-
ysis.AnAgilent 5973 instrument (www.agilent.com)wasused in
a selected ion monitoring mode.
5-reductase activity was measured using LC/MS. Briefly,
cells were incubated with 100 nM Testosterone for 30min. Me-
dia was removed and transferred into glass tubes. 5ml dichlo-
romethane was added to each tube, vortexed for 30 seconds and
then centrifuged for 10minutes at 1600 rpm. The aqueous phase
was removed and the steroid-containing organic solvent phase
evaporated in air to dryness. The steroid extract was analyzed
usingLC/MSMS(XevoTQmass spectrometer combinedwithan
acquity uPLC system) with an electro-spray ionisation source in
positive ion mode. Steroid hormones were eluted from a BEH
C18 2.1  50 mm 1.7 m column using a methanol/water gra-
dient system, solvent A was water 0.1% formic acid, and B was
methanol 0.1% formic acid. The flow rate was 0.6 mL/min and
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starting conditionswere45%Bincreasing linearly to75%Bover
5 minutes. Steroid hormones were positively identified by com-
parison of retention times and mass transitions to steroid
standards.
Statistical analysis
Data are presented as mean  standard error. Where data
were normally distributed, t-tests (paired or unpaired where ap-
propriate) were used to compare single treatments to control. If
normality tests failed, nonparametric tests were used. ANOVA
was used to compare multiple doses and / or treatments. Statis-
tical analysis on real-time PCR data was performed onmeanct
values andnot fold changes.All analysiswasperformedusing the
GraphPadPrism6.0 software package (GraphPad Software, Inc.
La Jolla, CA)
Results
Regulation of lipogenesis human hepatocytes by
androgens
Fatty acid synthase (FASN), ACC1, ACC2 and CPT1
mRNA expression increased after treatment with testos-
terone in a dose-dependent manner (Figure 1a-d) in C3A
human hepatoma cells. Observationswere similar follow-
ing DHT treatment (Figure 1a-d). Absolute changes in
mRNA expression levels are presented in Supplemental
Table2.Lipogenic gene expression changesweremirrored
by functional assays of 1-[14C]-acetate incorporation into
lipid; both testosterone and DHT increased lipogenesis
Lipogenic gene expression changesweremirroredby func-
tional assays of 1-[14C]-acetate incorporation into lipid;
both testosterone and DHT increased lipogenesis (ctrl
100% vs. T (50 nM, 24h) 124.9  6.2%, DHT (10 nM,
24h) 128.1  4.7%). AR overexpression was confirmed
by real-time PCR (ctrl 0.02  0.003 vs. AR 30.04 
0.018AU, P .05). Even in the absence of testosterone or
DHT, AR overexpression alone caused a significant in-
creases in 1-[14C]-acetate incorporation into lipid (ctrl
vector only 100%vs.AR202.710.8%,P .05). Treat-
ment with both testosterone and DHT did not further
enhance lipid accumulation (ctrl 202.7 10.8% vs. T (50
nM, 24h) 209.6  16.5%, DHT (10 nM, 24h) 224.6 
8.6%) (Figure 1e). In addition, AR overexpression in-
creased lipid metabolism gene expression compared to
cells transfected with vector alone (FASN: ctrl 13.9 2.0
vs. AR 66.8 6.2, ACC1: ctrl 1.0 0.3 vs. AR 3.5 0.3,
ACC2: ctrl 0.5  0.1 vs. AR 1.0  0.1, CPT1: ctrl 1.8 
0.3 vs. AR 4.3  0.2, P  .05).
Studies were also performed in primary cultures of hu-
man hepatocytes frombothmale and female donors. Both
testosteroneandDHTwerewithout effect in cultures from
male patients, however, in samples from female donors,
testosterone increased lipogenesis (139.6  17.6% (Tes-
tosterone, 5 nM, 24h) vs. 100% (control), P  .05). In-
terestingly, DHT decreased lipogenesis in hepatocytes
from female donors only (Figure 1f).
Regulation of lipid flux in human hepatocytes by
glucocorticoids and insulin
GC receptor, IRS1/2, Insulin receptor and AKT1/2
were all expressed in primary cultures of human hepato-
cytes frommale donors. Incubation with cortisol alone or
in combination with insulin did not alter gene expression
levels (Supplemental Table 3). Cortisol decreased 1-[14C]-
acetate incorporation into lipid in a dose-dependent man-
ner (Figure 2a). Insulin increased lipogenesis in primary
cultures of human hepatocytes (123.6  10.7% (insulin,
5 nM, 24h) vs. 100% (control), P  .05) (Figure 2b).
Interestingly, coincubation with increasing doses of cor-
tisol increased the ability of insulin to simulate lipogenesis
suggesting that insulin and glucocorticoidsmaywork syn-
ergistically to promote lipid storage in human hepatocytes
(43.9  12.7% [250 nM], 66.13  9.8% [1000 nM] vs.
control (23.61  10.7%), P  .05) (Figure 2c).
Cortisol treatment did not alter total PKB/akt levels.
However, insulin-stimulated phosphorylation of PKB/akt
at serine 473 increased following cortisol pretreatment in
a dose dependant manner (1.23-fold [100 nM], 1.68-fold
[250 nM], 2.44-fold [1000 nM] vs. control n 4 P .05)
(Figure 2d and e).
Cortisol treatment did not alter rates of -oxidation of
free fatty acid uptake in C3A cells (data not shown)
SRD5A2 regulates lipogenesis in human
hepatocytes
The effects of testosterone were similar to that of DHT
upon lipogenesis in our hepatocyte models and we there-
fore postulated that SRD5A2 may have a more important
role to regulate GC exposure in this context.
SRD5A2 overexpression was confirmed using real-
time PCR (Figure 3a). Functional activity was assessed
through increased DHT generation following incubation
with T (Figure 3b) and clearance of cortisol (Figure 3c) as
measuredbyLC/MSMSandGC/MSrespectively.Themu-
tant SRD5A2 construct, R246Q, was without activity.
Conversion of testosterone to DHT was similar to that
observed in the vector only transfection control (Figure
3b).
As observed previously, cortisol decreased lipogenesis
in a dose dependent manner in C3A cells transfected with
vector construct alone and in the absence of cortisol,
SRD5A2 overexpression had no effect. However, in the
presenceof cortisol, SRD5A2restored lipogenesis to levels
observed in untreated controls (eg, 61.9 7.6%[cortisol]
vs. 103.8 8.8% [SRD5A2cortisol],P .05, control
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100%) (Figure 4a). Complementary experiments using
theR246QSRD5A2 construct that is devoid of functional
activity did not alter cortisol-mediated suppression of
DNL (Figure 4b). To further endorse these findings, ex-
periments were undertaken using pharmacological inhib-
itors of 5-reductase isoforms in primary cultures of hu-
man hepatocytes. Consistent with our transfection
studies, both finasteride (selective SRD5A2 inhibitor) and
Figure 1. Testosterone [To] and dihydrotestosterone [DHT] cause a dose-dependent increase in lipogenic genes as well as increasing carnitine
palmitoyl trasferase 1 [CPT1], the rate-limiting step in mitochondrial -oxidation, in human C3A cells (a-d). Changes in lipogenic gene expression
are paralleled by function increases in 1-[14C]-acetate incorporation into lipid (e). Androgen receptor (AR) overexpression alone, and in the
presence of T or DHT increases functional lipogenesis (e). In primary cultures of human hepatocytes, T, but not DHT increases 1-[14C]-acetate
incorporation into lipid in female patients (black bars), but have no effect in samples from male patients (white bars) (f). Data presented are
meanSE of n  3–5 experiments performed in triplicate, *P  .05.
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dutasteride (nonselective SRD5A1 and 2 inhibitor) aug-
mented the action of cortisol to suppress DNL (eg, 88.3
5.3 vs. 76.95.2%, cortisol vs. cortisol finasteride,P
.05) (Figure 4c).
Discussion
In this study, we have shown that androgens are able to
increase lipid accumulation within human hepatocytes.
Cross-sectional clinical studies have shown that low tes-
tosterone concentrations are associatedwith increased he-
patic steatosis in men (8, 9) and are consistent with find-
ings in rodent models suggesting that DHT treatment can
decrease hepatic lipid accumulation (16). In contrast,
womenwith polycystic ovarian syndrome (PCOS), a con-
dition characterized by androgen excess as well as insulin
resistance, are at an increased risk of developing NAFLD
although the precise contribution of each of these pro-
cesses (insulin resistance and androgen excess) to the de-
velopment of NALFD remains unclear (17, 18).
Figure 2. a. Cortisol decreases 1-[14C]-acetate incorporation into lipid in primary human hepatocytes from male donors. b. While cortisol (black
bars) decreases lipogenesis, under hyperinsulinemic conditions (white bars), cortisol increases acetate incorporation into lipid. c. Cortisol treatment
increases the ability of insulin to stimulate lipogenesis in a dose-dependent manner. d. Pretreatment of primary human hepatocytes from male
donors with cortisol increases insulin-stimulated phosphorylation of AKT at residue ser473. The formal quantification of Western blot densitometry
relative to -actin (n  4 experiments) is presented (total AKT (black bars) and pAKT ser473 (white bars)). e. Representative Western blot. Data
presented are meanSE, *P  .05.
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Although in vitro cellmodels are not able to replicate all
the processes that contribute to the development of NA-
FLDinvivo, inC3Acells, testosteroneandDHT increased
lipid accumulation, but interestingly, in primary cultures,
we observed sexually dimorphic effects. In cells derived
from male donors, androgen treatment failed to have a
Figure 3. Increased 5-reductase type 2 expression following
transfection into C3A cells (a). Transfection of wild-type 5-reductase
type 2 (in contrast to the mutant R246Q construct) is associated with
increased dihydrotestosterone [DHT] generation from Testosterone [To]
(b) as well as clearance of cortisol (c). Data presented are meanSE of
n  3 experiments performed in triplicate, *P  .05
Figure 4. In C3A cells, the decrease in lipogenesis associated with
increasing doses of cortisol (black bars, vector only transfection) was
abolished in cells transfected with wild-type 5-reductase type 2
(white bars) (a). Transfection of mutant R246Q 5-reductase type 2
was without effect (vector only black bars, R246Q white bars) (b). In
primary cultures of human hepatocytes, pharmacological inhibition of
5-reductase type 2 with either the selective (Finasteride) or
nonselective inhibitor (Dutasteride), augments the action of cortisol to
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significant impact upon lipogenesis, however in female
samples, 5 nM testosterone increased DNL. It is interest-
ing to note that DHT did not alter lipogenesis in hepato-
cytes from male donors, but decreased lipogenesis in fe-
male hepatocytes. The mechanisms underpinning this
observation and the physiological relevance (the concen-
trations of DHT used far exceed those seen in the female
circulation) are not clear. The discrepancy between the
effects of androgens on C3A cells and in primary cultures
may reflect origin of C3A cells from human hepatoma
(and the well described impact of androgens upon their
pathogenesis (19)) and serves to emphasize the important
of endorsing in vitro observations in additional models
including human primary cultures.
Enhancing androgen action throughandrogen receptor
overexpression increasedDNLproviding further evidence
as to the potent ability of this pathway to regulate lipid
accumulation. Interestingly, we observed no additional
effects of providing additional AR ligand, perhaps sug-
gestingmaximal stimulationwith receptoroverexpression
alone. Furthermore, AR over expression alone in the ab-
sence of ligand was able to increase lipogenesis. While, it
is possible that this may reflect existing intracellular an-
drogen availability, ligand-independent activation of the
AR remains plausible. This has been identified as a po-
tential mechanism that might be crucial in regulating cell
growth in the context of malignancy (20) notably in pros-
tate cancer (21) although the precise mechanisms that un-
derpin ligand-independent AR activation remain unclear.
Importantly, not all actions of androgens upon the liver
may be mediated by classical AR signaling. AR-indepen-
dent regulation of lipogenesis in the liver has been ob-
served in testicular feminized mice that lack a functional
androgen receptor, with a reduction in lipogenesis follow-
ing testosterone treatment (22).
The impact of GCs to regulate carbohydrate metabo-
lism in particular gluconeogenesis in the fasting state is
well described.However, their impacton lipidmetabolism
remains relatively poorly understood in human models.
We have previously shown in adipose and skeletal muscle
that GCs decrease lipogenesis in the absence of insulin
consistent with their role to mobilize fuel in the fasting
state (23, 24). In the fed state, however, GCs and insulin
act synergistically to drive lipid accumulation. Studies per-
formed in rodent hepatocytes have demonstrated this re-
lationship (25) and we have now shown this in primary
cultures of human hepatocytes. In our in vitro model, the
ability of GCs to enhance the ability of insulin to drive
lipogenesiswas associatedwith increased activation of the
insulin signaling cascade as demonstrated by increased
phosphorylation of PKB/akt, similar to our published ob-
servations in human adipose tissue (26, 27). Although
augmentation of insulin action by GCs has been observed
in rodent hepatocytes (25), these in vitro data may not be
reflective of more complex in vivo physiology. Clinical
studies that have administered GCs have shown evidence
of increased hepatic insulin resistance in most cases (28).
There is now an emerging role for the 5-reductase
isoforms in the regulation of metabolic phenotype. The
ability of testosterone to regulate lipid metabolism does
not appear tobedependent upon thepresenceof SRD5A2.
The C3A cell line does not express SRD5A2, and yet both
Testosterone and DHT were able to stimulate lipogenesis
to a similar extent. Our experiments therefore focused on
the role of SRD5A2 to regulate the effects of GCs upon
liver metabolism. While genetic ablation of SRD5A1 in
rodent models increases lipid accumulation and fibrosis,
the precisemechanisms that underpin this are not clear (6,
7). In a recently published clinical study, nonselective 5-
reductase inhibitionwithDutasteridewas associatedwith
peripheral insulin resistance and it has been suggested that
thismay reflect a specific role for SRD5A1 in skeletalmus-
cle (29). The precise impact upon liver fat accumulation
could not be determined as pre and post intervention as-
sessment of hepatic lipid content was not performed.
The role of SRD5A2 in clearing cortisol is well estab-
lished through the examination of urinary steroid metab-
olite profiles in patients with proven SRD5A2 mutations
(5). Detailed metabolic studies in patients with mutations
SRD5A2, have not been performed. Increasing 5-reduc-
tase activity is associated with an adverse metabolic phe-
notype (12, 30). This may reflect a compensatory mech-
anism to clear activeGCs, in particular from the liver in an
attempt to protect it from lipid accumulation. With more
severe disease activity decreases and this may increase GC
exposure and may serve and a local anti-inflammatory
measure to try to limit the progression of nonalcoholic
steatohepatitis, fibrosis and scarring (31).
In conclusion,wehavedemonstrated thepotent actions
of androgens and GCs to regulate lipid metabolism in hu-
man hepatocytes in vitro and shown that prereceptor reg-
ulation through that expression and activity of SRD5A2 is
able to modify their action. This has important implica-
tions not only in terms of predisposing individuals to the
development of hepatic steatosis, but also to the large
numbers of patients prescribed 5-reductase inhibitors.
While the role of these compounds in the treatment of
prostate-related disease is established, the long-term met-
Legend to Figure 4 Continued. . .
suppress lipogenesis. Data presented are meanSE of n  3–5
experiments performed in triplicate, *P  .05, **P  .01 vs. control
and § P  .05, §§ P  .01 vs. cortisol)
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abolic consequences of these medications have not been
assessed.
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